Anti-tissue factor antibodies and antibody conjugates, compositions comprising Anti-tissue factor antibodies or antibody conjugates, and methods of making and using Anti-tissue factor antibodies and antibody conjugates

Abstract

The present disclosure relates to antibodies and antibody conjugates that selectively bind to tissue factor and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies and antibody conjugates, such as therapeutic and diagnostic methods.

Description

ANTI-TISSUE FACTOR ANTIBODIES AND ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-TISSUE FACTOR ANTIBODIES OR ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-TISSUE FACTOR ANTIBODIES AND ANTIBODY CONJUGATES CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 590,343, filed October 13, 2023, and U.S. Provisional Application No. 63 / 684,699, filed August 19, 2024. Each of these applications are incorporated for all purposes in their entirety. REFERENCE TO ELECTRONIC SEQUENCE LISTING

[0002] The application contains a Sequence Listing which has been submitted electronically in .XML format and is hereby incorporated by reference in its entirety. Said .XML copy, created on October 7, 2024, is named “108843.00506.xml” and is 1,460,613 bytes in size. The sequence listing contained in this .XML file is part of the specification and is hereby incorporated by reference herein in its entirety. FIELD OF THE INVENTION

[0003] The present disclosure generally relates to antibodies and antibody conjugates with binding specificity for tissue factor and compositions comprising the antibodies or antibody conjugates, including pharmaceutical compositions, diagnostic compositions, and kits. Also provided are methods of making anti-tissue factor antibodies and antibody conjugates, and methods of using anti-tissue factor antibodies and antibody conjugates, for example, for therapeutic purposes, diagnostic purposes, and research purposes. BACKGROUND

[0004] Tissue factor (TF), also known as CD142, is a cellular membrane glycoprotein. Tissue factor is sometimes referred to as Coagulation Factor III because it is the primary initiator of blood coagulation, where complexation of Factor VIIa and tissue factor (TF:FVIIa complex) activates the coagulation protease cascade. Mackman, et al., 2004, Atherosclerosis, Thrombosis, and Vascular Biology 24:1015-1022. TF is expressed in the subendothelium. When endothelium is damaged, tissue factor combines with circulating factor VII to activate factor X. Activated factor X initiates the coagulation cascade, allowing clot formation.

[0005] Aberrant expression of TF plays a role in thrombosis in disease, including sepsis, atherosclerosis, and cancer. TF has also been implicated in inflammation, angiogenesis, metastasis, and cell migration. Mackman, et al., 2004, Atherosclerosis, Thrombosis, andVascular Biology 24:1015-1022. TF is broadly expressed across multiple solid tumor indications.

[0006] Accordingly, there is a need for improved methods of modulating the activity of TF and the downstream signaling coagulation processes activated by TF. Moreover, given the implication of TF in thrombosis, there is a need for improved therapeutics that specifically target cells and tissues that express TF. Antibody conjugates to TF could be used to deliver therapeutic or diagnostic payload moieties to target cells expressing TF for the treatment or diagnosis of such diseases. SUMMARY

[0007] Provided herein are antibodies that selectively bind tissue factor (TF). In some embodiments, the antibodies bind human TF. In some embodiments, the antibodies also bind homologs of human TF. In some aspects, the homologs include a cynomolgus monkey homolog.

[0008] Also provided herein are antibody conjugates that selectively bind TF. The antibody conjugates comprise an antibody that binds TF linked to one or more payload moieties. The antibody can be linked to the payload directly by a covalent bond or indirectly by way of a linker. TF antibodies are described in detail herein, as are useful payload moieties, and useful linkers.

[0009] In some embodiments, the antibodies or antibody conjugates comprise an illustrative CDR, VH, VL, HC, or LC sequence provided in this disclosure, or a variant thereof. In some aspects, the variant is a variant with one or more conservative amino acid substitutions. In some aspects, the variant has sequence identity to the illustrative sequence or sequences.

[0010] In another aspect, provided are compositions comprising the antibodies or antibody conjugates. In some embodiments, the compositions are pharmaceutical compositions. In some embodiments, the pharmaceutical composition is for parenteral administration. Any suitable pharmaceutical composition may be used. In some embodiments, the pharmaceutical composition is a composition for parenteral administration. In a further aspect, provided herein are kits comprising the antibodies or antibody conjugates or pharmaceutical compositions.

[0011] This disclosure also provides methods of using the anti-TF antibodies or antibody conjugates provided herein. In some embodiments, the methods are methods of delivering one or more payload moieties to a target cell or tissue expressing TF. In some embodiments, the method is a method of treatment. In some embodiments, the method is a diagnostic method. In some embodiments, the method is an analytical method. In some embodiments, the method is a method of purifying and / or quantifying TF.

[0012] In some embodiments, the antibodies, antibody conjugates, or pharmaceutical compositions thereof are used to treat a disease or condition. In some aspects, the disease or condition is a TF-expressing malignancy. In some aspects, the disease or condition is selected from a cancer, autoimmune disease, and infection.

[0013] In some embodiments, the antibodies or antibody conjugates bind human TF. In some embodiments, the antibodies or antibody conjugates also bind homologs of human TF. In some aspects, the antibodies or antibody conjugates also bind homologs of cynomolgus monkey and / or mouse TF.

[0014] These and other embodiments of the invention along with many of its features are described in more detail in conjunction with the text below and attached figures. BRIEF DESCRIPTION OF THE FIGURES

[0015] FIG.1A provides a comparison of the Kabat and Chothia numbering systems for CDR-H1. Adapted from Martin A.C.R. (2010). Protein Sequence and Structure Analysis of Antibody Variable Domains. In R. Kontermann & S. Dübel (Eds.), Antibody Engineering vol.2 (pp.33-51). Springer-Verlag, Berlin Heidelberg.

[0016] FIG. 1B provides a general schematic design for a representative antibody conjugate of the present disclosure where 1 is TF, 2 is a non-natural amino acid (pAMF), 3 is a β-glucuronidase linker and 4 is an exatecan payload.

[0017] FIG.2 provides thrombin production data for Conjugate 1 and Conjugate 26.

[0018] FIG. 3A provides HPLC-SEC results for formulation buffer comparison for Conjugate 7 at 4oC, 25oC and 37oC conditions.

[0019] FIG. 3B provides HPLC-SEC results for Conjugate 2 at 4oC, 25oC and 37oC conditions.

[0020] FIG.4 provides HPLC-SEC results over 5x freeze / thaw cycles for Conjugate 2 in one formulation buffer and for Conjugate 7 in three different formulation buffers.

[0021] FIG. 5 provides the viability of CD66b+ cells as a percentage relative to PBS control for Neutrophil precursor cells treated with Conjugates 2, 3 and 6.

[0022] FIG.6A provides measured DAR of Conjugates 2, 6 and 7 over 21 days.

[0023] FIG. 6B provides deconvoluted mass spectra of anti-TF ADC samples from in vivo linker payload stability study for Conjugates 2, 6 and 7.

[0024] FIGS. 7A-C provide HCC1954 tumor growth curves in response to treatment with a single i.v. dose of TF-targeted ADCs, with doses (FIG. 7A) 0.5 mg / kg or (FIG. 7B) 5 mg / kg. FIG.7C provides a scatter plot of individual tumor volumes on day 35 post treatment, when control tumors reached the study endpoint. Arrows represent dosing days. Statistical analysis was performed on tumor volumes on day 35 using one-way ANOVA with Dunnett’s multiple comparisons test versus the vehicle group. A probability of less than 5% (p<0.05) was considered significant. **** = p<0.0001. All graphs are presented as individual values or mean ^ SEM.

[0025] FIGS. 8A-B provide (FIG. 8A) H1975 tumor growth curves in response to treatment with a single i.v. dose of TF-targeted ADCs at 1 mg / kg or 2 mg / kg. (FIG.8B) Scatter plot of individual tumor volumes on day 17 post treatment, when control tumors reached the study endpoint. Arrows represent dosing days. Statistical analysis was performed on tumor volumes on day 17 using one-way ANOVA with Dunnett’s multiple comparisons test versus the vehicle group. A probability of less than 5% (p<0.05) was considered significant. **** = p<0.0001. All graphs are presented as individual values or mean ^ SEM.

[0026] FIGS. 9A-B provide (FIG. 9A) H1975 tumor growth curves in response to treatment with a single i.v. dose of TF-targeted ADCs at doses ranging from 0.5 mg / kg to 2 mg / kg. (FIG. 9B) Scatter plot of individual tumor volumes on day 18 post treatment, when control tumors reached the study endpoint. Arrows represent dosing days. Statistical analysis was performed on tumor volumes on day 18 using one-way ANOVA with Dunnett’s multiple comparisons test versus the vehicle group. A probability of less than 5% (p<0.05) was considered significant. **** = p<0.0001. All graphs are presented as individual values or mean ^ SEM.

[0027] FIGS. 10A-D provide (FIG. 10A) MDA-MB-231 tumor growth curves in response to treatment with two weekly i.v. doses (qwx2) of TF-targeted ADCs at doses ranging from 0.5 mg / kg to 2 mg / kg. (FIG.10B) Scatter plot of individual tumor volumes on day 42 post treatment, when control tumors reached the study endpoint. Arrows represent dosing days. Statistical analysis was performed on tumor volumes on day 42 using one-way ANOVA with Dunnett’s multiple comparisons test versus the vehicle group. A probability of less than 5% (p<0.05) was considered significant. **** = p<0.0001. All graphs are presented as individual values or mean ^ SEM. (FIG.10C) MDA-MB-231 tumor growth curves in response to treatment with two weekly i.v. doses (qwx2) of a TF-targeted ADC at doses ranging from 0.25 mg / kg to 1 mg / kg. (FIG. 10D) Scatter plot of individual tumor volumes on day 41 post treatment, when control tumors reached the study endpoint. Arrows represent dosing days. Statistical analysis was performed on tumor volumes on day 41 using one-way ANOVA with Dunnett’s multiplecomparisons test versus the vehicle group. A probability of less than 5% (p<0.05) was considered significant. **** = p<0.0001. All graphs are presented as individual values or mean ^ SEM.

[0028] FIGS. 11A-D provide (FIG. 11A) H1975 tumor growth curves in response to treatment with a single i.v. dose of TF-targeted ADCs at doses ranging from 0.25 mg / kg to 2 mg / kg. (FIG. 11B) Scatter plot of individual tumor volumes on day 24 post treatment, when control tumors reached the study endpoint. Arrows represent dosing days. Statistical analysis was performed on tumor volumes on day 24 using one-way ANOVA with Dunnett’s multiple comparisons test versus the vehicle group. A probability of less than 5% (p<0.05) was considered significant. *** = p<0.001; **** = p<0.0001. All graphs are presented as individual values or mean ^ SEM. (FIG.11C) H1975 tumor growth curves in response to treatment with a single i.v. dose of TF-targeted ADCs at doses ranging from 0.125 mg / kg to 1 mg / kg. (FIG.11D) Scatter plot of individual tumor volumes on day 25 post treatment, when control tumors reached the study endpoint. Statistical analysis was performed on tumor volumes on day 25 using one-way ANOVA with Dunnett’s multiple comparisons test versus the vehicle group. A probability of less than 5% (p<0.05) was considered significant. ** = p<0.01; **** = p<0.0001. All graphs are presented as individual values or mean ^ SEM.

[0029] FIGS.12A-D provide (FIG.12A) Detroit562 tumor growth curves in response to treatment with a single i.v. dose of Conjugate 7 at 1 mg / kg or 2 mg / kg. (FIG. 12B) Scatter plot of individual tumor volumes on day 21 post treatment, when control tumors reached the study endpoint. Arrow represents dosing day. Statistical analysis was performed on tumor volumes on day 21 using one-way ANOVA with Dunnett’s multiple comparisons test versus the vehicle group. A probability of less than 5% (p<0.05) was considered significant. **** = p<0.0001. All graphs are presented as individual values or mean ± SEM. (FIG.12C) Detroit562 tumor growth curves in response to treatment with a single i.v. dose of TF-targeted ADCs at doses ranging from 0.25 mg / kg to 2 mg / kg. (FIG.12D) Scatter plot of individual tumor volumes on day 21 post treatment, when control tumors reached the study endpoint. Statistical analysis was performed on tumor volumes on day 21 using one-way ANOVA with Dunnett’s multiple comparisons test versus the vehicle group. A probability of less than 5% (p<0.05) was considered significant. **** = p<0.0001. All graphs are presented as individual values or mean ± SEM.

[0030] FIGS.13A-B provide (FIG.13A) HCT-116 tumor growth curves in response to treatment with a single i.v. dose of TF-targeted ADCs at doses ranging from 2.5 mg / kg to 15 mg / kg. (FIG. 13B) Scatter plot of individual tumor volumes on day 21 post treatment, when control tumors reached the study endpoint. Statistical analysis was performed on tumor volumes on day 21 using one-way ANOVA with Dunnett’s multiple comparisons test versus the vehiclegroup. A probability of less than 5% (p<0.05) was considered significant. **** = p<0.0001. All graphs are presented as individual values or mean ± SEM.

[0031] FIGS.14A-D provide (FIG.14A) MC38-hTF tumor growth curves in response to treatment with a single i.v. dose of Conjugate 7 at 10 mg / kg, multiple i.p. doses of anti-PD-1 at 10 mg / kg, or combination treatment. Number of complete responses (CRs) are designated to the right of the tumor growth curves. (FIG. 14B) Scatter plot of individual tumor volumes on day 6 post treatment, when control tumors reached the study endpoint. Arrows represent dosing days. Statistical analysis was performed on tumor volumes on day 6 using one-way ANOVA with Dunnett’s multiple comparisons test versus the vehicle group. A probability of less than 5% (p<0.05) was considered significant. ** = p<0.01; **** = p<0.0001. All graphs are presented as individual values or mean ± SEM. (FIG.14C) MC38-hTF tumor growth curves in response to treatment with a single i.v. dose of Conjugate 35 at 5 mg / kg, multiple i.p. doses of anti-PD-1 at 10 mg / kg, or combination treatment. Number of complete responses (CRs) are designated to the right of the tumor growth curves. (FIG.14D) Scatter plot of individual tumor volumes on day 8 post treatment, when control tumors reached the study endpoint. Arrows represent dosing days. Statistical analysis was performed on tumor volumes on day 8 using one-way ANOVA with Dunnett’s multiple comparisons test versus the vehicle group. A probability of less than 5% (p<0.05) was considered significant. **** = p<0.0001. All graphs are presented as individual values or mean ± SEM.

[0032] FIGS.15A-B provide (FIG.15A) Tumor growth curves of a NSCLC PDX model in response to treatment with a single i.v. dose of Conjugate 7 at doses ranging from 0.3 mg / kg to 10 mg / kg. (FIG. 15B) Scatter plot of individual tumor volumes on day 37 post treatment, when control tumors reached the study endpoint. Arrow represents dosing day. Statistical analysis was performed on tumor volumes on day 37 using one-way ANOVA with Dunnett’s multiple comparisons test versus the vehicle group. A probability of less than 5% (p<0.05) was considered significant. **** = p<0.01; **** = p<0.001. All graphs are presented as individual values or mean ± SEM. DETAILED DESCRIPTION OF THE EMBODIMENTS 1. Definitions

[0033] Unless otherwise defined, all terms of art, notations and other scientific terminology used herein are intended to have the meanings commonly understood by those of skill in the art to which this invention pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and / or for ready reference, and the inclusion of suchdefinitions herein should not necessarily be construed to represent a difference over what is generally understood in the art. The techniques and procedures described or referenced herein are generally well understood and commonly employed using conventional methodologies by those skilled in the art, such as, for example, the widely utilized molecular cloning methodologies described in Sambrook et al., Molecular Cloning: A Laboratory Manual 2nd ed. (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. As appropriate, procedures involving the use of commercially available kits and reagents are generally carried out in accordance with manufacturer-defined protocols and conditions unless otherwise noted.

[0034] As used herein, the singular forms “a,” “an,” and “the” include the plural referents unless the context clearly indicates otherwise.

[0035] The term “about” indicates and encompasses an indicated value and a range above and below that value. In certain embodiments, the term “about” indicates the designated value ± 10%, ± 5%, or ± 1%. In certain embodiments, the term “about” indicates the designated value ± one standard deviation of that value.

[0036] The term “combinations thereof” includes every possible combination of elements to which the term refers to. For example, a sentence stating “A, B, C, and combinations thereof” includes the following combinations: (1) A, (2) A and B, (3) A, B and C, (4) A and C, (5) B, (6) B and C, and (7) C.

[0037] The terms “tissue factor,” “TF,” and “TF antigen” are used interchangeably herein. Unless specified otherwise, the terms include any variants, isoforms and species homologs of human tissue factor that are naturally expressed by cells, or that are expressed by cells transfected with a tissue factor gene. Tissue factor proteins include, for example, human tissue factor (SEQ ID NO: 1). In some embodiments, tissue factor proteins include cynomolgus monkey tissue factor (SEQ ID NO: 2). In some embodiments, tissue factor proteins include murine tissue factor (SEQ ID NO: 3160). In some embodiments, tissue factor proteins include human tissue factor isoform 2 precursor (SEQ ID NO: 3161). In some embodiments, tissue factor proteins include murine tissue factor precursor (SEQ ID NO: 3162).

[0038] The term “immunoglobulin” refers to a class of structurally related proteins generally comprising two pairs of polypeptide chains: one pair of light (L) chains and one pair of heavy (H) chains. In an “intact immunoglobulin,” all four of these chains are interconnected by disulfide bonds. The structure of immunoglobulins has been well characterized. See, e.g., Paul, Fundamental Immunology 7th ed., Ch. 5 (2013) Lippincott Williams & Wilkins, Philadelphia, PA. Briefly, each heavy chain typically comprises a heavy chain variable region(VH) and a heavy chain constant region (CH). The heavy chain constant region typically comprises three domains, abbreviated CH1, CH2, and CH3. Each light chain typically comprises a light chain variable region (VL) and a light chain constant region. The light chain constant region typically comprises one domain, abbreviated CL.

[0039] The term “antibody” describes a type of immunoglobulin molecule and is used herein in its broadest sense. An antibody specifically includes intact antibodies (e.g., intact immunoglobulins), and antibody fragments. Antibodies comprise at least one antigen-binding domain. One example of an antigen-binding domain is an antigen binding domain formed by a VH -VL dimer. A “tissue factor antibody,” “anti-tissue factor antibody,” “tissue factor Ab,” “tissue factor-specific antibody” or “anti-tissue factor Ab” or the equivalent is an antibody, as described herein, which binds specifically to the antigen tissue factor. In some embodiments, the antibody binds the extracellular domain of tissue factor.

[0040] The VH and VL regions may be further subdivided into regions of hypervariability (“hypervariable regions (HVRs);” also called “complementarity determining regions” (CDRs)) interspersed with regions that are more conserved. The more conserved regions are called framework regions (FRs). Each VH and VL generally comprises three CDRs and four FRs, arranged in the following order (from N-terminus to C-terminus): FR1 - CDR1 - FR2 - CDR2 - FR3 - CDR3 - FR4. The CDRs are involved in antigen binding, and influence antigen specificity and binding affinity of the antibody. See Kabat et al., Sequences of Proteins of Immunological Interest 5th ed. (1991) Public Health Service, National Institutes of Health, Bethesda, MD, incorporated by reference in its entirety.

[0041] The light chain from any vertebrate species can be assigned to one of two types, called kappa and lambda, based on the sequence of the constant domain.

[0042] The heavy chain from any vertebrate species can be assigned to one of five different classes (or isotypes): IgA, IgD, IgE, IgG, and IgM. These classes are also designated α, δ, ε, γ, and µ, respectively. The IgG and IgA classes are further divided into subclasses on the basis of differences in sequence and function. Humans express the following subclasses: IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2.

[0043] The amino acid sequence boundaries of a CDR can be determined by one of skill in the art using any of a number of known numbering schemes, including those described by Kabat et al., supra (“Kabat” numbering scheme); Al-Lazikani et al., 1997, J. Mol. Biol., 273:927- 948 (“Chothia” numbering scheme); MacCallum et al., 1996, J. Mol. Biol. 262:732-745 (“Contact” numbering scheme); Lefranc et al., Dev. Comp. Immunol., 2003, 27:55-77 (“IMGT”numbering scheme); and Honegge and Plückthun, J. Mol. Biol., 2001, 309:657-70 (“AHo” numbering scheme), each of which is incorporated by reference in its entirety.

[0044] Table 1 provides the positions of CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR- H2, and CDR-H3 as identified by the Kabat and Chothia schemes. For CDR-H1, residue numbering is provided using both the Kabat and Chothia numbering schemes. Table 1. Residues in CDRs according to Kabat and Chothia numbering schemes.* The C-terminus of CDR-H1, when numbered using the Kabat numbering convention, varies between H32 and H34, depending on the length of the CDR, as illustrated in FIG.1A.

[0045] Unless otherwise specified, the numbering scheme used for identification of a particular CDR herein is the Kabat / Chothia numbering scheme. Where the residues encompassed by these two numbering schemes diverge (e.g., CDR-H1 and / or CDR-H2), the numbering scheme is specified as either Kabat or Chothia. For convenience, CDR-H3 is sometimes referred to herein as either Kabat or Chothia. However, this is not intended to imply differences in sequence where they do not exist, and one of skill in the art can readily confirm whether the sequences are the same or different by examining the sequences.

[0046] CDRs may be assigned, for example, using antibody numbering software, such as Abnum, available at http: / / www.bioinf.org.uk / abs / abnum / , and described in Abhinandan and Martin, Immunology, 2008, 45:3832-3839, incorporated by reference in its entirety.

[0047] The “EU numbering scheme” is generally used when referring to a residue in an antibody heavy chain constant region (e.g., as reported in Kabat et al., supra). Unless stated otherwise, the EU numbering scheme is used to refer to residues in antibody heavy chain constant regions described herein.

[0048] An “antibody fragment” comprises a portion of an intact antibody, such as the antigen binding or variable region of an intact antibody. Antibody fragments include, for example, Fv fragments, Fab fragments, F(ab’)2fragments, Fab’ fragments, scFv (sFv) fragments, and scFv-Fc fragments.

[0049] “Fv” fragments comprise a non-covalently-linked dimer of one heavy chain variable domain and one light chain variable domain.

[0050] “Fab” fragments comprise, in addition to the heavy and light chain variable domains, the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab fragments may be generated, for example, by recombinant methods or by papain digestion of a full-length antibody.

[0051] “F(ab’)2” fragments contain two Fab’ fragments joined, near the hinge region, by disulfide bonds. F(ab’)2fragments may be generated, for example, by recombinant methods or by pepsin digestion of an intact antibody. The F(ab’) fragments can be dissociated, for example, by treatment with ß-mercaptoethanol.

[0052] “Single-chain Fv” or “sFv” or “scFv” antibody fragments comprise a VHdomain and a VLdomain in a single polypeptide chain. The VHand VLare generally linked by a peptide linker. See Plückthun A. (1994). In some embodiments, the linker is SEQ ID NO: 3071. Antibodies from Escherichia coli. In Rosenberg M. & Moore G.P. (Eds.), The Pharmacology of Monoclonal Antibodies vol. 113 (pp. 269-315). Springer-Verlag, New York, incorporated by reference in its entirety.

[0053] “scFv-Fc” fragments comprise an scFv attached to an Fc domain. For example, an Fc domain may be attached to the C-terminus of the scFv. The Fc domain may follow the VHor VL, depending on the orientation of the variable domains in the scFv (i.e., VH -VL or VL -VH ). Any suitable Fc domain known in the art or described herein may be used. In some cases, the Fc domain comprises an IgG1 Fc domain. In some embodiments, the IgG1 Fc domain comprises SEQ ID NO: 3062, or a portion thereof, or SEQ ID NO: 3068. SEQ ID NO: 3062 provides the sequence of CH1, CH2, and CH3 of the human IgG1 constant region. In some embodiments, the constant region can comprise sequences selected from SEQ ID NOs: 3062, 3063, 3064, and 3065. SEQ ID NO: 3068 provides the sequence of the constant region used in the illustrative scFv-Fc antibodies provided herein. In some embodiments, the sequence of the constant region can be linked to the scFv by a linker such as, by way of example, but not limitation, the linker of SEQ ID NO: 3071. In some embodiments, the linker can be N-terminal to the sequence of SEQ ID NO: 3068. In some embodiments, the constant region can further include a FlagHis Tag, such as that of SEQ ID NO: 3069 which can, by way of example but not limitation, be C- terminal to the Fc sequence.

[0054] The term “monoclonal antibody” refers to an antibody from a population of substantially homogeneous antibodies. A population of substantially homogeneous antibodiescomprises antibodies that are substantially similar and that bind the same epitope(s), except for variants that may normally arise during production of the monoclonal antibody. Such variants are generally present in only minor amounts. A monoclonal antibody is typically obtained by a process that includes the selection of a single antibody from a plurality of antibodies. For example, the selection process can be the selection of a unique clone from a plurality of clones, such as a pool of hybridoma clones, phage clones, yeast clones, bacterial clones, or other recombinant DNA clones. The selected antibody can be further altered, for example, to improve affinity for the target (“affinity maturation”), to humanize the antibody, to improve its production in cell culture, and / or to reduce its immunogenicity in a subject.

[0055] The term “chimeric antibody” refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, while the remainder of the heavy and / or light chain is derived from a different source or species.

[0056] “Humanized” forms of non-human antibodies are chimeric antibodies that contain minimal sequence derived from the non-human antibody. A humanized antibody is generally a human immunoglobulin (recipient antibody) in which residues from one or more CDRs are replaced by residues from one or more CDRs of a non-human antibody (donor antibody). The donor antibody can be any suitable non-human antibody, such as a mouse, rat, rabbit, chicken, or non-human primate antibody having a desired specificity, affinity, or biological effect. In some instances, selected framework region residues of the recipient antibody are replaced by the corresponding framework region residues from the donor antibody. Humanized antibodies may also comprise residues that are not found in either the recipient antibody or the donor antibody. Such modifications may be made to further refine antibody function. For further details, see Jones et al., Nature, 1986, 321:522-525; Riechmann et al., Nature, 1988, 332:323-329; and Presta, Curr. Op. Struct. Biol., 1992, 2:593-596, each of which is incorporated by reference in its entirety.

[0057] A “human antibody” is one which possesses an amino acid sequence corresponding to that of an antibody produced by a human or a human cell, or derived from a non-human source that utilizes a human antibody repertoire or human antibody-encoding sequences (e.g., obtained from human sources or designed de novo). Human antibodies specifically exclude humanized antibodies.

[0058] An “isolated antibody” is one that has been separated and / or recovered from a component of its natural environment. Components of the natural environment may include enzymes, hormones, and other proteinaceous or nonproteinaceous materials. In some embodiments, an isolated antibody is purified to a degree sufficient to obtain at least 15 residuesof N-terminal or internal amino acid sequence, for example by use of a spinning cup sequenator. In some embodiments, an isolated antibody is purified to homogeneity by gel electrophoresis (e.g., SDS-PAGE) under reducing or nonreducing conditions, with detection by Coomassie blue or silver stain. An isolated antibody includes an antibody in situ within recombinant cells, since at least one component of the antibody’s natural environment is not present. In some aspects, an isolated antibody is prepared by at least one purification step.

[0059] In some embodiments, an isolated antibody is purified to at least 80%, 85%, 90%, 95%, or 99% by weight. In some embodiments, an isolated antibody is purified to at least 80%, 85%, 90%, 95%, or 99% by volume. In some embodiments, an isolated antibody is provided as a solution comprising at least 85%, 90%, 95%, 98%, 99% to 100% by weight. In some embodiments, an isolated antibody is provided as a solution comprising at least 85%, 90%, 95%, 98%, 99% to 100% by volume.

[0060] The term “non-natural amino acid” refers to an amino acid that is not a proteinogenic amino acid, or a post-translationally modified variant thereof. In particular, the term refers to an amino acid that is not one of the 20 common amino acids or pyrrolysine or selenocysteine, or post-translationally modified variants thereof.

[0061] “Affinity” refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of a molecule X for its partner Y can be represented by the dissociation constant (KD). Affinity can be measured by common methods known in the art, including those described herein. Affinity can be determined, for example, using surface plasmon resonance (SPR) technology, such as a Biacore®instrument. In some embodiments, the affinity is determined at 25°C.

[0062] With regard to the binding of an antibody to a target molecule, the terms “specific binding,” “specifically binds to,” “specific for,” “selectively binds,” and “selective for” a particular antigen (e.g., a polypeptide target) or an epitope on a particular antigen mean binding that is measurably different from a non-specific or non-selective interaction. Specific binding can be measured, for example, by determining binding of a molecule compared to binding of a control molecule. Specific binding can also be determined by competition with a control molecule that mimics the antibody binding site on the target. In that case, specific binding is indicated if the binding of the antibody to the target is competitively inhibited by the control molecule.

[0063] The term “kd” (sec-1), as used herein, refers to the dissociation rate constant of a particular antibody-antigen interaction. This value is also referred to as the koffvalue.

[0064] The term “ka” (M-1×sec-1), as used herein, refers to the association rate constant of a particular antibody-antigen interaction. This value is also referred to as the kon value.

[0065] The term “KD” (M), as used herein, refers to the dissociation equilibrium constant of a particular antibody-antigen interaction. KD = kd / ka.

[0066] The term “KA” (M-1), as used herein, refers to the association equilibrium constant of a particular antibody-antigen interaction. KA= ka / kd.

[0067] An “affinity matured” antibody is one with one or more alterations in one or more CDRs or FRs that result in an improvement in the affinity of the antibody for its antigen, compared to a parent antibody which does not possess the alteration(s). In one embodiment, an affinity matured antibody has nanomolar or picomolar affinity for the target antigen. Affinity matured antibodies may be produced using a variety of methods known in the art. For example, Marks et al. (Bio / Technology, 1992, 10:779-783, incorporated by reference in its entirety) describes affinity maturation by VHand VLdomain shuffling. Random mutagenesis of CDR and / or framework residues is described by, for example, Barbas et al. (Proc. Nat. Acad. Sci. U.S.A., 1994, 91:3809-3813); Schier et al., Gene, 1995, 169:147-155; Yelton et al., J. Immunol., 1995, 155:1994-2004; Jackson et al., J. Immunol., 1995, 154:3310-33199; and Hawkins et al, J. Mol. Biol., 1992, 226:889-896, each of which is incorporated by reference in its entirety.

[0068] When used herein in the context of two or more antibodies, the term “competes with” or “cross-competes with” indicates that the two or more antibodies compete for binding to an antigen (e.g., TF). In one exemplary assay, TF is coated on a plate and allowed to bind a first antibody, after which a second, labeled antibody is added. If the presence of the first antibody reduces binding of the second antibody, then the antibodies compete. In another exemplary assay, a first antibody is coated on a plate and allowed to bind the antigen, and then the second antibody is added. The term “competes with” also includes combinations of antibodies where one antibody reduces binding of another antibody, but where no competition is observed when the antibodies are added in the reverse order. However, in some embodiments, the first and second antibodies inhibit binding of each other, regardless of the order in which they are added. In some embodiments, one antibody reduces binding of another antibody to its antigen by at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%.

[0069] The term “epitope” means a portion of an antigen capable of specific binding to an antibody. Epitopes frequently consist of surface-accessible amino acid residues and / or sugarside chains and may have specific three-dimensional structural characteristics, as well as specific charge characteristics. Conformational and non-conformational epitopes are distinguished in that the binding to the former but not the latter is lost in the presence of denaturing solvents. An epitope may comprise amino acid residues that are directly involved in the binding, and other amino acid residues, which are not directly involved in the binding. The epitope to which an antibody binds can be determined using known techniques for epitope determination such as, for example, testing for antibody binding to TF variants with different point-mutations, or to chimeric TF variants as described further in the Examples provided herein.

[0070] Percent “identity” between a polypeptide sequence and a reference sequence, is defined as the percentage of amino acid residues in the polypeptide sequence that are identical to the amino acid residues in the reference sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, MEGALIGN (DNASTAR), CLUSTALW, CLUSTAL OMEGA, or MUSCLE software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.

[0071] A “conservative substitution” or a “conservative amino acid substitution,” refers to the substitution of an amino acid with a chemically or functionally similar amino acid. Conservative substitution tables providing similar amino acids are well known in the art. Polypeptide sequences having such substitutions are known as “conservatively modified variants.” Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles. By way of example, the groups of amino acids provided in Tables 2-4 are, in some embodiments, considered conservative substitutions for one another.Table 2. Selected groups of amino acids that are considered conservative substitutions for one another, in certain embodiments.Table 3. Additional selected groups of amino acids that are considered conservative substitutions for one another, in certain embodiments.Table 4. Further selected groups of amino acids that are considered conservative substitutions for one another, in certain embodiments.

[0072] Additional conservative substitutions may be found, for example, in Creighton, Proteins: Structures and Molecular Properties 2nd ed. (1993) W. H. Freeman & Co., New York, NY. An antibody generated by making one or more conservative substitutions of amino acid residues in a parent antibody is referred to as a “conservatively modified variant.”

[0073] The term “payload” refers to a molecular moiety that can be conjugated to an antibody. In particular embodiments, payloads are selected from the group consisting of therapeutic moieties and labelling moieties.

[0074] "Triple negative breast cancer” (TNBC) refers to a breast cancer characterized as estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (HER2-negative). The TNBC can be BRCA1 / 2 wildtype or BRCA1 / 2 mutated. The determination of negative status of the estrogen, progesterone, and Her2 / neu expression is readily determined by one of skill in the art, e.g., in accordance with the current accepted guidelines. For example, guidelines set forth by the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) are widely accepted. The ASCO / CAP recommends testing by immunohistochemistry (IHC) or in situ hybridization (ISH) techniques. Further, a cancer is Her2 negative if a single test (or all tests) performed on a tumor specimen show: (a) IHC negative, IHC 1+ or IHC 0, or (b) ISH negative using single-probe ISH or dual-probe ISH. One of skill in the art would recognize that the triple negative cancer described herein does not include any cancer having an apparent histopathologic discordance as observed by the pathologist. Wolff, A C et al. J Clin Oncol.2013 Nov. 1:31(31):3997-4013. Cancer is ER-negative or PR-negative if <1% of tumor cell nuclei are immunoreactive in the presence of evidence that the sample can express ER or PR (positive intrinsic controls are seen).

[0075] As used herein, the term “inhibits growth” (e.g., referring to cells, such as tumor cells) is intended to include any measurable decrease in cell growth (e.g., tumor cell growth) when contacted with a TF antibody or antibody conjugate described herein, as compared to the growth of the same cells not in contact with a TF antibody. In some embodiments, growth may be inhibited by at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 99%, or 100%. The decrease in cell growth can occur by a variety of mechanisms, including but not limited to antibody internalization, apoptosis, necrosis, and / or effector function-mediated activity.

[0076] In some chemical structures illustrated herein, certain substituents, chemical groups, and atoms are depicted with a curvy / wavy line (e.g.,that intersects a bond or bonds to indicate the atom through which the substituents, chemical groups, and atoms are bonded. For example, in some structures, such as but not limited,, this curvy / wavy line indicates the atoms in the backbone of a conjugate or linker-payload to which the illustrated chemical entity is bonded. In some structures, such as but not limited t, this curvy / wavy line indicates the atoms in the antibody or antibody fragment as well as the atoms in the backbone of a conjugate or linker-payload to which the illustrated chemical entity is bonded.

[0077] Spiro compounds depicted with overlapping rings indicate that the rings can bondat any vertex. For instance, in the spiro group, the two rings can bond at any of the three available vertex atoms in either ring.

[0078] When referring to the compounds provided herein, the following terms have the following meanings unless indicated otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art. In the event that there is a plurality of definitions for a term herein, those in this section prevail unless stated otherwise.

[0079] “Alkoxy” and “alkoxyl,” refer to the group –OR′′ where R′′ is alkyl or cycloalkyl. Alkoxy groups include, in certain embodiments, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, 1,2-dimethylbutoxy, and the like.

[0080] The term “alkoxyamine,” as used herein, refers to the group -alkylene-O-NH2, wherein alkylene is as defined herein. In some embodiments, alkoxyamine groups can react with aldehydes to form oxime residues. Examples of alkoxyamine groups include -CH2CH2-O-NH2, -CH2-O-NH2, and -O-NH2.

[0081] The term “alkyl,” as used herein, unless otherwise specified, refers to a saturated straight or branched hydrocarbon. In certain embodiments, the alkyl group is a primary, secondary, or tertiary hydrocarbon. In certain embodiments, the alkyl group includes one to ten carbon atoms (i.e., C1 to C10 alkyl). In certain embodiments, the alkyl is a lower alkyl, for example, C1-6alkyl, and the like. In certain embodiments, the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl, 3-methylpentyl, 2,2-dimethylbutyl, and 2,3- dimethylbutyl. In certain embodiments, “substituted alkyl” refers to an alkyl substituted with, for example, one, two, or three groups independently selected from a halogen (e.g., fluoro (F), chloro (Cl), bromo (Br), or iodo (I)), alkyl, -CN, -NO2, amido, -C(O)-, -C(S)-, ester, carbamate, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, dialkylamino, haloalkyl, hydroxyl, amino, alkylamino, and alkoxy. In some embodiments, alkyl is unsubstituted.

[0082] The term “alkylene,” as used herein, unless otherwise specified, refers to a divalent alkyl group, as defined herein. “Substituted alkylene” refers to an alkylene group substituted as described herein for alkyl. In some embodiments, alkylene is unsubstituted.

[0083] “Alkenyl” refers to an olefinically unsaturated hydrocarbon group, in certain embodiments, having up to about eleven carbon atoms or from two to six carbon atoms (e.g., “lower alkenyl”), which can be straight-chained or branched, and having at least one or from one to two sites of olefinic unsaturation. “Substituted alkenyl” refers to an alkenyl group substituted as described herein for alkyl.

[0084] “Alkenylene” refers to a divalent alkenyl as defined herein. Lower alkenylene is, for example, C2-C6-alkenylene.

[0085] “Alkynyl” refers to acetylenically unsaturated hydrocarbon groups, in certain embodiments, having up to about eleven carbon atoms or from two to six carbon atoms (e.g., “lower alkynyl”), which can be straight-chained or branched, and having at least one or from one to two sites of acetylenic unsaturation. Non-limiting examples of alkynyl groups include acetylene (-C≡CH), propargyl (-CH2C≡CH), and the like. “Substituted alkynyl” refers to an alkynyl group substituted as described herein for alkyl.

[0086] “Alkynylene” refers to a divalent alkynyl as defined herein. Lower alkynylene is, for example, C2-C6-alkynylene.

[0087] “Amino” refers to -NH2.

[0088] The term “alkylamino,” as used herein, and unless otherwise specified, refers to the group –NHR′′ where R′′ is, for example, C1-10alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-12carbocycle, 3- to 12-membered heterocycle, C1-10haloalkyl, and the like as defined herein. In certain embodiments, alkylamino is C1-6alkylamino.

[0089] The term “dialkylamino,” as used herein, and unless otherwise specified, refers to the group –NR′′R′′ where each R′′ is independently C1-10alkyl, as defined herein. In certain embodiments, dialkylamino is, for example, di-C1-6alkylamino, C2-10alkenyl, C2-10alkynyl, C3-12 carbocycle, 3- to 12-membered heterocycle, C1-10 haloalkyl, and the like.

[0090] The term “aryl,” as used herein, and unless otherwise specified, refers to phenyl, biphenyl, or naphthyl. The term includes both substituted and unsubstituted moieties. An aryl group can be substituted with any described moiety including, but not limited to, one or more moieties (e.g., in some embodiments one, two, or three moieties) selected from the group consisting of halogen (e.g., fluoro (F), chloro (Cl), bromo (Br), or iodo (I)), alkyl, haloalkyl, hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, and phosphonate, wherein each moiety is independently either unprotected, or protected as necessary, as would be appreciated by those skilled in the art (see, e.g., Greene, et al., Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991); and wherein the aryl in the arylamino and aryloxy substituents are not further substituted.

[0091] The term “arylamino,” as used herein, and unless otherwise specified, refers to an -NR′R′′ group where R′ is hydrogen or C1-C6-alkyl; and R′′ is aryl, as defined herein.

[0092] The term “arylene,” as used herein, and unless otherwise specified, refers to a divalent aryl group, as defined herein.

[0093] The term “aryloxy,” as used herein, and unless otherwise specified, refers to an -OR group where R is aryl, as defined herein.

[0094] “Alkarylene” refers to an arylene group, as defined herein, wherein the aryl ring is substituted with one or two alkyl groups. “Substituted alkarylene” refers to an alkarylene, as defined herein, where the arylene group is further substituted, as defined herein for aryl.

[0095] “Aralkylene” refers to a -CH2-arylene-, -arylene-CH2-, or -CH2-arylene-CH2- group, where arylene is as defined herein. “Substituted aralkylene” refers to an aralkylene, as defined herein, where the aralkylene group is substituted, as defined herein for aryl.

[0096] “Carboxyl” or “carboxy” refers to -C(O)OH or -COOH.

[0097] The term “cycloalkyl” as used herein, unless otherwise specified, refers to a saturated cyclic hydrocarbon. In certain embodiments, the cycloalkyl group may be saturated, and / or bridged, and / or non-bridged, and / or a fused bicyclic group and / or a spirocyclic bicyclic group. In certain embodiments, the cycloalkyl group includes three to ten carbon atoms (i.e., C3 to C10cycloalkyl). In some embodiments, the cycloalkyl has from three to fifteen carbons (C3-15), from three to ten carbons (C3-10), from three to seven carbons (C3-7), or from three to six carbons (C3-C6) (i.e., “lower cycloalkyl”). In certain embodiments, the cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexylmethyl, cycloheptyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, decalinyl, or adamantyl. Exemplary “cycloalkyl” or “carbocycles” include cyclopentyl, cyclohexyl, cyclohexenyl, adamantyl, phenyl, indanyl, and naphthyl. “Cycloalkyl” or “carbocycle” includes 3- to 10-membered monocyclic rings, 6- to 12- membered bicyclic rings, and 6- to 12-membered bridged rings. Each ring of a bicyclic cycloalkyl or carbocycle may be selected from saturated, unsaturated, and aromatic rings. A bicyclic cycloalkyl or carbocycle includes any combination of saturated, unsaturated and aromatic bicyclic rings, as valence permits. A bicyclic cycloalkyl or carbocycle includes any combination of ring sizes such as 4-5 fused ring systems, 5-5 fused ring systems, 5-6 fused ring systems, 6-6 fused ring systems, 5-7 fused ring systems, 6-7 fused ring systems, 5-8 fused ring systems, and 6-8 fused ring systems. Non-limiting examples of bridged bicyclic cycloalkyl or carbocycle groups include, but are not limited to, bicyclo[1.1.1]pentyl, bicyclo[2.1.1]hexyl, bicyclo[2.1.1]hexyl, bicyclo[3.1.1]heptyl, bicyclo[2.2.1]heptyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octyl, bicyclo[3.3.1]nonyl, bicyclo[3.3.2]decyl, and 2-oxabicyclo[2.2.2]octyl. Non-limiting examples of spirocyclic cycloalkyl or carbocycle groups include, but are not limited to, spiro[3.3]heptyl, spiro[3.4]octyl, spiro[3.5]nonyl, spiro[3.6]decyl, spiro[4.4]nonyl, spiro[4.5]decyl, spiro[5.5]undecyl, spiro[5.6]dodecyl, and spiro[5.7]tridecyl.

[0098] The term “bicyclic ring system” includes 6-12 (e.g., 8-12 or 9-, 10-, or 11-) membered structures that form two rings, wherein the two rings have at least one atom in common (e.g., two atoms in common). Bicyclic rings can be fused, bridged, or spirocyclic. Bicyclic ring systems include bicycloaliphatics (e.g., bicycloalkyl or bicycloalkenyl), bicycloheteroaliphatics, bicyclic aryls, and bicyclic heteroaryls.

[0099] The term “bridged bicyclic ring system” refers to a bicyclic heterocyclicalipahtic ring system or bicyclic cycloaliphatic ring system in which the rings are bridged. Examples of bridged bicyclic ring systems include, but are not limited to, adamantanyl, norbornanyl, bicyclo[1.1.1]pentyl, bicyclo[2.1.1]hexyl, bicyclo[2.1.1]hexyl, bicyclo[3.1.1]heptyl, bicyclo[2.2.1]heptyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octyl, bicyclo[3.3.1]nonyl,bicyclo[3.3.2]decyl, 2-oxabicyclo[2.2.2]octyl, 6-azabicyclo[3.1.1]heptyl, 6- azabicyclo[3.1.1]heptyl, 1-azabicyclo[2.2.1]heptyl, 2-azabicyclo[2.2.1]heptyl, 7- azabicyclo[2.2.1]heptyl, 1-azabicyclo[2.2.2]octyl, 3-azabicyclo[3.2.1]octyl, and 2- oxabicyclo[3.1.1]heptyl, 2,6-dioxa-tricyclo[3.3.1.03,7]nonyl. A bridged bicyclic ring system can be optionally substituted with one or more substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalkylalkyl)carbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycloalkyl)carbonylamino, (heterocycloalkylalkyl)carbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, cyano, halo, hydroxy, acyl, mercapto, alkylsulfanyl, sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, or carbamoyl.

[0100] The term “spiro bicyclic ring system” refers to a bicyclic heterocyclicalipahtic ring system or bicyclic cycloaliphatic ring system in which 2 or 3 rings are linked together by one common atom. Spiro compounds depicted with overlapping rings indicate that the rings canbond at any vertex. For instance, in the spiro group , the two rings can bond at any of the three available vertex atoms in either ring.

[0101] The term “cycloalkylene,” as used herein refers to a divalent cycloalkyl group, as defined herein. In certain embodiments, the cycloalkylene group is cyclopropylene, , cyclopentylene, cyclohexylene, cycloheptylene, a he like. Lower cycloalkylene refers to a C3-C6-cycloalkylene.

[0102] The term “cycloalkylalkyl,” as used herein, unless otherwise specified, refers to an alkyl group, as defined herein, substituted with one or two cycloalkyl, as defined herein.

[0103] The term “ester,” as used herein, refers to -C(O)OR or -COOR where R is alkyl, as defined herein.

[0104] The term “fluorene” as used herein refers to, wherein any one or more carbons bearing one or more hydrogens can be substituted with a chemical functional group as described herein.

[0105] The term “haloalkyl” refers to an alkyl group, as defined herein, substituted with one or more halogen atoms (e.g., in some embodiments one, two, three, four, or five) which are independently selected.

[0106] The term “heteroalkyl” refers to an alkyl, as defined herein, in which one or more carbon atoms are replaced by heteroatoms. As used herein, “heteroalkenyl” refers to an alkenyl, as defined herein, in which one or more carbon atoms are replaced by heteroatoms. As used herein, “heteroalkynyl” refers to an alkynyl, as defined herein, in which one or more carbon atoms are replaced by heteroatoms. Suitable heteroatoms include, but are not limited to, nitrogen (N), oxygen (O), and sulfur (S) atoms. Heteroalkyl, heteroalkenyl, and heteroalkynyl are optionally substituted. Examples of heteroalkyl moieties include, but are not limited to, aminoalkyl, sulfonylalkyl, and sulfinylalkyl. Examples of heteroalkyl moieties also include, but are not limited to, methylamino, methylsulfonyl, and methylsulfinyl. “Substituted heteroalkyl” refers to heteroalkyl substituted with one, two, or three groups independently selected from halogen (e.g., fluoro (F), chloro (Cl), bromo (Br), or iodo (I)), alkyl, haloalkyl, hydroxyl, amino, alkylamino, and alkoxy. In some embodiments, a heteroalkyl group may comprise one, two, three, or four heteroatoms. Those of skill in the art will recognize that a 4-membered heteroalkyl may generally comprise one or two heteroatoms, a 5- or 6-membered heteroalkyl may generally comprise one, two, or three heteroatoms, and a 7- to 10-membered heteroalkyl may generally comprise one, two, three, or four heteroatoms.

[0107] The term “heteroalkylene,” as used herein, refers to a divalent heteroalkyl, as defined herein. “Substituted heteroalkylene” refers to a divalent heteroalkyl, as defined herein, substituted as described for heteroalkyl.

[0108] The term “heterocycloalkyl” refers to a monovalent, monocyclic, or multicyclic non-aromatic ring system, wherein one or more of the ring atoms are heteroatoms independently selected from oxygen (O), sulfur (S), and nitrogen (N) (e.g., where the nitrogen or sulfur atoms may be optionally oxidized, and the nitrogen atoms may be optionally quaternized) and the remaining ring atoms of the non-aromatic ring are carbon atoms. In certain embodiments, heterocycloalkyl is a monovalent, monocyclic, or multicyclic fully-saturated ring system. In certain embodiments, the heterocycloalkyl group has from three to twenty, from three to fifteen,from three to ten, from three to eight, from four to seven, from four to eleven, or from five to six ring atoms. The heterocycloalkyl may be attached to a core structure at any heteroatom or carbon atom which results in the creation of a stable compound. In certain embodiments, the heterocycloalkyl is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include a fused, and / or bridged bicyclic group, and / or a spirocyclic bicyclic group ring system and in which the nitrogen or sulfur atoms may be optionally oxidized, and / or the nitrogen atoms may be optionally quaternized. In some embodiments, heterocycloalkyl radicals include, but are not limited to, 2,5-diazabicyclo[2.2.2]octanyl, decahydroisoquinolinyl, dihydrobenzisoxazinyl, dihydrofuryl, dihydroisoindolyl, dihydropyranyl, dihydropyrazolyl, dihydropyrazinyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dioxolanyl, 1,4-dithianyl, furanonyl, imidazolidinyl, imidazolinyl, indolinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, oxazolidinonyl, oxazolidinyl, oxiranyl, piperazinyl, piperidinyl, 4-piperidonyl, pyrazolidinyl, pyrazolinyl, pyrrolidinyl, pyrrolinyl, quinuclidinyl, tetrahydrofuryl, tetrahydroisoquinolinyl, tetrahydropyranyl, tetrahydrothienyl, thiamorpholinyl, thiazolidinyl, tetrahydroquinolinyl, and 1,3,5-trithianyl. In certain embodiments, heterocycloalkyl may also be optionally substituted as described herein. In certain embodiments, heterocycloalkyl is substituted with one, two, or three groups independently selected from halogen (e.g., fluoro (F), chloro (Cl), bromo (Br), or iodo (I)), alkyl, haloalkyl, hydroxyl, amino, alkylamino, and alkoxy. In some embodiments, a heterocycloalkyl group may comprise one, two, three, or four heteroatoms. Those of skill in the art will recognize that a 4-membered heterocycloalkyl may generally comprise one or two heteroatoms, a 5- or 6-membered heterocycloalkyl may generally comprise one, two, or three heteroatoms, and a 7- to 10- membered heterocycloalkyl may generally comprise one, two, three, or four heteroatoms. In some embodiments, “heterocycloalkyl” or “heterocycle” radicals include, but are not limited to, 2,5-diazabicyclo[2.2.2]octanyl, decahydroisoquinolinyl, dihydrobenzisoxazinyl, dihydrofuryl, dihydroisoindolyl, dihydropyranyl, dihydropyrazolyl, dihydropyrazinyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dioxolanyl, 1,4-dithianyl, furanonyl, imidazolidinyl, imidazolinyl, indolinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, oxazolidinonyl, oxazolidinyl, oxiranyl, piperazinyl, piperidinyl, 4- piperidonyl, pyrazolidinyl, pyrazolinyl, pyrrolidinyl, pyrrolinyl, quinuclidinyl, tetrahydrofuryl, tetrahydroisoquinolinyl, tetrahydropyranyl, tetrahydrothienyl, thiamorpholinyl, thiazolidinyl, tetrahydroquinolinyl, and 1,3,5-trithianyl. Non-limiting examples of bridged heterocycloalkyl or heterocycle groups include, but are not limited to, 6-azabicyclo[3.1.1]heptyl, 6- azabicyclo[3.1.1]heptyl, 1-azabicyclo[2.2.1]heptyl, 2-azabicyclo[2.2.1]heptyl, 7- azabicyclo[2.2.1]heptyl, 1-azabicyclo[2.2.2]octyl, 3-azabicyclo[3.2.1]octyl, and 2-oxabicyclo[3.1.1]heptyl, 2,6-dioxa-tricyclo[3.3.1.03,7]nonyl. Non-limiting examples of spirocyclic heterocycloalkyl or heterocycle groups include, but are not limited to, 2,8- diazaspiro[4.5]decyl; 2,7-diazaspiro[3.5]nonyl; 3,9-diazaspiro[5.5]undecyl; 3- azaspiro[5.5]undecyl; 2-oxa-6-azaspiro[3.4]octyl; 2-oxa-9-azaspiro[5.5]undecyl; 3-oxa-9- azaspiro[5.5]undecyl; 7-azaspiro[3.5]nonyl; 2-azaspiro[3.5]nonyl; 7-oxaspiro[3.5]nonyl; and, 2- oxaspiro[3.5]nonyl.

[0109] “Heterocycloalkylene” refers to a divalent heterocycloalkyl as defined herein.

[0110] The term “heteroaryl” refers to a monovalent, monocyclic aromatic group and / or multicyclic aromatic group, wherein at least one aromatic ring contains one or more heteroatoms independently selected from oxygen, sulfur, and nitrogen within the ring. Each ring of a heteroaryl group can contain one or two oxygen atoms, one or two sulfur atoms, and / or one to four nitrogen atoms, provided that the total number of heteroatoms in each ring is four or less and each ring contains at least one carbon atom. In certain embodiments, the heteroaryl has from five to twenty, from five to fifteen, or from five to ten ring atoms. A heteroaryl may be attached to the rest of the molecule via a nitrogen or a carbon atom. In some embodiments, monocyclic heteroaryl groups include, but are not limited to, furanyl, imidazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, triazolyl, thiadiazolyl, thiazolyl, thienyl, tetrazolyl, and triazinyl. Examples of bicyclic heteroaryl groups include, but are not limited to, benzofuranyl, benzimidazolyl, benzoisoxazolyl, benzopyranyl, benzothiadiazolyl, benzothiazolyl, benzothienyl, benzotriazolyl, benzoxazolyl, furopyridyl, imidazopyridinyl, imidazothiazolyl, indolizinyl, indolyl, indazolyl, isobenzofuranyl, isobenzothienyl, isoindolyl, isoquinolinyl, naphthyridinyl, oxazolopyridinyl, phthalazinyl, pteridinyl, purinyl, pyridopyridyl, pyrrolopyridyl, quinolinyl, quinoxalinyl, quinazolinyl, thiadiazolopyrimidyl, and thienopyridyl. Examples of tricyclic heteroaryl groups include, but are not limited to, acridinyl, benzindolyl, carbazolyl, dibenzofuranyl, perimidinyl, phenanthrolinyl, phenanthridinyl, phenarsazinyl, phenazinyl, phenothiazinyl, phenoxazinyl, and xanthenyl. In certain embodiments, heteroaryl may also be optionally substituted as described herein. “Substituted heteroaryl” is a heteroaryl substituted as defined for aryl.

[0111] The term “heteroarylene” refers to a divalent heteroaryl group, as defined herein. “Substituted heteroarylene” is a heteroarylene substituted as defined for aryl.

[0112] The term “protecting group,” as used herein, and unless otherwise specified, refers to a group that is added to an oxygen, nitrogen, or phosphorus atom to prevent further reaction at the (protected) oxygen, nitrogen, or phosphorus, or for other purposes. A wide variety of oxygen and nitrogen protecting groups are known to those skilled in the art of organicsynthesis (see, e.g., Greene, et al., Protective Groups in Organic Synthesis, John Wiley and Sons, Fourth Edition, 2006, which is incorporated herein by reference in its entirety).

[0113] “Pharmaceutically acceptable salt” refers to any salt of a compound provided herein which retains its biological properties and which is not toxic or otherwise undesirable for pharmaceutical use. Such salts may be derived from a variety of organic and inorganic counter- ions well known in the art. Such salts include, but are not limited to (1) acid addition salts formed with organic or inorganic acids such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, sulfamic, acetic, trifluoroacetic, trichloroacetic, propionic, hexanoic, cyclopentylpropionic, glycolic, glutaric, pyruvic, lactic, malonic, succinic, sorbic, ascorbic, malic, maleic, fumaric, tartaric, citric, benzoic, 3-(4-hydroxybenzoyl)benzoic, picric, cinnamic, mandelic, phthalic, lauric, methanesulfonic, ethanesulfonic, 1,2-ethane-disulfonic, 2-hydroxyethanesulfonic, benzenesulfonic, 4-chlorobenzenesulfonic, 2-naphthalenesulfonic, 4-toluenesulfonic, camphoric, camphorsulfonic, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic, glucoheptonic, 3- phenylpropionic, trimethylacetic, tert-butylacetic, lauryl sulfuric, gluconic, glutamic, hydroxynaphthoic, salicylic, stearic, cyclohexylsulfamic, quinic, and muconic acids, and the like; or (2) salts formed when an acidic proton present in the parent compound either (a) is replaced by a metal ion, for example, an alkali metal ion, an alkaline earth ion, or an aluminum ion, or alkali metal or alkaline earth metal hydroxides, such as sodium, potassium, calcium, magnesium, aluminum, lithium, zinc, and barium hydroxide, or ammonia; or (b) coordinates with an organic base, such as aliphatic, alicyclic, or aromatic organic amines, including, without limitation, ammonia, methylamine, dimethylamine, diethylamine, picoline, ethanolamine, diethanolamine, triethanolamine, ethylenediamine, lysine, arginine, ornithine, choline, N,N′- dibenzylethylene-diamine, chloroprocaine, procaine, N-benzylphenethylamine, N- methylglucamine piperazine, tris(hydroxymethyl)-aminomethane, tetramethylammonium hydroxide, and the like.

[0114] Pharmaceutically acceptable salts further include, by way of example and without limitation, sodium, potassium, calcium, magnesium, ammonium, and tetraalkylammonium salts, and the like, and when the compound contains a basic functionality, salts of non-toxic organic or inorganic acids, such as hydrohalides, for example, hydrochloride and hydrobromide, sulfate, phosphate, sulfamate, nitrate, acetate, trifluoroacetate, trichloroacetate, propionate, hexanoate, cyclopentylpropionate, glycolate, glutarate, pyruvate, lactate, malonate, succinate, sorbate, ascorbate, malate, maleate, fumarate, tartarate, citrate, benzoate, 3-(4-hydroxybenzoyl)benzoate, picrate, cinnamate, mandelate, phthalate, laurate, methanesulfonate (mesylate), ethanesulfonate, 1,2-ethane-disulfonate, 2-hydroxyethanesulfonate, benzenesulfonate (besylate), 4-chlorobenzenesulfonate, 2-naphthalenesulfonate, 4-toluenesulfonate, camphorate, camphorsulfonate, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylate, glucoheptonate, 3- phenylpropionate, trimethylacetate, tert-butylacetate, lauryl sulfate, gluconate, glutamate, hydroxynaphthoate, salicylate, stearate, cyclohexylsulfamate, quinate, muconate, and the like.

[0115] The term “substantially free of” or “substantially in the absence of” with respect to a composition refers to a composition that includes at least 85% or 90% by weight, in certain embodiments 95%, 98%, 99%, or 100% by weight; or in certain embodiments, 95%, 98%, 99%, or 100% of the designated enantiomer or diastereomer of a compound. In certain embodiments, in the methods and compounds provided herein, the compounds are substantially free of one of two enantiomers. In certain embodiments, in the methods and compounds provided herein, the compounds are substantially free of one of two diastereomers. In certain embodiments, in the methods and compounds provided herein, the compounds are substantially free of enantiomers (i.e., the compounds are not a racemic or 50:50 mixture of compounds).

[0116] Similarly, the term “isolated” with respect to a composition refers to a composition that includes at least 85%, 90%, 95%, 98%, or 99% to 100% by weight, of the compound, the remainder comprising other chemical species, enantiomers, or diastereomers.

[0117] “Solvate” refers to a compound provided herein, or a salt thereof, that further includes a stoichiometric or non-stoichiometric amount of solvent bound by non-covalent intermolecular forces. Where the solvent is water, the solvate is a hydrate.

[0118] “Isotopic composition” refers to the amount of each isotope present for a given atom, and “natural isotopic composition” refers to the naturally occurring isotopic composition or abundance for a given atom. Atoms containing their natural isotopic composition may also be referred to herein as “non-enriched” atoms. Unless otherwise designated, the atoms of the compounds recited herein are meant to represent any stable isotope of that atom. For example, unless otherwise stated, when a position is designated specifically as hydrogen (H), the position is understood to have hydrogen at its natural isotopic composition.

[0119] “Isotopic enrichment” refers to the percentage of incorporation of an amount of a specific isotope at a given atom in a molecule in the place of that atom’s natural isotopic abundance. For example, deuterium (D) enrichment of 1% at a given position means that 1% of the molecules in a given sample contain deuterium at the specified position. Because the naturally occurring distribution of deuterium is about 0.0156%, deuterium enrichment at any position in a compound synthesized using non-enriched starting materials is about 0.0156%. The isotopic enrichment of the compounds provided herein can be determined using conventionalanalytical methods known to one of ordinary skill in the art, including mass spectrometry and nuclear magnetic resonance spectroscopy.

[0120] “Isotopically enriched” refers to an atom having an isotopic composition other than the natural isotopic composition of that atom. “Isotopically enriched” may also refer to a compound containing at least one atom having an isotopic composition other than the natural isotopic composition of that atom.

[0121] As used herein, “alkyl,” “alkylene,” “alkylamino,” “dialkylamino,” “cycloalkyl,” “aryl,” “arylene,” “alkoxy,” “amino,” “carboxyl,” “heterocycloalkyl,” “heteroaryl,” “heteroarylene,” “carboxyl,” and “amino acid” groups optionally comprise deuterium (D) at one or more positions where hydrogen (H) atoms are present, and wherein the deuterium composition of the atom or atoms is other than the natural isotopic composition.

[0122] Also as used herein, “alkyl,” “alkylene,” “alkylamino,” “dialkylamino,” “cycloalkyl,” “aryl,” “arylene,” “alkoxy,” “amino,” “carboxyl,” “heterocycloalkyl,” “heteroaryl,” “heteroarylene,” “carboxyl,” and “amino acid” groups optionally comprise carbon- 13 (13C) at an amount other than the natural isotopic composition.

[0123] The term “macromolecule” or “macromolecular moiety” refers to a protein, peptide, antibody, nucleic acid, carbohydrate, or other large molecule composed of polymerized monomers. They include peptides of two or more residues, or ten or more residues. In certain embodiments, a macromolecule is at least 1000 Da in mass. In certain embodiments, a macromolecule has at least 1000 atoms. In certain embodiments, a macromolecule can be modified. For instance, a protein, peptide, or antibody can be modified with one or more carbohydrates and / or small molecule therapeutic compounds.

[0124] The term “amino acid” refers to the twenty common naturally occurring amino acids. Naturally occurring amino acids include alanine (Ala; A), arginine (Arg; R), asparagine (Asn; N), aspartic acid (Asp; D), cysteine (Cys; C); glutamic acid (Glu; E), glutamine (Gln; Q), Glycine (Gly; G); histidine (His; H), isoleucine (Ile; I), leucine (Leu; L), lysine (Lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y), and valine (Val; V) , and the less common pyrrolysine and selenocysteine. Natural amino acids also include citrulline. Naturally encoded amino acids include post-translational variants of the twenty-two naturally occurring amino acids such as prenylated amino acids, isoprenylated amino acids, myrisoylated amino acids, palmitoylated amino acids, N-linked glycosylated amino acids, O-linked glycosylated amino acids, phosphorylated amino acids, and acylated amino acids. The term “amino acid” also includesnon-natural (or unnatural) or synthetic ^-, ^-, ^-, or ^-amino acids, and includes, but is not limited to, amino acids found in proteins, i.e., glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartate, glutamate, lysine, arginine, and histidine. In certain embodiments, the amino acid is in the L-configuration. In certain embodiments, the amino acid is in the D- configuration. Alternatively, the amino acid can be a derivative of alanyl, valinyl, leucinyl, isoleucinyl, prolinyl, phenylalaninyl, tryptophanyl, methioninyl, glycinyl, serinyl, threoninyl, cysteinyl, tyrosinyl, asparaginyl, glutaminyl, aspartoyl, glutaroyl, lysinyl, argininyl, histidinyl, ^-alanyl, ^-valinyl, ^-leucinyl, ^-isoleucinyl, ^-prolinyl, ^-phenylalaninyl, ^-tryptophanyl, ^- methioninyl, ^-glycinyl, ^-serinyl, ^-threoninyl, ^-cysteinyl, ^-tyrosinyl, ^-asparaginyl, ^- glutaminyl, ^-aspartoyl, ^-glutaroyl, ^-lysinyl, ^-argininyl, or ^-histidinyl. Unnatural amino acids are not proteinogenic amino acids, or post-translationally modified variants thereof. In particular, the term unnatural amino acid refers to an amino acid that is not one of the twenty common amino acids or pyrrolysine or selenocysteine, or post-translationally modified variants thereof.

[0125] The term “conjugate” or “antibody conjugate” refers to a compound or drug moiety described herein linked to one or more macromolecular moieties. The macromolecular moiety is as defined herein or is any macromolecule deemed suitable to the person of skill in the art. The compound or drug moiety can be any compound or drug moiety described herein. The compound or drug moiety can be directly linked to the macromolecular moiety via a covalent bond, or the compound or drug moiety can be linked to the macromolecular moiety indirectly via a linker. Typically, the linker is covalently bonded to the macromolecular moiety and also covalently bonded to the compound or drug moiety.

[0126] “pAMF,” “pAMF residue,” or “pAMF mutation” refers to a variant phenylalanine residue (i.e., para-azidomethyl-L-phenylalanine) added or substituted into a polypeptide.

[0127] The term “linker” refers to a molecular moiety that is capable of forming at least two covalent bonds. Typically, a linker is capable of forming at least one covalent bond to a macromolecular moiety and at least another covalent bond to a compound or drug moiety. In certain embodiments, a linker can form more than one covalent bond to a macromolecular moiety. In certain embodiments, a linker can form more than one covalent bond to a compound or drug moiety or can form covalent bonds to more than one compound or drug moiety. After a linker forms a bond to a macromolecular moiety, or a compound or drug moiety, or both, the remaining structure (i.e. the residue of the linker (“linker residue”) after one or more covalent bonds are formed) may still be referred to as a “linker” herein. The term “linker precursor” refersto a linker having one or more reactive groups capable of forming a covalent bond with a macromolecule, or compound or drug moiety, or both. A person of ordinary skill in the art, given the context of how the term linker is used, would understand whether “linker” means linker precursor with one reactive group, a linker precursor with more than one reactive groups, a linker residue which is covalently bonded to the macromolecule, a linker residue which is covalently bonded to a compound or drug moiety, and / or a linker residue which is covalently bonded to the macromolecule and is covalently bonded to a compound or drug moiety. In some embodiments, the linker is a cleavable linker. For example, a cleavable linker can be one that is released by a bio-labile or enzymatic function, which may or may not be engineered. In some embodiments, the linker is a non-cleavable linker. For example, a non-cleavable linker can be one that is released upon degradation of the macromolecular moiety.

[0128] As used herein, term “EC50” refers to a dosage, concentration, or amount of a particular test compound that elicits a dose-dependent response at 50% of maximal expression of a particular response that is induced, provoked, or potentiated by the particular test compound.

[0129] As used herein, and unless otherwise specified, the term “IC50” refers to an amount, concentration, or dosage of a particular test compound that achieves a 50% inhibition of a maximal response in an assay that measures such response.

[0130] As used herein, the terms “subject” and “patient” are used interchangeably. The terms “subject” and “subjects” refer to an animal, such as a mammal including a non-primate (e.g., a cow, pig, horse, cat, dog, rat, mouse, camel, avian, goat, and sheep) and a primate (e.g., a monkey, such as a cynomolgous monkey, a chimpanzee, and a human), and in certain embodiments, a human. In certain embodiments, the subject is a farm animal (e.g., a horse, a cow, a pig, etc.) or a pet (e.g., a dog or a cat). In certain embodiments, the subject is a human. In some embodiments, the subject has a disease that can be treated or diagnosed with an antibody or antibody conjugate provided herein. In some embodiments, the disease is gastric carcinoma, colorectal carcinoma, renal cell carcinoma, cervical carcinoma, non-small cell lung carcinoma, ovarian cancer, breast cancer, triple-negative breast cancer, endometrial cancer, prostate cancer, and / or a cancer of epithelial origin.

[0131] As used herein, the terms “therapeutic agent” and “therapeutic agents” refer to any agent(s) which can be used in the treatment or prevention of a disorder or one or more symptoms thereof. In certain embodiments, the term “therapeutic agent” includes an antibody or antibody conjugate provided herein. In certain embodiments, a therapeutic agent is an agent which is known to be useful for, or has been or is currently being used for the treatment or prevention of a disorder or one or more symptoms thereof.

[0132] “Treating” or “treatment” of any disease or disorder refers, in certain embodiments, to ameliorating a disease or disorder that exists in a subject. In another embodiment, “treating” or “treatment” includes ameliorating at least one physical parameter, which may be indiscernible by the subject. In yet another embodiment, “treating” or “treatment” includes modulating the disease or disorder, either physically (e.g., stabilization of a discernible symptom) or physiologically (e.g., stabilization of a physical parameter) or both. In yet another embodiment, “treating” or “treatment” includes delaying or preventing the onset of the disease or disorder, or delaying or preventing recurrence of the disease or disorder. In yet another embodiment, “treating” or “treatment” includes the reduction or elimination of either the disease or disorder, or retarding the progression of the disease or disorder or of one or more symptoms of the disease or disorder, or reducing the severity of the disease or disorder or of one or more symptoms of the disease or disorder.

[0133] As used herein, the terms “prophylactic agent” and “prophylactic agents” as used refer to any agent(s) which can be used in the prevention of a disorder or one or more symptoms thereof. In certain embodiments, the term “prophylactic agent” includes a compound, drug moiety, or conjugate provided herein. In certain other embodiments, the term “prophylactic agent” does not refer a compound, drug moiety, or conjugate provided herein. For example, a prophylactic agent is an agent which is known to be useful for, or has been or is currently being used to prevent or impede the onset, development, progression, and / or severity of a disorder.

[0134] As used herein, the phrase “prophylactically effective amount” refers to the amount of a therapy (e.g., prophylactic agent) which is sufficient to result in the prevention or reduction of the development, recurrence, or onset of one or more symptoms associated with a disorder or to enhance or improve the prophylactic effect(s) of another therapy (e.g., another prophylactic agent).

[0135] In some chemical structures illustrated herein, certain substituents, chemical groups, and atoms are depicted with a curvy / wavy / wiggly line (e.g.,) that intersects a bond or bonds to indicate the atom through which the substituents, chemical groups, and atoms are bonded. For example, in some structures, such as but not limited to,, or, this curvy / wavy / wiggly line indicates the atoms in the backbone of a conjugate, compound, or drug moiety structure to which the illustrated chemical entity is bonded. In some structures, such as but not limited, this curvy / wavy / wiggly line indicates the atoms in the macromolecule as well as the atoms in the backbone of a conjugate, compound, or drug moiety structure to which the illustrated chemical entity is bonded.

[0136] As used herein, illustrations showing substituents bonded to a cyclic group (e.g., aromatic, heteroaromatic, fused ring, and saturated or unsaturated cycloalkyl or heterocycloalkyl) through a bond between ring atoms are meant to indicate, unless specified otherwise, that the cyclic group may be substituted with that substituent at any ring position in the cyclic group or on any ring in the fused ring group, according to techniques set forth herein or which are known in the field to which the instant disclosure pertains. For example, the group,, wherein subscript q is an integer from zero to four and in which the positions of substituent R1are described generically, i.e., not directly attached to any vertex of the bond line structure, i.e., specific ring carbon atom, includes the following, non-limiting examples of groups in which the substituent R1is bonded to a specific ring carbon atom:

[0137] The term “carbocycle” as used herein, unless otherwise specified, refers to a saturated, unsaturated, or aromatic ring in which atom of the ring is carbon. In certain embodiments, the carbocycle group may be saturated, and / or bridged, and / or non-bridged, and / or a fused bicyclic group, and / or a spirocyclic bicyclic group. In certain embodiments, the carbocycle group includes three to ten carbon atoms (i.e., C3 to C10 carbocycle). In some embodiments, the carbocycle has from three to fifteen carbons (C3-15), from three to ten carbons (C3-10), from three to seven carbons (C3-7), or from three to six carbons (C3-C6). In certain embodiments, the carbocycle group is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexylmethyl, cycloheptyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, decalinyl, or adamantyl.

[0138] The term “heterocycle” refers to a saturated, unsaturated or aromatic ring comprising one or more heteroatoms. Exemplary heteroatoms include N, O, Si, P, B, and S atoms where the nitrogen or sulfur atoms may be optionally oxidized, and the nitrogen atoms may be optionally quaternized and the remaining ring atoms of the non-aromatic ring are carbon atoms. Heterocycles include 3- to 10-membered monocyclic rings, 6- to 12-membered bicyclic rings, and 6- to 12-membered bridged rings. In certain embodiments, heterocycle is a monovalent, monocyclic, or multicyclic fully-saturated ring system. In certain embodiments, the heterocycloalkyl or “heterocycle” group may be unsaturated, and / or bridged, and / or non- bridged, and / or a fused bicyclic group, and / or a spirocyclic bicyclic group.

[0139] The term “site-specific” refers to a modification of a polypeptide at a predetermined sequence location in the polypeptide. The modification is at a single, predictable residue of the polypeptide with little or no variation. In particular embodiments, a modified amino acid is introduced at that sequence location, for instance recombinantly or synthetically. Similarly, a moiety can be “site-specifically” linked to a residue at a particular sequence location in the polypeptide. In certain embodiments, a polypeptide can comprise more than one site- specific modification.

[0140] As used herein, the term “therapeutically effective amount” or “effective amount” refers to an amount of an antibody, antibody conjugate, or composition that when administered to a subject is effective to treat a disease or disorder. In some embodiments, a therapeutically effective amount or effective amount refers to an amount of an antibody, antibody conjugate, or composition that when administered to a subject is effective to prevent or ameliorate a disease or the progression of the disease, or result in amelioration of symptoms. A “therapeutically effective amount” can vary depending on, inter alia, the compound, the disease or disorder and its severity, and the age, weight, etc., of the subject to be treated.

[0141] As used herein, the term “subject” means a mammalian subject. Exemplary subjects include, but are not limited to humans, monkeys, dogs, cats, mice, rats, cows, horses, camels, avians, goats, and sheep. In certain embodiments, the subject is a human. In some embodiments, the subject has a disease that can be treated or diagnosed with an antibody provided herein. In some embodiments, the disease is gastric carcinoma, colorectal carcinoma, renal cell carcinoma, cervical carcinoma, non-small cell lung carcinoma, ovarian cancer, prostate cancer, and / or a cancer of epithelial origin. 2. Antibodies and Antibody Specificity

[0142] The present disclosure provides antibodies as described here that selectively bind to TF. Provided herein are antibodies that selectively bind human TF. In some aspects, the antibody selectively binds to the extracellular domain of human TF.

[0143] Also provided herein are conjugates that comprise antibodies that selectively bind human TF. In some aspects, the antibody of the conjugate selectively binds to the extracellular domain of human TF.

[0144] In some embodiments, the antibody binds to a homolog of human TF. In some aspects, the antibody binds to a homolog of human TF from a species selected from monkeys, mice, dogs, cats, rats, cows, horses, goats and sheep. In some aspects, the homolog is a cynomolgus monkey homolog.

[0145] In some embodiments, the antibody has one or more CDRs having particular lengths, in terms of the number of amino acid residues. In some embodiments, the Chothia CDR- H1 of the antibody is 6, 7, or 8 residues in length. In some embodiments, the Kabat CDR-H1 of the antibody is 4, 5, or 6 residues in length. In some embodiments, the Chothia CDR-H2 of the antibody is 5, 6, or 7 residues in length. In some embodiments, the Kabat CDR-H2 of the antibody is 16, 17, or 18 residues in length. In some embodiments, the Kabat / Chothia CDR-H3 of the antibody is 7, 8, 9, 10, 11, 12, or 13 residues in length.

[0146] In some aspects, the Kabat / Chothia CDR-L1 of the antibody is 10, 11, 12, 13, 14, 15, or 16 residues in length. In some aspects, the Kabat / Chothia CDR-L2 of the antibody is 6, 7, or 8 residues in length. In some aspects, the Kabat / Chothia CDR-L3 of the antibody is 8, 9, or 10 residues in length.

[0147] In some embodiments, the antibody comprises a light chain. In some aspects, the light chain is a kappa light chain. In some aspects, the light chain is a lambda light chain.

[0148] In some embodiments, the antibody comprises a heavy chain. In some aspects, the heavy chain is an IgA. In some aspects, the heavy chain is an IgD. In some aspects, the heavy chain is an IgE. In some aspects, the heavy chain is an IgG. In some aspects, the heavy chain is an IgM. In some aspects, the heavy chain is an IgG1. In some aspects, the heavy chain is an IgG2. In some aspects, the heavy chain is an IgG3. In some aspects, the heavy chain is an IgG4. In some aspects, the heavy chain is an IgA1. In some aspects, the heavy chain is an IgA2.

[0149] In some embodiments, the antibody is an antibody fragment. In some aspects, the antibody fragment is an Fv fragment. In some aspects, the antibody fragment is a Fab fragment. In some aspects, the antibody fragment is a F(ab’)2fragment. In some aspects, the antibody fragment is a Fab’ fragment. In some aspects, the antibody fragment is an scFv (sFv) fragment. In some aspects, the antibody fragment is an scFv-Fc fragment.

[0150] In some embodiments, the scFv-Fc fragment comprises a constant region wherein the constant region comprises SEQ ID NO: 3068. The constant region in SEQ ID NO: 3068 differs from the human IgG1 constant region of SEQ ID NO: 3062 in several respects. First, the sequence in SEQ ID NO: 3068 comprises the linker AAGSDQEPKSS (SEQ ID NO: 3071). SEQ ID NO: 3068 also does not comprise the CH1 domain of the IgG1 constant region. SEQ ID NO: 3068 further comprises a C220S (EU numbering system) mutation, which removes an unpaired cysteine reside that is not needed when the light chain constant region is not present (e.g., in an scFv-Fc format). SEQ ID NO: 3068 further comprises two, optional, P to S mutations (P230S and P238S by the EU numbering system). Either or both of these serine residues can be reverted to the naturally occurring proline residues. Finally, SEQ ID NO: 3068 comprises an aspartic acid (D) residue at EU position 356 and a leucine (L) residue at EU position 358. In contrast, SEQ ID NO: 3062 comprises glutamic acid (E) in EU position 356 and methionine (M) in EU position 358. In some embodiments, the antibodies provided herein comprise constant regions comprising D356 / L358, E356 / M358, D356 / M358, or E356 / L358 (EU numbering). However, a skilled person will recognize that the antibodies provide herein may comprise any suitable constant region and that the constant region sequences provided herein are for illustrative purposes.

[0151] In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is a polyclonal antibody.

[0152] In some embodiments, the antibody is a chimeric antibody. In some embodiments, the antibody is a humanized antibody. In some embodiments, the antibody is a human antibody.

[0153] In some embodiments, the antibody is an affinity matured antibody. In some aspects, the antibody is an affinity matured antibody derived from an illustrative sequence provided in this disclosure.

[0154] The antibodies provided herein may be useful for the treatment of a variety of diseases and conditions including cancers. In some embodiments, the antibodies provided herein may be useful for the treatment of cancers of solid tumors. For example, the antibodies provided herein can be useful for the treatment of colorectal cancer. 2.2 VH Sequences Comprising Illustrative CDRs

[0155] In some embodiments, the antibody comprises a VH sequence comprising one or more CDR-H sequences comprising, consisting of, or consisting essentially of one or more illustrative CDR-H sequences provided in this disclosure, and variants thereof. In some embodiments, the CDR-H sequences comprise, consist of, or consist essentially of one or more CDR-H sequences provided in a VHsequence selected from SEQ ID NOs: 2625-2949. 2.2.1. VH Sequences Comprising Illustrative Kabat CDRs

[0156] In some embodiments, the antibody comprises a VH sequence comprising one or more Kabat CDR-H sequences comprising, consisting of, or consisting essentially of one or more illustrative Kabat CDR-H sequences provided in this disclosure, and variants thereof. 2.2.1.1. Kabat CDR-H1 + Kabat CDR-H2 + Kabat CDR-H3

[0157] In some embodiments, the antibody comprises a VH sequence comprising a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 430, 439, 442, 454-541, 543, 549, 554, 560, 562, and 563, a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 1080, 1089, 1092, 1104-1191, 1193, 1199, 1204, 1200, 1212, and 1213, and a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 1730, 1739, 1742, 1754-1841, 1843, 1849, 1854, 1860, 1862, and 1863. In some aspects, the Kabat CDR-H1 sequence, Kabat CDR-H2 sequence, and Kabat CDR-H3 sequence are all from a single illustrative VHsequence provided in this disclosure. For example,in some aspects, the Kabat CDR-H1, Kabat CDR-H2, and Kabat CDR-H3 are all from a single illustrative VHsequence selected from SEQ ID NOs: 2727, 2736, 2739, 2751-2838, 2840, 2846, 2851, 2857, 2859, and 2860. 2.2.1.2. Variants of VH Sequences Comprising Illustrative Kabat CDRs

[0158] In some embodiments, the VHsequences provided herein comprise a variant of an illustrative Kabat CDR-H3, CDR-H2, and / or CDR-H1 sequence provided in this disclosure.

[0159] In some aspects, the Kabat CDR-H3 sequence comprises, consists of, or consists essentially of a variant of an illustrative Kabat CDR-H3 sequence provided in this disclosure. In some aspects, the Kabat CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Kabat CDR-H3 sequences provided in this disclosure. In some aspects, the Kabat CDR-H3 sequence comprises, consists of, or consists essentially of any of the illustrative Kabat CDR-H3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.

[0160] In some aspects, the Kabat CDR-H2 sequence comprises, consists of, or consists essentially of a variant of an illustrative Kabat CDR-H2 sequence provided in this disclosure. In some aspects, the Kabat CDR-H2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Kabat CDR-H2 sequences provided in this disclosure. In some aspects, the Kabat CDR-H2 sequence comprises, consists of, or consists essentially of any of the illustrative Kabat CDR-H2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.

[0161] In some aspects, the Kabat CDR-H1 sequence comprises, consists of, or consists essentially of a variant of an illustrative Kabat CDR-H1 sequence provided in this disclosure. In some aspects, the Kabat CDR-H1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Kabat CDR-H1 sequences provided in this disclosure. In some aspects, the Kabat CDR-H1 sequence comprises, consists of, or consists essentially of any of the illustrative Kabat CDR-H1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.2.2.2. VHSequences Comprising Illustrative Chothia CDRs

[0162] In some embodiments, the antibody comprises a VHsequence comprising one or more Chothia CDR-H sequences comprising, consisting of, or consisting essentially of one or more illustrative Chothia CDR-H sequences provided in this disclosure, and variants thereof. 2.2.2.1. Chothia CDR-H1 + Chothia CDR-H2 + Chothia CDR-H3

[0163] In some embodiments, the antibody comprises a VH sequence comprising a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 105, 114, 117, 129-216, 218, 224, 229, 235, 237, and 238, a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 755, 764, 767, 779-866, 868, 874, 879, 885, 887, and 888, and a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 1405, 1414, 1417, 1429-1516, 1518, 1524, 1529, 1535, 1537, and 1538. In some aspects, the Chothia CDR-H1 sequence, Chothia CDR-H2 sequence, and Chothia CDR- H3 sequence are all from a single illustrative VH sequence provided in this disclosure. For example, in some aspects, the Chothia CDR-H1, Chothia CDR-H2, and Chothia CDR-H3 are all from a single illustrative VH sequence selected from SEQ ID NOs: 2727, 2736, 2739, 2751- 2838, 2840, 2846, 2851, 2857, 2859, and 2860. 2.2.2.2. Variants of VHSequences Comprising Illustrative Chothia CDRs

[0164] In some embodiments, the VH sequences provided herein comprise a variant of an illustrative Chothia CDR-H3, CDR-H2, and / or CDR-H1 sequence provided in this disclosure.

[0165] In some aspects, the Chothia CDR-H3 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia CDR-H3 sequence provided in this disclosure. In some aspects, the Chothia CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Chothia CDR-H3 sequences provided in this disclosure. In some aspects, the Chothia CDR-H3 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia CDR-H3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.

[0166] In some aspects, the Chothia CDR-H2 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia CDR-H2 sequence provided in this disclosure. In some aspects, the Chothia CDR-H2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or99% identity with any of the illustrative Chothia CDR-H2 sequences provided in this disclosure. In some aspects, the Chothia CDR-H2 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia CDR-H2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.

[0167] In some aspects, the Chothia CDR-H1 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia CDR-H1 sequence provided in this disclosure. In some aspects, the Chothia CDR-H1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Chothia CDR-H1 sequences provided in this disclosure. In some aspects, the Chothia CDR-H1 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia CDR-H1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. 2.3. VHSequences

[0168] In some embodiments, the antibody comprises, consists of, or consists essentially of a VH sequence of an scFv sequence provided in SEQ ID NOs: 3073 and 3079. In some embodiments, the antibody comprises, consists of, or consists essentially of a VHsequence provided in SEQ ID NOs.: 2727, 2736, 2739, 2751-2838, 2840, 2846, 2851, 2857, 2859, and 2860.

[0169] In some embodiments, the antibody comprises a VHsequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 2727, 2736, 2739, 2751-2838, 2840, 2846, 2851, 2857, 2859, and 2860.

[0170] In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2727. In some aspects, the antibody comprises a VHsequence comprising, consisting of, or consisting essentially of SEQ ID NO:2736. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2739.

[0171] In some aspects, the antibody comprises a VHsequence comprising, consisting of, or consisting essentially of SEQ ID NO:2751. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2752. In some aspects, the antibody comprises a VHsequence comprising, consisting of, or consisting essentially of SEQ ID NO:2753. In some aspects, the antibody comprises a VH sequencecomprising, consisting of, or consisting essentially of SEQ ID NO:2754. In some aspects, the antibody comprises a VHsequence comprising, consisting of, or consisting essentially of SEQ ID NO:2755. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2756. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2757. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2758. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2759. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2760. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2761. In some aspects, the antibody comprises a VHsequence comprising, consisting of, or consisting essentially of SEQ ID NO:2762. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2763. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2764. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2765. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2766. In some aspects, the antibody comprises a VHsequence comprising, consisting of, or consisting essentially of SEQ ID NO:2767. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2768. In some aspects, the antibody comprises a VHsequence comprising, consisting of, or consisting essentially of SEQ ID NO:2769. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2770. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2771. In some aspects, the antibody comprises a VHsequence comprising, consisting of, or consisting essentially of SEQ ID NO:2772. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2773. In some aspects, the antibody comprises a VHsequence comprising, consisting of, or consisting essentially of SEQ ID NO:2774. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2775. In some aspects, the antibody comprises a VHsequence comprising, consisting of, or consisting essentially of SEQ ID NO:2776. In some aspects, the antibody comprises a VHsequence comprising, consisting of, or consisting essentially of SEQ ID NO:2777. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2778. In some aspects, the antibody comprises a VHsequencecomprising, consisting of, or consisting essentially of SEQ ID NO:2779. In some aspects, the antibody comprises a VHsequence comprising, consisting of, or consisting essentially of SEQ ID NO:2780. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2781. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2782. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2783. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2784. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2785. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2786. In some aspects, the antibody comprises a VHsequence comprising, consisting of, or consisting essentially of SEQ ID NO:2787. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2788. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2789. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2790. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2791. In some aspects, the antibody comprises a VHsequence comprising, consisting of, or consisting essentially of SEQ ID NO:2792. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2793. In some aspects, the antibody comprises a VHsequence comprising, consisting of, or consisting essentially of SEQ ID NO:2794. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2795. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2796. In some aspects, the antibody comprises a VHsequence comprising, consisting of, or consisting essentially of SEQ ID NO:2797. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2798. In some aspects, the antibody comprises a VHsequence comprising, consisting of, or consisting essentially of SEQ ID NO:2799. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2800. In some aspects, the antibody comprises a VHsequence comprising, consisting of, or consisting essentially of SEQ ID NO:2801. In some aspects, the antibody comprises a VHsequence comprising, consisting of, or consisting essentially of SEQ ID NO:2802. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2803. In some aspects, the antibody comprises a VHsequencecomprising, consisting of, or consisting essentially of SEQ ID NO:2804. In some aspects, the antibody comprises a VHsequence comprising, consisting of, or consisting essentially of SEQ ID NO:2805. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2806. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2807. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2808. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2809. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2810. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2811. In some aspects, the antibody comprises a VHsequence comprising, consisting of, or consisting essentially of SEQ ID NO:2812. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2813. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2814. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2815. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2816. In some aspects, the antibody comprises a VHsequence comprising, consisting of, or consisting essentially of SEQ ID NO:2817. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2818. In some aspects, the antibody comprises a VHsequence comprising, consisting of, or consisting essentially of SEQ ID NO:2819. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2820. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2821. In some aspects, the antibody comprises a VHsequence comprising, consisting of, or consisting essentially of SEQ ID NO:2822. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2823. In some aspects, the antibody comprises a VHsequence comprising, consisting of, or consisting essentially of SEQ ID NO:2824.

[0172] In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2825. In some aspects, the antibody comprises a VHsequence comprising, consisting of, or consisting essentially of SEQ ID NO:2826. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2827. In some aspects, the antibody comprises a VH sequencecomprising, consisting of, or consisting essentially of SEQ ID NO:2828. In some aspects, the antibody comprises a VHsequence comprising, consisting of, or consisting essentially of SEQ ID NO:2829. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2830. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2831. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2832. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2833. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2834. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2835. In some aspects, the antibody comprises a VHsequence comprising, consisting of, or consisting essentially of SEQ ID NO:2836. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2837. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2838.

[0173] In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2840. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2846. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2851. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2857. In some aspects, the antibody comprises a VHsequence comprising, consisting of, or consisting essentially of SEQ ID NO:2859. In some aspects, the antibody comprises a VH sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2860. 2.3.1. Variants of VHSequences

[0174] In some embodiments, the VH sequences provided herein comprise, consist of, or consist essentially of a variant of an illustrative VH sequence provided in this disclosure.

[0175] In some aspects, the VHsequence comprises, consists of, or consists essentially of a variant of an illustrative VHsequence provided in this disclosure. In some aspects, the VHsequence comprises, consists of, or consists essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identity with any of the illustrative VHsequences provided in this disclosure.

[0176] In some embodiments, the VHsequence comprises, consists of, or consists essentially of any of the illustrative VHsequences provided in this disclosure having 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. 2.4. VL Sequences Comprising Illustrative CDRs

[0177] In some embodiments, the antibody comprises a VLsequence comprising one or more CDR-L sequences comprising, consisting of, or consisting essentially of one or more illustrative CDR-L sequences provided in this disclosure, and variants thereof. 2.4.1. VLSequences Comprising Illustrative Kabat CDRs

[0178] In some embodiments, the antibody comprises a VLsequence comprising one or more Kabat CDR-L sequences comprising, consisting of, or consisting essentially of one or more illustrative Kabat CDR-L sequences provided in this disclosure, and variants thereof. 2.4.1.1. Kabat CDR-L1 + Kabat CDR-L2 + Kabat CDR-L3

[0179] In some embodiments, the antibody comprises a VL sequence comprising a Kabat CDR-L1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 2066, 2072, 2077, 2083, 2085, 2086, and 2176, a Kabat CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 2290, 2296, 2301, 2307, 2309, 2310, and 2400, and a Kabat CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 2514, 2520, 2525, 2531, 2533, 2534, and 2624. In some aspects, the Kabat CDR-L1 sequence, Kabat CDR- L2 sequence, and Kabat CDR-L3 sequence are all from a single illustrative VL sequence provided in this disclosure. For example, in some aspects, the Kabat CDR-L1, Kabat CDR-L2, and Kabat CDR-L3 are all from a single illustrative VLsequence selected from SEQ ID NOs: 2951, 2957, 2962, 2968, 2970, 2971, and 3061. 2.4.1.2. Variants of VL Sequences Comprising Illustrative Kabat CDRs

[0180] In some embodiments, the VLsequences provided herein comprise a variant of an illustrative Kabat CDR-L3, CDR-L2, and / or CDR-L1 sequence provided in this disclosure.

[0181] In some aspects, the Kabat CDR-L3 sequence comprises, consists of, or consists essentially of a variant of an illustrative Kabat CDR-L3 sequence provided in this disclosure. In some aspects, the Kabat CDR-L3 sequence comprises, consists of, or consists essentially of asequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Kabat CDR-L3 sequences provided in this disclosure. In some aspects, the Kabat CDR-L3 sequence comprises, consists of, or consists essentially of any of the illustrative Kabat CDR-L3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.

[0182] In some aspects, the Kabat CDR-L2 sequence comprises, consists of, or consists essentially of a variant of an illustrative Kabat CDR-L2 sequence provided in this disclosure. In some aspects, the Kabat CDR-L2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Kabat CDR-L2 sequences provided in this disclosure. In some aspects, the Kabat CDR-L2 sequence comprises, consists of, or consists essentially of any of the illustrative Kabat CDR-L2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.

[0183] In some aspects, the Kabat CDR-L1 sequence comprises, consists of, or consists essentially of a variant of an illustrative Kabat CDR-L1 sequence provided in this disclosure. In some aspects, the Kabat CDR-L1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Kabat CDR-L1 sequences provided in this disclosure. In some aspects, the Kabat CDR-L1 sequence comprises, consists of, or consists essentially of any of the illustrative Kabat CDR-L1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. 2.4.2. VLSequences Comprising Illustrative Chothia CDRs

[0184] In some embodiments, the antibody comprises a VL sequence comprising one or more Chothia CDR-L sequences comprising, consisting of, or consisting essentially of one or more illustrative Chothia CDR-L sequences provided in this disclosure, and variants thereof. 2.4.2.1. Chothia CDR-L1 + Chothia CDR-L2 + Chothia CDR-L3

[0185] In some embodiments, the antibody comprises a VL sequence comprising a Chothia CDR-L1 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 1954, 1960, 1965, 1971, 1973, 1974 and 2064, a Chothia CDR-L2 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQID NOs: 2178, 2184, 2189, 2195, 2197, 2198, and 2288, and a Chothia CDR-L3 sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 2402, 2408, 2413, 2419, 2421, 2422, and 2512. In some aspects, the Chothia CDR-L1 sequence, Chothia CDR-L2 sequence, and Chothia CDR-L3 sequence are all from a single illustrative VLsequence provided in this disclosure. For example, in some aspects, the Chothia CDR-L1, Chothia CDR-L2, and Chothia CDR-L3 are all from a single illustrative VL sequence selected from SEQ ID NOs: 2951, 2957, 2962, 2968, 2970, 2971, and 3061. 2.4.2.2. Variants of VLSequences Comprising Illustrative Chothia CDRs

[0186] In some embodiments, the VH sequences provided herein comprise a variant of an illustrative Chothia CDR-L3, CDR-L2, and / or CDR-L1 sequence provided in this disclosure.

[0187] In some aspects, the Chothia CDR-L3 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia CDR-L3 sequence provided in this disclosure. In some aspects, the Chothia CDR-L3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Chothia CDR-L3 sequences provided in this disclosure. In some aspects, the Chothia CDR-L3 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia CDR-L3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.

[0188] In some aspects, the Chothia CDR-L2 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia CDR-L2 sequence provided in this disclosure. In some aspects, the Chothia CDR-L2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Chothia CDR-L2 sequences provided in this disclosure. In some aspects, the Chothia CDR-L2 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia CDR-L2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.

[0189] In some aspects, the Chothia CDR-L1 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia CDR-L1 sequence provided in this disclosure. In some aspects, the Chothia CDR-L1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Chothia CDR-L1 sequences provided in this disclosure.In some aspects, the Chothia CDR-L1 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia CDR-L1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. 2.5. VLSequences

[0190] In some embodiments, the antibody comprises, consists of, or consists essentially of a VL sequence of an scFv sequence provided in SEQ ID NOs.: 3073 and 3079. In some embodiments, the antibody comprises, consists of, or consists essentially of a VLsequence provided in SEQ ID NOs.: 2951, 2957, 2962, 2968, 2970, 2971, and 3061.

[0191] In some embodiments, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of a sequence selected from SEQ ID NOs: 2951, 2957, 2962, 2968, 2970, 2971, and 3061.

[0192] In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2951. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2957. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2962. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2968. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2970. In some aspects, the antibody comprises a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NO:2971. In some aspects, the antibody comprises a VLsequence comprising, consisting of, or consisting essentially of SEQ ID NO:3061. 2.5.1. Variants of VL Sequences

[0193] In some embodiments, the VL sequences provided herein comprise, consist of, or consist essentially of a variant of an illustrative VLsequence provided in this disclosure.

[0194] In some aspects, the VL sequence comprises, consists of, or consists essentially of a variant of an illustrative VL sequence provided in this disclosure. In some aspects, the VL sequence comprises, consists of, or consists essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identity with any of the illustrative VLsequences provided in this disclosure.

[0195] In some embodiments, the VLsequence comprises, consists of, or consists essentially of any of the illustrative VLsequences provided in this disclosure having 20 or fewer,19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. 2.6. Pairs 2.6.1. VH – VL Pairs

[0196] In some embodiments, the antibody comprises a VH sequence and a VL sequence.

[0197] In some aspects, the VHsequence is a VHsequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 2727, 2736, 2739, 2751-2838, 2840, 2846, 2851, 2857, 2859, and 2860, and the VL sequence is a VL sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 2951, 2957, 2962, 2968, 2970, 2971, and 3061.

[0198] In some embodiments, the antibody comprises a VH / VLpair together comprising, consisting of, or consisting essentially of the sequences of any pair selected from the group consisting of SEQ ID NOs: 2727 / 3061, 2736 / 3061, 2739 / 3061, 2751 / 3061, 2752 / 3061, 2753 / 3061, 2754 / 3061, 2755 / 3061, 2756 / 3061, 2757 / 3061, 2758 / 3061, 2759 / 3061, 2760 / 3061, 2761 / 3061, 2762 / 3061, 2763 / 3061, 2764 / 3061, 2765 / 3061, 2766 / 3061, 2767 / 3061, 2768 / 3061, 2769 / 3061, 2770 / 3061, 2771 / 3061, 2772 / 3061, 2773 / 3061, 2774 / 3061, 2775 / 3061, 2776 / 3061, 2777 / 3061, 2778 / 3061, 2779 / 3061, 2780 / 3061, 2781 / 3061, 2782 / 3061, 2783 / 3061, 2784 / 3061, 2785 / 3061, 2786 / 3061, 2787 / 3061, 2788 / 3061, 2789 / 3061, 2790 / 3061, 2791 / 3061, 2792 / 3061, 2793 / 3061, 2794 / 3061, 2795 / 3061, 2796 / 3061, 2797 / 3061, 2798 / 3061, 2799 / 3061, 2800 / 3061, 2801 / 3061, 2802 / 3061, 2803 / 3061, 2804 / 3061, 2805 / 3061, 2806 / 3061, 2807 / 3061, 2808 / 3061, 2809 / 3061, 2810 / 3061, 2811 / 3061, 2812 / 3061, 2813 / 3061, 2814 / 3061, 2815 / 3061, 2816 / 3061, 2817 / 3061, 2818 / 3061, 2819 / 3061, 2820 / 3061, 2821 / 3061, 2822 / 3061, 2823 / 3061, 2824 / 3061, 2825 / 3061, 2826 / 3061, 2827 / 3061, 2828 / 3061, 2829 / 3061, 2830 / 3061, 2831 / 3061, 2832 / 3061, 2833 / 3061, 2834 / 3061, 2835 / 3061, 2836 / 3061, 2837 / 3061, 2838 / 3061, 2840 / 2951, 2846 / 2957, 2851 / 2962, 2857 / 2968, 2859 / 2970, and 2860 / 2971.

[0199] In some aspects, the antibody comprises a VH / VL pair together comprising, consisting of, or consisting essentially of the sequences of any pair as shown in the Table 5 below: Table 5. VH / VL pairs.2.6.1.1. Variants of VH– VLPairs

[0200] In some embodiments, the VH – VL pairs provided herein comprise a variant of an illustrative VHand / or VLsequence provided in this disclosure.

[0201] In some aspects, the VHsequence comprises, consists of, or consists essentially of a variant of an illustrative VH sequence provided in this disclosure. In some aspects, the VH sequence comprises, consists of, or consists essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identity with any of the illustrative VHsequences provided in this disclosure.

[0202] In some embodiments, the VH sequence comprises, consists of, or consists essentially of any of the illustrative VHsequences provided in this disclosure having 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.

[0203] In some aspects, the VL sequence comprises, consists of, or consists essentially of a variant of an illustrative VL sequence provided in this disclosure. In some aspects, the VL sequence comprises, consists of, or consists essentially of a sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identity with any of the illustrative VL sequences provided in this disclosure.

[0204] In some embodiments, the VLsequence comprises, consists of, or consists essentially of any of the illustrative VLsequences provided in this disclosure having 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 orfewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. 2.7. Antibodies Comprising All Six CDRs

[0205] In some embodiments, the antibody comprises a CDR-H1 sequence, a CDR-H2 sequence, a CDR-H3 sequence, a CDR-L1 sequence, and a CDR-L3 sequence. In some aspects, the CDR sequences are part of a VH (for CDR-H) or VL (for CDR-L).

[0206] In some aspects, the CDR-H1 sequence is a Chothia CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 105, 114, 117, 129-216, 218, 224, 229, 235, 237, and 238; the CDR-H2 sequence is a Chothia CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 755, 764, 767, 779-866, 868, 874, 879, 885, 887, and 888; the CDR-H3 sequence is a Chothia CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 1405, 1414, 1417, 1429- 1516, 1518, 1524, 1529, 1535, 1537, and 1538; the CDR-L1 sequence is a Chothia CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 1954, 1960, 1965, 1971, 1973, 1974 and 2064; the CDR-L2 sequence is a Chothia CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 2178, 2184, 2189, 2195, 2197, 2198, and 2288; and the CDR-L3 sequence is a Chothia CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 2402, 2408, 2413, 2419, 2421, 2422, and 2512.

[0207] In some aspects, the CDR-H1 sequence is a Kabat CDR-H1 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 430, 439, 442, 454-541, 543, 549, 554, 560, 562, and 563; the CDR-H2 sequence is a Kabat CDR-H2 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 1080, 1089, 1092, 1104-1191, 1193, 1199, 1204, 1200, 1212, and 1213; the CDR-H3 sequence is a Kabat CDR-H3 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 1730, 1739, 1742, 1754-1841, 1843, 1849, 1854, 1860, 1862, and 1863; the CDR-L1 sequence is a Kabat CDR-L1 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 2066, 2072, 2077, 2083, 2085, 2086, and 2176; the CDR-L2 sequence is a Kabat CDR-L2 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 2290, 2296, 2301, 2307, 2309, 2310, and 2400; and the CDR-L3 sequence is a Kabat CDR-L3 sequence comprising, consisting of, or consisting essentially of SEQ ID NOs: 2514, 2520, 2525, 2531, 2533, 2534, and 2624.

[0208] In some aspects, the antibody comprises three heavy chain CDRs from a VHsequence selected from SEQ ID NOs: 2727, 2736, 2739, 2751-2838, 2840, 2846, 2851, 2857,2859, and 2860, or variants thereof, and three light chain CDRs from a VLsequence selected from SEQ ID NOs: 2951, 2957, 2962, 2968, 2970, 2971, and 3061, or variants thereof. The CDRs can be according to any CDR scheme known to the person of skill. In certain embodiments, the CDRs are Kabat CDRs. In certain embodiments, the CDRs are Chothia CDRs.

[0209] In some embodiments, the antibody comprises three heavy chain CDRs, or variants thereof, and three light chain CDRs, or variants thereof, from a VH / VL pair selected from the group consisting of the group consisting of SEQ ID NOs: 2727 / 3061, 2736 / 3061, 2739 / 3061, 2751 / 3061, 2752 / 3061, 2753 / 3061, 2754 / 3061, 2755 / 3061, 2756 / 3061, 2757 / 3061, 2758 / 3061, 2759 / 3061, 2760 / 3061, 2761 / 3061, 2762 / 3061, 2763 / 3061, 2764 / 3061, 2765 / 3061, 2766 / 3061, 2767 / 3061, 2768 / 3061, 2769 / 3061, 2770 / 3061, 2771 / 3061, 2772 / 3061, 2773 / 3061, 2774 / 3061, 2775 / 3061, 2776 / 3061, 2777 / 3061, 2778 / 3061, 2779 / 3061, 2780 / 3061, 2781 / 3061, 2782 / 3061, 2783 / 3061, 2784 / 3061, 2785 / 3061, 2786 / 3061, 2787 / 3061, 2788 / 3061, 2789 / 3061, 2790 / 3061, 2791 / 3061, 2792 / 3061, 2793 / 3061, 2794 / 3061, 2795 / 3061, 2796 / 3061, 2797 / 3061, 2798 / 3061, 2799 / 3061, 2800 / 3061, 2801 / 3061, 2802 / 3061, 2803 / 3061, 2804 / 3061, 2805 / 3061, 2806 / 3061, 2807 / 3061, 2808 / 3061, 2809 / 3061, 2810 / 3061, 2811 / 3061, 2812 / 3061, 2813 / 3061, 2814 / 3061, 2815 / 3061, 2816 / 3061, 2817 / 3061, 2818 / 3061, 2819 / 3061, 2820 / 3061, 2821 / 3061, 2822 / 3061, 2823 / 3061, 2824 / 3061, 2825 / 3061, 2826 / 3061, 2827 / 3061, 2828 / 3061, 2829 / 3061, 2830 / 3061, 2831 / 3061, 2832 / 3061, 2833 / 3061, 2834 / 3061, 2835 / 3061, 2836 / 3061, 2837 / 3061, 2838 / 3061, 2840 / 2951, 2846 / 2957, 2851 / 2962, 2857 / 2968, 2859 / 2970, and 2860 / 2971.

[0210] In some embodiments, the antibody comprises three heavy chain CDRs, or variants thereof, and three light chain CDRs, or variants thereof, from a VH / VLpair selected from the group consisting of the group consisting of SEQ ID NOs: 2727 / 3061, 2736 / 3061, and 2739 / 3061. In some embodiments, the antibody comprises three heavy chain CDRs, or variants thereof, and three light chain CDRs, or variants thereof, from the VH / VL pair of SEQ ID NOs: 2752 / 3061.

[0211] The CDRs can be according to any CDR scheme known to the person of skill. In certain embodiments, the CDRs are Kabat CDRs. In certain embodiments, the CDRs are Chothia CDRs. In certain embodiments, the antibody further comprises the framework regions of the VH / VLpair. 2.7.1. Variants of Antibodies Comprising All Six CDRs

[0212] In some embodiments, the CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 provided herein comprise a variant of an illustrative CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and / or CDR-L3 sequence provided in this disclosure.

[0213] In some aspects, the CDR-H1 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia or Kabat CDR-H1 sequence provided in this disclosure. In some aspects, the CDR-H1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Chothia or Kabat CDR-H1 sequences provided in this disclosure. In some aspects, the CDR-H1 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia or Kabat CDR-H1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.

[0214] In some aspects, the CDR-H2 sequence comprises, consists of, or consists essentially of a variant of an illustrative Chothia or Kabat CDR-H2 sequence provided in this disclosure. In some aspects, the CDR-H2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative Chothia or Kabat CDR-H2 sequences provided in this disclosure. In some aspects, the CDR-H2 sequence comprises, consists of, or consists essentially of any of the illustrative Chothia or Kabat CDR-H2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.

[0215] In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-H3 sequence provided in this disclosure. In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative CDR-H3 sequences provided in this disclosure. In some aspects, the CDR-H3 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-H3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.

[0216] In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L1 sequence provided in this disclosure. In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative CDR-L1 sequences provided in this disclosure. In some aspects, the CDR-L1 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L1 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.

[0217] In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L2 sequence provided in this disclosure. In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative CDR-L2 sequences provided in this disclosure. In some aspects, the CDR-L2 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L2 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions.

[0218] In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a variant of an illustrative CDR-L3 sequence provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with any of the illustrative CDR-L3 sequences provided in this disclosure. In some aspects, the CDR-L3 sequence comprises, consists of, or consists essentially of any of the illustrative CDR-L3 sequences provided in this disclosure, with 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. 3. Conjugates

[0219] Provided herein are conjugates of antibodies to TF. The conjugates comprise an antibody to TF covalently linked directly or indirectly, via a linker, to a payload. In some embodiments, the conjugate comprises an antibody that specifically binds to TF linked site- specifically to at least one payload moiety, and the antibody comprises one or more non-natural amino acids. In certain embodiments, the antibody is linked to one payload. In further embodiments, the antibody is linked to more than one payload. In certain embodiments, the antibody is linked to two, three, four, five, six, seven, eight, nine, ten, or more payloads.

[0220] The payload can be any payload deemed useful by the practitioner of skill. In certain embodiments, the payload is a therapeutic moiety. In certain embodiments, the payload is a diagnostic moiety, e.g., a label. Useful payloads are described in the sections and examples below.

[0221] The linker can be any linker capable of forming at least one bond to the antibody and at least one bond to a payload. Useful linkers are described the sections and examples below.

[0222] In the conjugates provided herein, the antibody can be any antibody with binding specificity for TF. The TF can be from any species. In certain embodiments, the TF is a vertebrate TF. In certain embodiments, the TF is a mammalian TF. In certain embodiments, the TF ishuman TF. In certain embodiments, the TF is mouse TF. In certain embodiments, the TF is cynomolgus TF.

[0223] In certain embodiments, the antibody to TF competes with an antibody described herein for binding. In certain embodiments, the antibody to TF binds to the same epitope as an antibody described herein.

[0224] The antibody is typically a protein comprising multiple polypeptide chains. In certain embodiments, the antibody is a heterotetramer comprising two identical light (L) chains and two identical heavy (H) chains. Each light chain can be linked to a heavy chain by one covalent disulfide bond. Each heavy chain can be linked to the other heavy chain by one or more covalent disulfide bonds. Each heavy chain and each light chain can also have one or more intrachain disulfide bonds. As is known to those of skill in the art, each heavy chain typically comprises a variable domain (VH) followed by a number of constant domains. Each light chain typically comprises a variable domain at one end (VL) and a constant domain. As is known to those of skill in the art, antibodies typically have selective affinity for their target molecules, i.e., antigens.

[0225] The antibodies provided herein can have any antibody form known to those of skill in the art. They can be full-length, or fragments. Exemplary full-length antibodies include IgA, IgA1, IgA2, IgD, IgE, IgG, IgG1, IgG2, IgG3, IgG4, IgM, etc. Exemplary fragments include Fv, Fab, Fc, scFv, scFv-Fc, and etc.

[0226] In certain embodiments, the antibody of the conjugate comprises one, two, three, four, five, or six of the CDR sequences described herein. In certain embodiments, the antibody of the conjugate comprises a heavy chain variable domain (VH) described herein. In certain embodiments, the antibody of the conjugate comprises a light chain variable domain (VL) described herein. In certain embodiments, the antibody of the conjugate comprises a heavy chain variable domain (VH) described herein and a light chain variable domain (VL) described herein. In certain embodiments, the antibody of the conjugate comprises a paired heavy chain variable domain and a light chain variable domain described herein (VH - VL pair). In certain embodiments, the antibody of the conjugate comprises a heavy chain (HC) described herein. In certain embodiments, the antibody of the conjugate comprises a light chain (LC) described herein. In certain embodiments, the antibody of the conjugate comprises a heavy chain (HC) described herein and a light chain (LC) described herein. In certain embodiments, the antibody of the conjugate comprises a paired heavy chain and a light chain described herein (HC - LC pair). In certain embodiments, the antibody of the conjugate comprises a heavy chain (HC) described herein. In certain embodiments, the antibody of the conjugate comprises a light chain(LC) described herein. In certain embodiments, the antibody of the conjugate comprises a heavy chain (HC) described herein and a light chain (LC) described herein. In certain embodiments, the antibody of the conjugate comprises a paired heavy chain and a light chain described herein (HC - LC pair).

[0227] In certain embodiments, the antibody of the conjugate comprises any of the amino acid sequences of the antibodies described above. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 10 amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 9 amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 8 amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 7 amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 6 amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 5 amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 4 amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 3 amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 2 amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 1 conservative amino acid substitution. In some embodiments, the amino acid substitutions are conservative amino acid substitutions. For example, in certain embodiments, the antibody comprises any of the amino acid sequences above with up to 10 conservative amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 9 conservative amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 8 conservative amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 7 conservative amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 6 conservative amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 5 conservative amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 4 conservative amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 3 conservative amino acid substitutions. In certain embodiments, the antibody comprises any of the amino acid sequences above with up to 2 conservative amino acid substitutions. In certainembodiments, the antibody comprises any of the amino acid sequences above with up to 1 conservative amino acid substitution.

[0228] In certain embodiments, the antibody conjugate can be formed from an antibody that comprises one or more reactive groups. In certain embodiments, the antibody conjugate can be formed from an antibody comprising all naturally encoded amino acids. Those of skill in the art will recognize that several naturally encoded amino acids include reactive groups capable of conjugation to a payload or to a linker. These reactive groups include cysteine side chains, lysine side chains, and amino-terminal groups. In these embodiments, the antibody conjugate can comprise a payload or linker linked to the residue of an antibody reactive group. In these embodiments, the payload precursor or linker precursor comprises a reactive group capable of forming a bond with an antibody reactive group. Typical reactive groups include maleimide groups, activated carbonates (including but not limited to, p-nitrophenyl ester), activated esters (including but not limited to, N-hydroxysuccinimide, p-nitrophenyl ester, and aldehydes). Particularly useful reactive groups include maleimide and succinimide, for instance N- hydroxysuccinimide, for forming bonds to cysteine and lysine side chains. Additional reactive groups include alkynes, for example strained alkynes, and azides, for forming bonds to non- natural amino acids incorporated in antibody polypeptide chains. Further reactive groups are described in the sections and examples below.

[0229] In certain embodiments, the antibody comprises one or more modified amino acids having a reactive group, as described herein. Typically, the modified amino acid is not a naturally encoded amino acid. These modified amino acids can comprise a reactive group useful for forming a covalent bond to a linker precursor or to a payload precursor. One of skill in the art can use the reactive group to link the polypeptide to any molecular entity capable of forming a covalent bond to the modified amino acid. Thus, provided herein are conjugates comprising an antibody comprising a modified amino acid residue linked to a payload directly or indirectly via a linker. Exemplary modified amino acids are described in the sections below. Generally, the modified amino acids have reactive groups capable of forming bonds to linkers or payloads with complementary reactive groups.

[0230] The non-natural amino acids are positioned at select locations in a polypeptide chain of the antibody. These locations were identified as providing optimum sites for substitution with the non-natural amino acids. Each site is capable of bearing a non-natural amino acid with optimum structure, function and / or methods for producing the antibody.

[0231] In certain embodiments, a site-specific position for substitution provides an antibody that is stable. Stability can be measured by any technique apparent to those of skill in the art.

[0232] In certain embodiments, a site-specific position for substitution provides an antibody that has optimal functional properties. For instance, the antibody can show little or no loss of binding affinity for its target antigen compared to an antibody without the site-specific non-natural amino acid. In certain embodiments, the antibody can show enhanced binding compared to an antibody without the site-specific non-natural amino acid.

[0233] In certain embodiments, a site-specific position for substitution provides an antibody that can be made advantageously. For instance, in certain embodiments, the antibody shows advantageous properties in its methods of synthesis, discussed below. In certain embodiments, the antibody can show little or no loss in yield in production compared to an antibody without the site-specific non-natural amino acid. In certain embodiments, the antibody can show enhanced yield in production compared to an antibody without the site-specific non- natural amino acid. In certain embodiments, the antibody can show little or no loss of tRNA suppression compared to an antibody without the site-specific non-natural amino acid. In certain embodiments, the antibody can show enhanced tRNA suppression in production compared to an antibody without the site-specific non-natural amino acid.

[0234] In certain embodiments, a site-specific position for substitution provides an antibody that has advantageous solubility. In certain embodiments, the antibody can show little or no loss in solubility compared to an antibody without the site-specific non-natural amino acid. In certain embodiments, the antibody can show enhanced solubility compared to an antibody without the site-specific non-natural amino acid.

[0235] In certain embodiments, a site-specific position for substitution provides an antibody that has advantageous expression. In certain embodiments, the antibody can show little or no loss in expression compared to an antibody without the site-specific non-natural amino acid. In certain embodiments, the antibody can show enhanced expression compared to an antibody without the site-specific non-natural amino acid.

[0236] In certain embodiments, a site-specific position for substitution provides an antibody that has advantageous folding. In certain embodiments, the antibody can show little or no loss in proper folding compared to an antibody without the site-specific non-natural amino acid. In certain embodiments, the antibody can show enhanced folding compared to an antibody without the site-specific non-natural amino acid.

[0237] In certain embodiments, a site-specific position for substitution provides an antibody that is capable of advantageous conjugation. As described below, several non-natural amino acids have side chains or functional groups that facilitate conjugation of the antibody to a second agent, either directly or via a linker. In certain embodiments, the antibody can show enhanced conjugation efficiency compared to an antibody without the same or other non-natural amino acids at other positions. In certain embodiments, the antibody can show enhanced conjugation yield compared to an antibody without the same or other non-natural amino acids at other positions. In certain embodiments, the antibody can show enhanced conjugation specificity compared to an antibody without the same or other non-natural amino acids at other positions.

[0238] The one or more non-natural amino acids are located at selected site-specific positions in at least one polypeptide chain of the antibody. The polypeptide chain can be any polypeptide chain of the antibody without limitation, including either light chain or either heavy chain. The site-specific position can be in any domain of the antibody, including any variable domain and any constant domain.

[0239] In certain embodiments, the antibodies provided herein comprise one non-natural amino acid at a site-specific position. In certain embodiments, the antibodies provided herein comprise two non-natural amino acids at site-specific positions. In certain embodiments, the antibodies provided herein comprise three non-natural amino acids at site-specific positions. In certain embodiments, the antibodies provided herein comprise more than three non-natural amino acids at site-specific positions. In certain embodiments, the antibodies provided herein comprise four non-natural amino acids at site-specific positions.

[0240] In certain embodiments, the antibodies provided herein comprise one or more non-natural amino acids each at a position selected from the group consisting of heavy chain or light chain residues HC-F404, HC-K121, HC-Y180, HC-F241, HC-221, HC-Y391, LC-T22, LC-S7, LC-N152, LC-K42, LC-E161, LC-D170, HC-S136, HC-S25, HC-A40, HC-S119, HC- S190, HC-K222, HC-R19, HC-Y52, or HC-S70 according to the Kabat or Chothia or EU numbering scheme, or a post-translationally modified variant thereof. In certain embodiments, the antibodies provided herein comprise one or more non-natural amino acids each at a position selected from the group consisting of heavy chain or light chain residues HC-F404, HC-Y180, HC-F241, HC-Y391, LC-K42, and LC-E161, according to the Kabat or Chothia or EU numbering scheme, or a post-translationally modified variant thereof. In certain embodiments, the antibodies provided herein comprise one or more non-natural amino acids each at a position selected from the group consisting of heavy chain or light chain residues HC-F404, HC-Y180, LC-K42, and LC-E161, according to the Kabat or Chothia or EU numbering scheme, or a post-translationally modified variant thereof. In certain embodiments, the antibodies provided herein comprise one or more non-natural amino acids each at a position selected from the group consisting of heavy chain or light chain residues HC-F404, HC-Y180, HC-Y391, HC-F241, and LC-K42, according to the Kabat or Chothia or EU numbering scheme, or a post-translationally modified variant thereof. In certain embodiments, the antibodies provided herein comprise a non-natural amino acid at position HC-F404 according to the Kabat or Chothia or EU numbering scheme, or a post-translationally modified variant thereof. In certain embodiments, the antibodies provided herein comprise a non-natural amino acid at position HC-Y180, according to the Kabat or Chothia or EU numbering scheme, or a post-translationally modified variant thereof. In certain embodiments, the antibodies provided herein comprise non-natural amino acids at positions HC-F404 and HC-Y180, according to the Kabat or Chothia or EU numbering scheme, or a post-translationally modified variant thereof. In certain embodiments, the antibodies provided herein comprise a non-natural amino acid at position HC-F241 according to the Kabat or Chothia or EU numbering scheme, or a post-translationally modified variant thereof. In certain embodiments, the antibodies provided herein comprise a non-natural amino acid at position LC-K42 according to the Kabat or Chothia or EU numbering scheme, or a post- translationally modified variant thereof. In certain embodiments, the antibodies provided herein comprise a non-natural amino acid at position LC-E161 according to the Kabat or Chothia or EU numbering scheme, or a post-translationally modified variant thereof. In certain embodiments, the antibodies provided herein comprise non-natural amino acids at positions HC- F404, HC-Y180, and LC-K42, according to the Kabat or Chothia or EU numbering scheme, or a post-translationally modified variant thereof. In certain embodiments, the antibodies provided herein comprise non-natural amino acids at positions HC-F404, HC-Y180, LC-K42, and LC- E161, according to the Kabat or Chothia or EU numbering scheme, or a post-translationally modified variant thereof. In certain embodiments, the antibodies provided herein comprise non- natural amino acids at positions HC-F404, HC-Y180, and HC-F241, according to the Kabat or Chothia or EU numbering scheme, or a post-translationally modified variant thereof. In certain embodiments, the antibodies provided herein comprise non-natural amino acids at positions HC- F404, HC-Y180, HC-F241, and LC-K42, according to the Kabat or Chothia or EU numbering scheme, or a post-translationally modified variant thereof. In certain embodiments, the antibodies provided herein comprise non-natural amino acids at positions HC-F404, HC-Y180, HC-F241, and LC-K42, according to the Kabat or Chothia or EU numbering scheme, or a post- translationally modified variant thereof. In certain embodiments, the antibodies provided herein comprise non-natural amino acids at positions HC-F241 and HC-F404, according to the Kabat or Chothia or EU numbering scheme, or a post-translationally modified variant thereof. In certainembodiments, the antibodies provided herein comprise non-natural amino acids at positions HC- Y180, HC-F404, LC-K42 and LC-E161, according to the Kabat or Chothia or EU numbering scheme, or a post-translationally modified variant thereof. In certain embodiments, the antibodies provided herein comprise non-natural amino acids at positions HC-Y180, HC-F241, HC-F404 and HC-Y391, according to the Kabat or Chothia or EU numbering scheme, or a post- translationally modified variant thereof. In these designations, HC indicates a heavy chain residue, and LC indicates a light chain residue.

[0241] In some aspects, the present disclosure provides antibody conjugates according to the following formula:or a pharmaceutically acceptable salt, solvate, stereoisomer, regioisomer, or tautomer thereof, wherein: COMP is a residue of an anti-Tissue Factor antibody; i. PAY is a payload moiety; ii. LINK is a linker; and iii. n2 is an integer from 1 to 10, iv. wherein COMP comprises one or more non-natural amino acids.

[0242] In certain embodiments, provided herein are conjugates according to Formula (C1) or (C2):(C2) or a pharmaceutically acceptable salt, solvate, stereoisomer, regioisomer, or tautomer thereof, wherein: COMP is a residue of an anti-Tissue Factor antibody; PAY is a payload moiety; W1, W2, W3, W4, and W5are each independently a single bond, absent, or a divalent attaching group; EG is absent, or an eliminator group;each RT is a release trigger group, in the backbone of Formula (C1) or (C2) or bonded to EG, wherein each RT is optional; HP is a single bond, absent, or a divalent hydrophilic group; each SG is a single bond, absent, or a divalent spacer group; R is hydrogen, a terminal conjugating group, or a divalent residue of a terminal conjugating group; and n2 is an integer from 1 to 10.

[0243] In some embodiments, a conjugate according to Formula (C1) or (C2) comprises n2 number of linked PAY moieties, wherein n2 is an integer from 1 to 10. In some embodiments, n2 is 2. In some embodiments, n2 is 3. In some embodiments, n2 is 4. In some embodiments, n2 is 5. In some embodiments, n2 is 6. In some embodiments, n2 is 7. In some embodiments, n2 is 8. In some embodiments, n2 is 10. 1. Attaching Groups

[0244] Attaching groups facilitate incorporation of eliminator groups, release trigger groups, hydrophobic groups, spacer groups, and / or conjugating groups into a compound. Useful attaching groups are known to, and are apparent to, those of skill in the art. Examples of useful attaching groups are provided herein. In certain embodiments, attaching groups are designated W1, W2, W3, W4, or W5. In certain embodiments, an attaching group can comprise a divalent ketone, divalent ester, divalent ether, divalent amide, divalent amine, alkylene, arylene, sulfide, disulfide, carbonylene, or a combination thereof. In certain embodiments an attaching group can comprise –C(O)–, –O–, –C(O)NH–, –C(O)NH-alkyl–, –OC(O)NH–, –SC(O)NH–, –NH–, –NH-alkyl–, –N(CH3)CH2CH2N(CH3)–, –S–, –S-S–, –OCH2CH2O–, or the reverse (e.g. –NHC(O)–) thereof, or a combination thereof. 2. Eliminator Groups

[0245] Eliminator groups facilitate separation of a biologically active portion of a compound or conjugate described herein from the remainder of the compound or conjugate in vivo and / or in vitro. Eliminator groups can also facilitate separation of a biologically active portion of a compound or conjugate described herein in conjunction with a release trigger group. For example, the eliminator group and the release trigger group can react in a Releasing Reaction to release a biologically active portion of a compound or conjugate described herein from the compound or conjugate in vivo and / or in vitro. Upon initiation of the Releasing Reaction by the release trigger, the eliminator group cleaves the biologically active moiety, or a prodrug form ofthe biologically active moiety, and forms a stable, non-toxic entity that has no further effect on the activity of the biologically active moiety.

[0246] In certain embodiments, the eliminator group is designated EG herein. Useful eliminator groups include those described herein. In certain embodiments, the eliminator group is:wherein REGis selected from the group consisting of hydrogen, alkyl, biphenyl, -CF3, -NO2, - CN, fluoro, bromo, chloro, alkoxyl, alkylamino, dialkylamino, alkyl-C(O)O-, alkylamino-C(O)- and dialkylaminoC(O)-. In each structure, the phenyl ring can be bound to one, two, three, or in some cases, four REGgroups. In the second and third structures, those of skill will recognize that EG is bonded to an RT that is not within the backbone of formula (C1) as indicated in the above description of formula (C1). In some embodiments, REGis selected from the group consisting of hydrogen, alkyl, biphenyl, -CF3, alkoxyl, alkylamino, dialkylamino, alkyl-C(O)O-, alkylamino- C(O)- and dialkylaminoC(O)-. In further embodiments, REGis selected from the group consisting of hydrogen, -NO2, -CN, fluoro, bromo, and chloro. In certain embodiments, the eliminator. ce a e o e s, e e a o g oup s.

[0247] In some embodiments, provided herein is a conjugate according to Formula (C1) or (C2) or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein EG comprises phenylene, carboxylene, amine, or a combination thereof. In some embodiments, the eliminator group is:, wherein Z may be CH or N, REGis selected from the group consisting of hydrogen, alkyl, biphenyl, -CF3, -NO2, -CN, fluoro, bromo, chloro, alkoxyl, alkylamino, dialkylamino, alkyl- C(O)O-, alkylamino-C(O)- and dialkylaminoC(O)-. In each structure, the phenyl ring can be bound to one, two, three, or in some cases, four REGgroups. In the first and second structures,those of skill will recognize that EG is bonded to an RT that is not within the backbone of formula (C1) as indicated in the above description of formula (C1). In some embodiments, REGis selected from the group consisting of hydrogen, alkyl, biphenyl, -CF3, alkoxyl, alkylamino, dialkylamino, alkyl-C(O)O-, alkylamino-C(O)- and dialkylaminoC(O)-. In further embodiments, REGis selected from the group consisting of hydrogen, -NO2, -CN, fluoro, bromo, and chloro. In some embodiments, each REGin the EG is hydrogen. In certain embodiments, the eliminator group is. 3. Release Trigger Groups

[0248] Release trigger groups facilitate separation of a biologically active portion of a compound or conjugate described herein from the remainder of the compound or conjugate in vivo and / or in vitro. Release trigger groups can also facilitate separation of a biologically active portion of a compound or conjugate described herein in conjunction with an eliminator group. For example, the eliminator group and the release trigger group can react in a Releasing Reaction to release a biologically active portion of a compound or conjugate described herein from the compound or conjugate in vivo and / or in vitro. In certain embodiments, the release trigger can act through a biologically-driven reaction with high tumor:nontumor specificity, such as the proteolytic action of an enzyme overexpressed in a tumor environment.

[0249] In certain embodiments, the release trigger group is designated RT herein. In certain embodiments, RT is divalent and bonded within the backbone of formula (C1). In other embodiments, RT is monovalent and bonded to EG as depicted above. Useful release trigger groups include those described herein. In certain embodiments, the release trigger group comprises a residue of a natural or non-natural amino acid or residue of a sugar ring. In certain embodiments, the release trigger group is:. Those skilled in the art will recognize that the first structure is divalent and can be bonded within the backbone of Formula (C1) or as depicted in Formula (C2), and that the second structure is monovalent and can be bonded to EG as depicted in formula (C1) above. In certain embodiments, the release trigger group i. certain embodiments, the release trigger group.

[0250] In some embodiments, the release trigger group is a protease-cleavable R1-Val- X peptide having the structure of:wherein(CH2)3NHCONH2; a legumain-cleavable Ala-Ala-Asn or Ala-Ala-Asp peptide having the structure of:where Z is OH or NH2; or a ^-glucuronidase-cleavable ^-glucuronide having the structure of:or a Val-Lys-Gly peptide having the structure of:monovalent and can be bonded to EG as depicted in formula (C1) above.

[0251] In certain embodiments, the release trigger is selected from the group consisting of Val-Lys-Gly, Val-Ala-Asp, Ala-Ala-Ala, Val-Lys, Gly-Gly-Gly, Val-Ala, Gly-Gly-Phe-Gly, Val-Cit, Val-Cit, Val-Glu, Ala-Ala-Asn, and Gly. In certain embodiments, the release trigger further comprises a non-natural amino acid. In certain embodiments, the non-natural amino acidis accordingpolymer, for instance a hydrophilic polymer. In certain embodiments, the non-natural amino acid is according tis an integer from 1 to 25, for instance 8, 9, 10, 11, 12, 13, 14, 15, 20, or 25. 4. Hydrophilic Groups

[0252] Hydrophilic groups facilitate increasing the hydrophilicity of the compounds described herein. It is believed that increased hydrophilicity allows for greater solubility in aqueous solutions, such as aqueous solutions found in biological systems. Hydrophilic groups can also function as spacer groups, which are described in further detail herein.

[0253] In certain embodiments, the hydrophilic group is designated HP herein. Useful hydrophilic groups include those described herein. In certain embodiments, the hydrophilic group is a divalent poly(ethylene glycol). In certain embodiments, the hydrophilic group is a divalent poly(ethylene glycol) according to the formula:wherein m1 is an integer from 1 to 13, optionally 1 to 4, optionally 2 to 4, or optionally 4 to 8. In certain embodiments, m1 is 4. In certain embodiments, m1 is 12. In certain embodiments, m1 is 13.

[0254] In some embodiments, the hydrophilic group is a divalent poly(ethylene glycol) having the following formula:.

[0255] In some other embodiments, the hydrophilic group is a divalent poly(ethylene glycol) having the following formula:.

[0256] In other embodiments, the hydrophilic group is a divalent poly(ethylene glycol) having the following formula:.

[0257] In other embodiments, the hydrophilic group is a divalent poly(ethylene glycol) having the following formula:.

[0258] In some embodiments, the hydrophilic group is sulfonic acid. In some embodiments, the hydrophilic group is the side chain of cysteic acid. In some embodiments, the hydrophilic group can bear a chain-presented sulfonic acid having the formula:. (a) In certain embodiments, the hydrophilic group is the side chain of a non- natural amino acid according tinteger from 1 to 25, for instance 8, 9, 10, 11, 12, 13, 14, 15, 20, or 25. 5. Spacer Groups

[0259] Spacer groups facilitate spacing of the conjugating group from the other groups of the compounds described herein. This spacing can lead to more efficient conjugation of the compounds described herein to an antibody as well as more efficient cleavage of the active catabolite. The spacer group can also stabilize the conjugating group and lead to improved overall antibody-drug conjugate properties.

[0260] In certain embodiments, the spacer group is designated SP herein. Useful spacer groups include those described herein. In certain embodiments, the spacer group is:In certain embodiments, the spacer group, W4, and the hydrophilic group combine to form a divalent poly(ethylene glycol) according to the formula:wherein m1 is an integer from 1 to 13, optionally 1 to 4, optionally 2 to 4, or optionally 4 to 8.

[0261] In some embodiments, the.

[0262] In some embodiments, the divalent poly(ethylene glycol) has the following formula:.

[0263] In some other embodiments, the divalent poly(ethylene glycol) has the following formula:.

[0264] In other embodiments, the divalent poly(ethylene glycol) has the following formula:.

[0265] In other embodiments, the divalent poly(ethylene glycol) has the following formula:.

[0266] In some embodiments, the spacer group can bear a chain-presented sulfonic acid having the formula:.

[0267] In some embodiments, the spacer group is a diamine. In some embodiments, the spacer group is according to.

[0268] In some embodiments, the spacer group comprises fused rings or spiro rings. In some embodiments, the spacer group is according to, where each na, ma, oa, and pais an integer independently selected from 1, 2, 3, 4, and 5. In some embodiments, the spacer group is according toma, oa, and pais an integer independently selected from 1, 2, 3, 4, and 5. In some embodiments, the spacer group is selected from the group consisting of:6. Conjugating Groups and Residues Thereof

[0269] Conjugating groups facilitate conjugation of the payloads described herein to a second compound, such as an antibody described herein. In certain embodiments, the conjugating group is designated R herein. Conjugating groups can react via any suitable reaction mechanism known to those of skill in the art. In certain embodiments, a conjugating group reacts through a [3+2] alkyne-azide cycloaddition reaction, inverse-electron demand Diels-Alder ligation reaction, thiol-electrophile reaction, or carbonyl-oxyamine reaction, as described indetail herein. In certain embodiments, the conjugating group comprises an alkyne, strained alkyne, tetrazine, thiol, para-acetyl-phenylalanine residue, oxyamine, maleimide, or azide. In certain embodiments, the conjugating group is:wherein R201is lower alkyl. In an embodiment, R201is methyl, ethyl, or propyl. In an embodiment, R201is methyl. Additional conjugating groups are described in, for example, U.S. Patent Publication No. 2014 / 0356385, U.S. Patent Publication No.2013 / 0189287, U.S. Patent Publication No.2013 / 0251783, U.S. Patent No. 8,703,936, U.S. Patent No. 9,145,361, U.S. Patent No.9,222,940, and U.S. Patent No.8,431,558.

[0270] After conjugation, a divalent residue of the conjugating group is formed and is bonded to the residue of an antibody. The structure of the divalent residue is determined by the type of conjugation reaction employed to form the conjugate.

[0271] In certain embodiments when a conjugate is formed through a [3+2] alkyne-azide cycloaddition reaction, the divalent residue of the conjugating group comprises a triazole ring or fused cyclic group comprising a triazole ring. In certain embodiment when a conjugate is formed through a strain-promoted [3+2] alkyne-azide cycloaddition (SPAAC) reaction, the divalent residue of the conjugating group is:.

[0272] In certain embodiments when a conjugate is formed through a tetrazine inverse electron demand Diels-Alder ligation reaction, the divalent residue of the conjugating group comprises a fused bicyclic ring having at least two adjacent nitrogen atoms in the ring. In certainembodiments when a conjugate is formed through a tetrazine inverse electron demand Diels- Alder ligation reaction, the divalent residue of the conjugating group is:.

[0273] In certain embodiments when a conjugate is formed through a thiol-maleimide reaction, the divalent residue of the conjugating group comprises succinimidylene and a sulfur linkage. In certain embodiments when a conjugate is formed through a thiol-maleimide reaction, the divalent residue of the conjugating group is:.

[0274] In certain embodiments, a conjugate is formed through a thiol-N- hydroxysuccinimide reaction using the following group:. The reaction involved for formation of the conjugate comprises the following step:, and the resulting divalent residue of the conjugating group is:.

[0275] In certain embodiments when a conjugate is formed through a carbonyl-oxyamine reaction, the divalent residue of the conjugating group comprises a divalent residue of a non- natural amino acid. In certain embodiments when a conjugate is formed through a carbonyl- oxyamine reaction, the divalent residue of the conjugating group is:.

[0276] In certain embodiments when a conjugate is formed through a carbonyl-oxyamine reaction, the divalent residue of the conjugating group comprises an oxime linkage. In certain embodiments when a conjugate is formed through a carbonyl-oxyamine reaction, the divalent residue of the conjugating group is:.

[0277] In an embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein R comprises a triazole ring. In an embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein R is a triazole ring or fused cyclic group comprising a triazole ring. In an embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein R is:.

[0278] In an embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein R comprises a fused bicyclic ring having at least two adjacent nitrogen atoms in the ring. In an embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein R is:.

[0279] In an embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein R comprises a sulfur linkage. In an embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein R is:

[0280] In an embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein R comprises a divalent residue of a non-natural amino acid. In an embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein R is:.

[0281] In an embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein comprises an amide linkage. In an embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein R is:.

[0282] In an embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein comprises an oxime linkage. In an embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein R is:.

[0283] In an embodiment, provided herein is a conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein R is: , ,

[0284] In an embodiment, provided herein is a compound according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein COMP is a residue of any compound known to be useful for conjugation to a payload, described herein, and an optional linker, described herein. In an embodiment, provided herein is a compound according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof; wherein COMP is a residue of an antibody chain.

[0285] In an aspect, provided herein is an antibody conjugate comprising payload, described herein, and an optional linker, described herein, linked to an anti-Tissue Factor antibody, wherein COMP is a residue of the antibody. In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the antibody; and R comprises a triazole ring or fused cyclic group comprising a triazole ring. In an embodiment,provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the antibody; and R is:.

[0286] In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the antibody; and R comprises a fused bicyclic ring, wherein the fused bicyclic ring has at least two adjacent nitrogen atoms in the ring. In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the antibody; and R is:.

[0287] In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the polypeptide; and R comprises a sulfur linkage. In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the polypeptide; and R is:

[0288] In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the polypeptide; and R comprises a divalent residue of a non-natural amino acid. In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the polypeptide; and R is:.

[0289] In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the polypeptide; and R comprises an amide linkage. In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the polypeptide; and R is:.

[0290] In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the polypeptide; and R comprises an amide linkage. In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the polypeptide; and R is:.

[0291] In an aspect, provided herein is an antibody conjugate comprising a payload, described herein, and an optional linker, described herein, linked to an antibody according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein COMP is a residue of the antibody. In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the antibody; and R comprises a triazole ring or fused cyclic group comprising a triazole ring. In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or apharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the antibody; and R is:.

[0292] In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the antibody; and R comprises a fused bicyclic ring, wherein the fused bicyclic ring has at least two adjacent nitrogen atoms in the ring. In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the antibody; and R is:.

[0293] In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the antibody; and R comprises a sulfur linkage. In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the antibody; and R is:

[0294] In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the antibody; and R comprises a divalent residue of a non-natural amino acid. In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the antibody; and R is:.

[0295] In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the antibody; and R comprises an amide linkage. In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the antibody; and R is:.

[0296] In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the antibody; and R comprises an oxime linkage. In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the antibody; and R is:.

[0297] In an aspect, provided herein is an antibody conjugate comprising a payload, described herein, and an optional linker, described herein, linked to an antibody chain according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein COMP is a residue of the antibody chain. In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the antibody chain; and R comprises a triazole ring or fused cyclic group comprising a triazole ring. In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or apharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the antibody chain; and R is:.

[0298] In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the antibody chain; and R comprises a fused bicyclic ring, wherein the fused bicyclic ring has at least two adjacent nitrogen atoms in the ring. In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the antibody chain; and R is:.

[0299] In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the antibody chain; and R comprises a sulfur linkage. In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the antibody chain; and R is:

[0300] In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the antibody chain; and R comprises a divalent residue of a non-natural amino acid. In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the antibody chain; and R is:.

[0301] In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the antibody chain; and R comprises an amide linkage. In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the antibody chain; and R is:.

[0302] In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the antibody chain; and R comprises an amide linkage. In an embodiment, provided herein is an antibody conjugate according to Formula (C1) or (C2), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, wherein: COMP is a residue of the antibody chain; and R is:. (b) Conjugates

[0303] In an embodiment, provided herein is a conjugate according to any of the following formulas, where COMP indicates a residue of the anti-Tissue Factor antibody and PAY indicates a payload moiety:

[0304] In an embodiment, provided herein is a conjugate according to any of the following formulas, where COMP indicates a residue of the anti-Tissue Factor antibody and PAY indicates a payload moiety:.

[0305] In an embodiment, provided herein is a conjugate according to any of the following formulas, where COMP indicates a residue of the anti-Tissue Factor antibody and PAY indicates a payload moiety:.

[0306] In an embodiment, provided herein is a conjugate according to any of Formulas 101a-104b, where COMP indicates a residue of the anti-Tissue Factor antibody and PAY indicates a payload moiety:

[0307] In any of the foregoing embodiments, the conjugate comprises n2 number of PAY moieties, wherein n2 is an integer from 1 to 10. In some embodiments, n2 is 2. In some embodiments, n2 is 3. In some embodiments, n2 is 4. In some embodiments, n2 is 5. In some embodiments, n2 is 6. In some embodiments, n2 is 7. In some embodiments, n2 is 8. In some embodiments, n2 is 9. In some embodiments, n2 is 10.

[0308] In some embodiments, provided herein are anti-Tissue Factor conjugates comprising a modified hemiasterlin and linker as described, for example, in PCT Publication No. WO 2016 / 123582. For example, the conjugate can have a structure comprising any of Formulas 1000-1000b, 1001-1001b, 1002-1002b, and I-XIXb-2, 101-111b, or 1-8b as described in PCT Publication No. WO 2016 / 123582. Examples of conjugates comprising a modified hemiasterlin and linker are provided below.

[0309] In some embodiments, provided is a conjugate of Formula (I)or a pharmaceutically acceptable salt thereof, wherein COMP is a residue of an anti-Tissue Factor antibody provided herein; L1is -C1-6 alkylene-; Y is –X1-C1-6alkylene-[X1-C1-6alkylene]n-[X1]p–, –X1-C2-6alkenylene-[X1-C2-6alkenylene]n-[X1]p–, –X1-C2-6alkynylene-[X1-C2-6alkynylene]n- [X1]p–, wherein at least one alkylene, alkenylene or alkynylene in Y is substituted with one or more substituents selected from R50; and wherein the alkylene, alkenylene, or alkynylene in Y is optionally substituted with one or more substituents selected from R51; R50is –C1-6 alkylene-X2-[C1-6 alkylene]m-POLY, –C2-6alkenylene-X2-[C2-6alkenylene]m-POLY, or –C2-6alkynylene-X2-[C2-6alkynylene]m- POLY, wherein each alkylene, alkenylene or alkynylene of R50is optionally substituted with one or more substituents selected from halogen, -CN, -NO2, -OH, -N(R10)2, -C(O)N(R10)2, -C(O)-, -C(S)-, -C(O)OCH2C6H5, -NHC(O)OCH2C6H5, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, C3-12carbocycle, 3- to 12-membered heterocycle, and C1-10haloalkyl; R51is independently selected from halogen, -CN, -NO2, -OH, -N(R10)2, -C(O)N(R10)2, - C(O)-, -C(S)-, -C(O)OCH2C6H5, -NHC(O)OCH2C6H5, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, C3-12carbocycle, 3- to 12- membered heterocycle, and C1-10 haloalkyl; X1and X2are independently selected from –C(O)– and –N(R10)C(O)–; R10is independently selected at each occurrence from hydrogen, C1-10alkyl, C2-10alkenyl, C2-10 alkynyl, C3-12 carbocycle, 3- to 12-membered heterocycle, and C1-10 haloalkyl; POLY is a water-soluble polymer; n is an integer selected from zero, one, two, and three; m is an integer selected from zero and one; p is an integer selected from zero and one; Su is a hexose form of a monosaccharide;D is a drug moiety; and RL is a reactive group residue.

[0310] In some embodiments, provided is a conjugate of Formula (II)or a pharmaceutically acceptable salt thereof, wherein COMP is a residue of an anti-Tissue Factor antibody provided herein; L1is -C1-6 alkylene-; Y is –X1-C1-6alkylene-[X1-C1-6alkylene]n-X1–, –X1-C2-6alkenylene-[X1-C2-6alkenylene]n-X1–, –X1-C2-6alkynylene-[X1-C2-6alkynylene]n-X1–, wherein at least one alkylene, alkenylene or alkynylene in Y is substituted with one or more substituents selected from R50; R50is –C1-6alkylene-X2-[C1-6alkylene]m-POLY, –C2-6 alkenylene-X2-[C2-6 alkenylene]m-POLY, or –C2-6 alkynylene-X2-[C2-6 alkynylene]m- POLY, wherein each alkylene, alkenylene or alkynylene of R50is optionally substituted with one or more substituents selected from halogen, -CN, -NO2, -OH, -N(R10)2, -C(O)N(R10)2, -C(O)-, -C(S)-, -C(O)OCH2C6H5, -NHC(O)OCH2C6H5, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, C3-12 carbocycle, 3- to 12-membered heterocycle, and C1-10 haloalkyl; X1and X2are independently selected from –C(O)– and –N(R10)C(O)–; R10is independently selected at each occurrence from hydrogen, C1-10alkyl, C2-10alkenyl, C2-10 alkynyl, C3-12 carbocycle, 3- to 12-membered heterocycle, and C1-10 haloalkyl; POLY is a water-soluble polymer; n is an integer selected from zero, one, two, and three; m is an integer selected from zero and one; Su is a hexose form of a monosaccharide; D is a drug moiety; and RL is a reactive group residue.

[0311] In some embodiments, provided is a conjugate of Formula (IIA)or a pharmaceutically acceptable salt thereof.

[0312] In some embodiments, the compound of Formula (II) is according to Formula (IIB)or a pharmaceutically acceptable salt thereof.

[0313] In some embodiments of Formula (I), (II), (IIA), or (IIB), L1is -C1-3 alkylene-. In some embodiments, L1is -CH2-. In some embodiments of Formula (I), (II), (IIA), or (IIB), L1is -CH2CH2-. In some embodiments, L1is -CH2CH2CH2-.

[0314] In some embodiments of Formula (I), including any of the foregoing, p is 0. In some embodiments of Formula (I), including any of the foregoing, p is 1.

[0315] In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, Y is –X1-C1-6 alkylene-[X1-C1-6 alkylene]n-X1–, wherein at least one alkylene in Y is substituted with one or more substituents selected from R50. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, Y is –X1-C1-6alkylene-[X1-C1-6alkylene]n-, wherein at least one alkylene in Y is substituted with one or more substituents selected from R50. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, Y is –X1-C2-6alkenylene-[X1-C2-6alkenylene]n-X1– wherein at least one alkenylene in Y is substituted with one or more substituents selected from R50. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, Y is –X1-C2-6 alkenylene-[X1-C2-6alkenylene]n- wherein at least one alkenylene in Y is substituted with one or more substituents selected from R50. In some embodiments of Formula (I), (II), (IIA), or (IIB),including any of the foregoing, Y is –X1-C2-6alkynylene-[X1-C2-6alkynylene]n-X1– wherein at least one alkynylene in Y is substituted with one or more substituents selected from R50. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, Y is –X1-C2-6 alkynylene-[X1-C2-6 alkynylene]n- wherein at least one alkynylene in Y is substituted with one or more substituents selected from R50. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, n is zero. In some embodiments of Formula (I), (II), (IIA), or (IIB), n is one. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, n is two. In some embodiments, including any of the foregoing, n is three.

[0316] In certain embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, Y is –X1-C1-4 alkylene-[X1-C1-4 alkylene]n-X1–, wherein at least one alkylene in Y is substituted with one or more substituents selected from R50. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, n is zero. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, n is one. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, n is two. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, n is three.

[0317] In certain embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, Y is –X1-C1-4 alkylene-X1-C1-4 alkylene-X1-C1-4 alkylene-X1-C1-4 alkylene-X1–, wherein at least one alkylene in Y is substituted with one or more substituents selected from R50. In certain embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, Y is –X1-C1-4 alkylene-X1-C1-4 alkylene-X1-C1-4 alkylene-X1–, wherein at least one alkylene in Y is substituted with one or more substituents selected from R50. In certain embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, Y is –X1-C1-4alkylene-X1-C1-4alkylene- X1–, wherein at least one alkylene in Y is substituted with one or more substituents selected from R50.

[0318] In certain embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, R50is –C1-6 alkylene-X2-[C1-6 alkylene]m-POLY, wherein each alkylene of R50is optionally substituted with one or more substituents selected from halogen, -CN, -NO2, -OH, -N(R10)2, -C(O)N(R10)2, -C(O)-, -C(S)-, -C(O)OCH2C6H5, -NHC(O)OCH2C6H5, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, C3-12carbocycle, 3- to 12-membered heterocycle, and C1-10haloalkyl. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, R50is –C1-4alkylene-X2-[C1-4alkylene]m-POLY, wherein each alkylene of R50is optionally substituted with one or more substituents selected from halogen, -CN, -NO2, -OH, -N(R10)2, -C(O)N(R10)2, -C(O)-, -C(S)-, -C(O)OCH2C6H5, -NHC(O)OCH2C6H5, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-12 carbocycle, 3- to 12-membered heterocycle, and C1-10 haloalkyl. In someembodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, each alkylene of R50is optionally substituted with one or more substituents selected from halogen, -OH, - N(R10)2, -C(O)N(R10)2, -C(O)-, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-12 carbocycle, 3- to 12- membered heterocycle, and C1-10haloalkyl. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, m is zero. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, m is one.

[0319] In certain embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, R50is –C2-6 alkenylene-X2-[C2-6 alkenylene]m-POLY, wherein each alkenylene of R50is optionally substituted with one or more substituents selected from halogen, -CN, -NO2, -OH, -N(R10)2, -C(O)N(R10)2, -C(O)-, -C(S)-, -C(O)OCH2C6H5, -NHC(O)OCH2C6H5, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, C3-12carbocycle, 3- to 12-membered heterocycle, and C1-10haloalkyl. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, m is zero. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, m is one.

[0320] In certain embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, R50is –C2-6 alkynylene-X2-[C2-6 alkynylene]m-POLY, wherein each alkynylene of R50is optionally substituted with one or more substituents selected from halogen, -CN, -NO2, - OH, -N(R10)2, -C(O)N(R10)2, -C(O)-, -C(S)-, -C(O)OCH2C6H5, -NHC(O)OCH2C6H5, C1-10 alkyl, C2-10alkenyl, C2-10alkynyl, C3-12carbocycle, 3- to 12-membered heterocycle, and C1-10haloalkyl. In come embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, m is zero. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, m is one.

[0321] In certain embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, POLY is polyethylene glycol (PEG), methoxypolyethylene glycol (mPEG), poly(propylene glycol) (PPG), copolymers of ethylene glycol and propylene glycol, poly(oxyethylated polyol), poly(olefinic alcohol), poly(vinylpyrrolidone), poly(hydroxyalkylmethacrylamide), poly(hydroxyalkylmethacrylate), poly(saccharides), poly(^-hydroxy acid), poly(vinyl alcohol), polyphosphazene, polyoxazolines (POZ), poly(N- acryloylmorpholine), polysarcosine, or a combination thereof. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, POLY is polyethylene glycol (PEG). In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, POLY is methoxypolyethylene glycol (mPEG). In some embodiments of Formula (I), (II), (IIA), or(IIB), including any of the foregoing, POLY is poly(propylene glycol) (PPG). In some embodiments, POLY is copolymers of ethylene glycol and propylene glycol. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, POLY is poly(oxyethylated polyol). In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, POLY is poly(olefinic alcohol). In some embodiments, POLY is poly(vinylpyrrolidone). In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, POLY is poly(hydroxyalkylmethacrylamide). In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, POLY is poly(hydroxyalkylmethacrylate). In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, POLY is poly(saccharides). In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, POLY is poly(^-hydroxy acid). In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, POLY is poly(vinyl alcohol). In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, POLY is polyphosphazene. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, POLY is polyoxazolines (POZ). In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, POLY is poly(N- acryloylmorpholine). In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, POLY is polysarcosine. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, POLY is a nonpeptidic, water-soluble polymer. In certain embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, POLY includes a polyethylene glycol (PEG) or methoxypolyethylene glycol (mPEG). In certain embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, POLY is, wherein represents attachment to the remainder of the compound, and wherein n1 is an integer from one to twenty. In certain embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, n1 is an integer between five to fifteen. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, n1 is one. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, n1 is two. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, n1 is three. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, n1 is four. In some embodiments of Formula (II), (IIA), or (IIB), including any of the foregoing, n1 is five. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, n1 is six. In some embodiment of Formula (I), (II), (IIA), or (IIB)s, n1 is seven. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, n1 is eight. In someembodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, n1 is nine. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, n1 is ten. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, n1 is eleven. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, n1 is twelve. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, n1 is thirteen. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, n1 is fourteen. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, n1 is fifteen. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, n1 is sixteen. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, n1 is seventeen. In some embodiments of Formula (I), (II), (IIA), or (IIB), n1 is eighteen. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, n1 is nineteen. In some embodiments of Formula (II), (IIA), or (IIB), including any of the foregoing, n1 is twenty. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, n1 is twenty-one. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, n1 is twenty-two. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, n1 is twenty- three. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, n1 is twenty-four. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, n1 is twenty-five. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, n1 is twenty-six. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, n1 is twenty-seven. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, n1 is twenty-eight. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, n1 is twenty-nine. In some embodiments of Formula (I), (II), (IIA), or (IIB), including any of the foregoing, n1 is thirty.

[0322] In certain embodiments, RL includes an alkyne, cyclooctyne, a strained alkene, a tetrazine, an amine, methylcyclopropene, a thiol, a para-acetyl-phenylalanine residue, an oxyamine, a maleimide, or an azide. In some embodiments, RL includes an alkyne. In some embodiments, RL includes an cyclooctyne. In some embodiments, RL includes a strained alkene. In some embodiments, RL includes a tetrazine. In some embodiments, RL includes an amine. In some embodiments, RL includes an methylcyclopropene. In some embodiments, RL includes a thiol. In some embodiments, RL includes a para-acetyl-phenylalanine residue. In some embodiments, RL includes an oxyamine. In some embodiments, RL includes a maleimide. In some embodiments, RL includes an azide. In certain embodiments, RL is selected from the(c) andrepresents attachment to the remainder of the compound. In someremainder of the compound. In one some embodiments,represents attachment to the remainder of the compound. In some embodiments,represents attachment to the remainder of the compound. In some embodiments, RL isrepresents attachment to the remainder of the compound. In some embodiments, RL isrepresentsattachment to the remainder of the compound. In some embodiments,represents attachment to the remainder of the compound. In some embodiments,represents attachment to the remainder of the compound. In some embodiments,represents attachment to the remainder of the compound. In some embodiments,represents attachment to the remainder of the compound. In some embodiments, Su is a sugar moiety. In some embodiments, Su is a hexose form of a monosaccharide. Su may be a glucuronic acid or mannose residue. In certain embodiments, Su, wherein represents attachment to the remainder of the compound. In certain embodiments,, wherein represents attachment to the remainder of the compound.

[0323] In one aspect, provided herein is a conjugate of Formula (III):or a pharmaceutically acceptable salt and / or regioisomer thereof; whereinRing A is an optionally substituted bridged, fused, or spirocyclic bicyclic carbocycle, or an optionally substituted bridged, fused, or spirocyclic bicyclic heterocycle, wherein the carbocycle or the heterocycle of Ring A are optionally substituted with one or more substituents selected from alkyl, alkenyl, alkynyl, cycloalkyl, halogen, alkoxy, -CN, -NO2, - OH, -N(R2R3)2, -C(O)-, -C(O)N(R2R3)2, -C(O)OR2, aminoalkyl, hydroxyalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl; Ring B is an optionally substituted N-linked bridged, fused, or spirocyclic bicyclic heterocycle, wherein Ring B is optionally substituted with one or more substituents selected from alkyl, alkenyl, alkynyl, cycloalkyl, halogen, alkoxy, -CN, -NO2, -OH, -N(R2R3)2, -C(O)-, -C(O)N(R2R3)2, -C(O)OR2, aminoalkyl, hydroxyalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl; Raand Rbare independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, halogen, alkoxy, -CN, -NO2, -OH, -N(R2R3)2, -C(O)N(R2R3)2, -C(O)OR2, aminoalkyl, hydroxyalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl; a is an integer independently selected from 0, 1, 2, 3, 4, 5, and 6; R1is hydrogen or alkyl optionally substituted with one or more substituents selected from cycloalkyl, halogen, alkoxy, -CN, -NO2, -OH, -N(R2R3)2, -C(O)N(R2R3)2, -C(O)OR2, aryl, and heteroaryl; R2and R3are independently selected from hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl;Yais *-C(O)-(CRaRb)c-NH- or *-C(O)-(CRaRb)c-, wherein * represents where Yais bound to RL; c is an integer selected from 1, 2, 3, 4, 5, or 6; RL is a reactive group residue; L2is absent or a linker comprising a hydrophilic polymer residue; L3is absent, -C(O)-AA-, -C(O)-AA-Z-(CRaRb)a-Z-(CRaRb)a-C(O)-, -C(O)-Z-(CRaRb)a- C(O)-Z-L4-OC(O)-, -Z-AA-, -AA-, -C(O)-, -C(O)-AA-Z-(CRaRb)a-, -AA-C(O)-, -C(O)- (CRaRb)a-Z-(CRaRb)-Z-AA-C(O)-, -C(O)O-L4-Z-C(O)-(CRaRb)a-Z-C(O)-, -AA-Z-, or – (CRaRb)a-Z-AA-C(O)-; Z is selected from -NR2- and -O-; AA is an amino acid residue or a peptide residue;wherein Su is a hexose form of a monosaccharide; d is an integer independently selected from 1, 2, and 3; D is a drug moiety; COMP is a residue of a Tissue Factor antibody; and represents attachment to the remainder of the compound.

[0324] In certain embodiments, the compound of Formula (III) is a compound of Formula (IIIA):or a pharmaceutically acceptable salt and / or regioisomer thereof; wherein integer c, RL, Ra, Rb, Ring B, L2, L3, D, and COMP are as defined herein.

[0325] In certain embodiments, the compound of Formula (IIIA) is selected from the following:,or a pharmaceutically acceptable salt and / or regioisomer thereof.

[0326] In certain embodiments, the compound of Formula (III) is a compound of Formula (IIIB):or a pharmaceutically acceptable salt and / or regioisomer thereof;wherein integer c, RL, Ra, Rb, Ring B, L2, L3, D, and COMP are as defined herein.

[0327] In certain embodiments, the compound of Formula (IIIB) is selected from the following:or a pharmaceutically acceptable salt and / or regioisomer thereof.

[0328] In certain embodiments, the compound of Formula (III) is a compound of Formula (IIIC):or a pharmaceutically acceptable salt and / or regioisomer thereof; wherein integer a, integer c, RL, Ra, Rb, Ring A, L2, L3, D, and COMP are as defined herein.

[0329] In certain embodiments, the compound of Formula (IIIC) is selected from the following:. Or a pharmaceutically acceptable salt and / or regioisomer thereof.

[0330] In certain embodiments, the compound of Formula (III) is a compound of Formula (IIID):or a pharmaceutically acceptable salt and / or regioisomer thereof; wherein integer a, integer c, RL, Ra, Rb, Ring A, L2, L3, D, and COMP are as defined herein.

[0331] In certain embodiments, the compound of Formula (IIID) is selected from the following:or a pharmaceutically acceptable salt and / or regioisomer thereof.

[0332] In certain embodiments, the compound of Formula (III) is a compound of Formula (IIIE):or a pharmaceutically acceptable salt and / or regioisomer thereof; wherein integer a, integer c, RL, Ra, Rb, Ring B, L3, POLY2, D, and COMP are as defined herein.

[0333] In certain embodiments, the compound of Formula (IIIE) is selected from the following:,,or a pharmaceutically acceptable salt and / or regioisomer thereof.

[0334] In certain embodiments, the compound of Formula (III) is a compound of Formula (IIIF):or a pharmaceutically acceptable salt and / or regioisomer thereof; wherein integer a, integer c, RL, Ra, Rb, Ring B, L3, POLY2, D, and COMP are as defined herein.

[0335] In certain embodiments, the compound of Formula (IIIF) is selected from the following:,or a pharmaceutically acceptable salt and / or regioisomer thereof.

[0336] In certain embodiments, the compound of Formula (III) is a compound of Formula (IIIG):or a pharmaceutically acceptable salt and / or regioisomer thereof; wherein integer a, integer c, RL, Ra, Rb, Ring A, L3, POLY2, D, and COMP are as defined herein.

[0337] In certain embodiments, the compound of Formula (IIIG) is selected from the following:or a pharmaceutically acceptable salt and / or regioisomer thereof.

[0338] In certain embodiments, the compound of Formula (III) is a compound of Formula (IIIH):or a pharmaceutically acceptable salt and / or regioisomer thereof; wherein integer a, integer c, RL, Ra, Rb, Ring A, L3, POLY2, D, and COMP are as defined herein.

[0339] In certain embodiments, the compound of Formula (IIIH) is selected from the following: , ,, andor a pharmaceutically acceptable salt and / or regioisomer thereof.

[0340] In one aspect, provided herein is a conjugate of Formula (V):or a pharmaceutically acceptable salt and / or regioisomer thereof; wherein L5is a linker comprising an unnatural amino acid; and RL, COMP, Ya, L2, L3, and D are as defined herein.

[0341] In certain embodiments, the compound of Formula (V) is a compound of Formula (VA):or a pharmaceutically acceptable salt and / or regioisomer thereof; wherein RL, COMP, Ya, L2, L3, and D are as defined herein.

[0342] In certain embodiments, the compound of Formula (V) is a compound of Formula (VB):or a pharmaceutically acceptable salt and / or regioisomer thereof; wherein integer a, integer c, RL, COMP, Ra, Rb, POLY1, AA, and D are as defined herein.

[0343] In certain embodiments, the compound of Formula (VB) is a compound of the formula:or a pharmaceutically acceptable salt and / or regioisomer thereof.

[0344] In certain embodiments of Formula (III)-(VB), including any of the foregoing,. (III)-(VB), including any of the foregoing,. certain embodiments of Formula (III)-(VB), including any of the foregoing, L1ais(VB), including any of the foregoing,embodiments of Formula (III)-(VB), including any of the foregoing, L1aiscertain embodiments of Formula (III)-(VB), including any of the foregoing, L1ais. In certain embodiments of Formula (III)-(VB),including any of the foregoing,. certain embodiments of Formula (III)-(VB), including any of the foregoing, L1ais. In certain embodiments of Formula (III)-(VB), including any of the foregoing, L1ais. In certain embodiments of Formula (III)-(VB), including any of the foregoing, L1aisor. In certain embodiments of Formula (III)-(VB), including any of the foregoing, L1a,

[0345] In certain embodiments of Formula (III)-(VB), including any of the foregoing, L1ais. In certain embodiments of Formula (III)-(VB), including any of the foregoing,.

[0346] In certain embodiments of Formula (III)-(VB), including any of the foregoing, Ring B of L1ais an optionally substituted 5- to 12- membered N-linked bridged, fused, or spirocyclic bicyclic heterocycle containing 1, 2, or 3 heteroatoms independently selected from N, O, and S including the N to which the ring is attached, wherein Ring B is optionally substituted with one or more substituents selected from alkyl, alkenyl, alkynyl, cycloalkyl, halogen, alkoxy, -CN, -NO2, -OH, -N(R2R3)2, -C(O)-, -C(O)N(R2R3)2, -C(O)OR2, aminoalkyl, hydroxyalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl. In certain embodiments of Formula (III)-(VB), including any of the foregoing, Ring B of L1ais an optionally substituted 5- to 12- membered N-linked spirocyclic bicyclic heterocycle containing 1, 2, or 3 heteroatoms independently selected from N, O, and S including the N to which the ring is attached.

[0347] In certain embodiments of Formula (III)-(VB), including any of the foregoing, Ring B of L1ais selected from, andwherein mais an integer selected from 1, 2, 3, 4, and 5; and each of naand oais an integer independently selected from 1, 2, and 3.

[0348] In certain embodiments of Formula (III)-(VB), including any of the foregoing, Ring B of L1ais. In certain embodiments of Formula (III)-(VB),

[0349] In certain embodiments of Formula (III)-(VB), including any of the foregoing, Ring B of L1ais. In certain embodiments of Formula (III)-(VB),. In certain embodiments of Formula (III)-(VB),is selected.

[0350] In certain embodiments of Formula (III)-(VB), including any of the foregoing,, , . mula (III)-(VB),, , , . of Formulawherein mais 1, 2, or 3.

[0351] In certain embodiments of Formula (III)-(VB),is . In certain embodiments of Formula (III)-(VB),is . In certain embodiments of Formula (III)-(VB),is. In certain embodiments of Formula (III)-(VB),is. In certain embodiments of Formula (III)-(VB),is.

[0352] In certain embodiments of Formula (III)-(VB), including any of the foregoing,, , . (III)-(VB),wherein mais 1, 2, or 3. In certain embodiments of Formula

[0353] In certain embodiments of Formula (III)-(VB). In certain embodiments of Formula (III)-(VB),. In certain embodiments of Formula (III)-(VB), is . In certain

[0354] In certain embodiments of Formula (III)-(VB), including any of the foregoing,.

[0355] In certain embodiments of Formula (III)-(VB), including any of the foregoing,.

[0356] In certain embodiments of Formula (III)-(VB), including any of the foregoing,

[0357] In certain embodiments of Formula (III)-(VB), including any of the foregoing,wherein mais an integer selected from 1, 2, 3, 4, and 5; and each of naand oais an integer independently selected from 1, 2, and 3.

[0358] In certain embodiments of Formula (III)-(VB), including any of the foregoing,.

[0359] In certain embodiments of Formula (III)-(VB), including any of the foregoing, Ring B of L1ais selected from,wherein X1a, X2a, X3, and X4are independently selected from -C(R4)2-, -NH-, -O-, and -S- wherein when X1a, X2a, and X3are present, at least one of X1a-X3is -C(R4)2- and when X1a, X2a, X3, and X4are present, at least two of X1a-X4are -C(R4)2-; and R4is independently selected from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, halogen, alkoxy, -CN, -NO2, -OH, -N(R2R3)2, -C(O)N(R2R3)2, - C(O)OR2, aminoalkyl, hydroxyalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl; or two R4groups on the same carbon are taken together to form an oxo group

[0360] In certain embodiments of Formula (III)-(VB), including any of the foregoing,wherein X1a, X2a, X3, and X4are independently selected from -C(R4)2-, -NH-, -O-, and - S- wherein when X1a, X2a, and X3are present, at least one of X1a-X3is -C(R4)2- and when X1a, X2a, X3, and X4are present, at least two of X1a-X4are -C(R4)2-; and R4is independently selected from hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-12 cycloalkyl, halogen, alkoxy, -CN, -NO2, -OH, -N(R2R3)2, -C(O)N(R2R3)2, - C(O)OR2, aminoalkyl, hydroxyalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl; or two R4groups on the same carbon are taken together to form an oxo group.

[0361] In certain embodiments of Formula (III)-(VB), including any of the foregoing, Ring A of L1ais an optionally substituted bridged, fused, or spirocyclic bicyclic carbocycle, wherein the carbocycle or the heterocycle of Ring A are optionally substituted with one or moresubstituents selected from alkyl, alkenyl, alkynyl, cycloalkyl, halogen, alkoxy, -CN, -NO2, - OH, -N(R2R3)2, -C(O)-, -C(O)N(R2R3)2, -C(O)OR2, aminoalkyl, hydroxyalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl. In certain embodiments, including any of the foregoing, Ring A of L1ais an optionally substituted C4-12 bridged, fused, or spirocyclic bicyclic carbocycle. In certain embodiments of Formula (III)-(VB), including any of the foregoing, Ring A of L1ais an optionally substituted C4-12 bridged bicyclic carbocycle. In certain embodiments of Formula (III)-(VB), including any of the foregoing, Ring A of L1ais an optionally substituted C4-8bridged bicyclic carbocycle.

[0362] In certain embodiments of Formula (III)-(VB), including any of the foregoing,wherein X1a, X2a, X3, and X4are independently selected from -C(R4)2-, -NH-, -O-, and - S- wherein when X1a, X2a, and X3are present, at least one of X1a-X3is -C(R4)2- and when X1a, X2a, X3, and X4are present, at least two of X1a-X4are -C(R4)2-; X5is CR4or N; and R4is independently selected from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, halogen, alkoxy, -CN, -NO2, -OH, -N(R2R3)2, -C(O)N(R2R3)2, -C(O)OR2, aminoalkyl, hydroxyalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl; or two R4groups on the same carbon are taken together to form an oxo group.

[0363] In certain embodiments of Formula (III)-(VB), including any of the foregoing, Ring A of L1ais selected from.

[0364] In certain embodiments of Formula (III)-(VB), including any of the foregoing,.

[0365] In certain embodiments of Formula (III)-(VB), including any of the foregoing,

[0366] In certain embodiments of Formula (III)-(VB), including any of the foregoing,. , of the foregoing, Ring.

[0368] In certain embodiments of Formula (III)-(VB), including any of the foregoing, X1a, X2a, X3, and / or X4is -C(R4)2-. In certain embodiments of Formula (III)-(VB), including any of the foregoing, X1aand X2aare -C(R4)2-. In certain embodiments of Formula (III)-(VB), including any of the foregoing, X1a, X2a, and X3are -C(R4)2-. In certain embodiments of Formula (III)-(VB), including any of the foregoing, X1a, X2a, X3, and X4are -C(R4)2-. In certain embodiments of Formula (III)-(VB), including any of the foregoing, X1ais -NH-. In certain embodiments of Formula (III)-(VB), including any of the foregoing, X2ais NH-. In certain embodiments of Formula (III)-(VB), including any of the foregoing, X3is -NH-. In certain embodiments of Formula (III)-(VB), including any of the foregoing, X4is NH-. In certain embodiments, including any of the foregoing, X1ais -O-. In certain embodiments of Formula (III)-(VB), including any of the foregoing, X2ais -O-. In certain embodiments of Formula (III)-(VB), including any of the foregoing, X3is -O-. In certain embodiments of Formula (III)-(VB), including any of the foregoing, X4is -O-.

[0369] In certain embodiments of Formula (III)-(VB), including any of the foregoing, L1ais

[0370] In certain embodiments, including any of the foregoing, a is 0. In certain embodiments, including any of the foregoing, a is 1. In certain embodiments, including any of the foregoing, a is 2. In certain embodiments, including any of the foregoing, a is 3. In certain embodiments, including any of the foregoing, a is 4. In certain embodiments, including any of the foregoing, a is 5. In certain embodiments, including any of the foregoing, a is 6.

[0371] In certain embodiments of Formula (III)-(VB), b is 0. In certain embodiments, b is 1.

[0372] In certain embodiments of Formula (III)-(VB), b is 0 and a is 0. In certain embodiments of Formula (III)-(VB), b is 0 and a is 1. In certain embodiments of Formula (III)- (VB), b is 0 and a is 2. In certain embodiments of Formula (III)-(VB), b is 0 and a is 3. In certain embodiments of Formula (III)-(VB), b is 0 and a is 4. In certain embodiments of Formula (III)- (VB), b is 0 and a is 5. In certain embodiments of Formula (III)-(VB), b is 0 and a is 6. In certain embodiments of Formula (III)-(VB), b is 1 and a is 1. In certain embodiments of Formula (III)- (VB), b is 1 and a is 2. In certain embodiments of Formula (III)-(VB), b is 1 and a is 3. In certain embodiments of Formula (III)-(VB), b is 1 and a is 4. In certain embodiments of Formula (III)- (VB), b is 1 and a is 5. In certain embodiments of Formula (III)-(VB), b is 1 and a is 6.

[0373] In certain embodiments of Formula (III)-(VB), including any of the foregoing, R1is hydrogen. In certain embodiments of Formula (III)-(VB), including any of the foregoing, R1is unsubstituted alkyl. In certain embodiments of Formula (III)-(VB), including any of the foregoing, R1is methyl. In certain embodiments of Formula (III)-(VB), including any of the foregoing, R1is alkyl optionally substituted with one or more substituent selected from cycloalkyl, halogen, alkoxy, -CN, -NO2, and -OH.

[0374] In certain embodiments of Formula (III)-(IVB), L5is a linker that comprises at least one amino acid selected from sulfoalanine, hydroxyproline (Hyp), beta-alanine, citrulline(Cit), ornithine (Orn), norleucine (Nle), 3-nitrotyrosine, nitroarginine, pyroglutamic acid (Pyr), naphtylalanine (Nal), 2,4-diaminobutyric acid (DAB), methionine sulfoxide, and methionine sulfone. In certain embodiments of Formula (III)-(IVB), L5is a linker that comprises . In certain embodiments of Formula (III)-(IVB), L5is a linker that comprises. In certain embodiments of Formulacertain embodiments of Formula

[0375] In certain embodiments, including any of the foregoing, Rais hydrogen and Rbis selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, halogen, alkoxy, -CN, -NO2, -OH, -N(R2R3)2, -C(O)N(R2R3)2, -C(O)OR2, aminoalkyl, hydroxyalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl. In certain embodiments, including any of the foregoing, Rais hydrogen and Rbis selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, halogen, alkoxy, -CN, -NO2, -OH, -NH2, -C(O)NH2, -C(O)OH, aminoalkyl, hydroxyalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl. In certain embodiments, including any of the foregoing, Rais hydrogen and Rbis selected from hydrogen, alkyl, halogen, alkoxy, -CN, -NO2, -OH, -NH2, - C(O)NH2, and -C(O)OH. In certain embodiments, including any of the foregoing, Raand Rbare both hydrogen.

[0376] In certain embodiments of Formula (III)-(VB), including any of the foregoing, Rais hydrogen; Rbis selected from hydrogen, alkyl, halogen, alkoxy, -CN, -NO2, -OH, -NH2, - C(O)NH2, and -C(O)OH; R1is hydrogen; a is 1; and b is 1. In certain embodiments of Formula (III)-(VB), including any of the foregoing, Rais hydrogen; Rbis selected from hydrogen, alkyl, halogen, alkoxy, -CN, -NO2, -OH, -NH2, -C(O)NH2, and -C(O)OH; R1is hydrogen; a is 2; and b is 1. In certain embodiments of Formula (III)-(VB), including any of the foregoing, Rais hydrogen; Rbis selected from hydrogen, alkyl, halogen, alkoxy, -CN, -NO2, -OH, -NH2, - C(O)NH2, and -C(O)OH; R1is hydrogen; a is 3; and b is 1.

[0377] In certain embodiments of Formula (III)-(VB), including any of the foregoing, Rais hydrogen; Rbis selected from hydrogen, alkyl, halogen, alkoxy, -CN, -NO2, -OH, -NH2,-C(O)NH2, and -C(O)OH; a is 1; and b is 0. In certain embodiments of Formula (III)-(VB), including any of the foregoing, Rais hydrogen; Rbis selected from hydrogen, alkyl, halogen, alkoxy, -CN, -NO2, -OH, -NH2, -C(O)NH2, and -C(O)OH; a is 2, and b is 0. In certain embodiments of Formula (III)-(VB), including any of the foregoing, Rais hydrogen; Rbis selected from hydrogen, alkyl, halogen, alkoxy, -CN, -NO2, -OH, -NH2, -C(O)NH2, and -C(O)OH; a is 3, and b is 0.

[0378] In certain embodiments of Formula (III)-(VB), including any of the foregoing, Rais hydrogen; Rbis selected from hydrogen, alkyl, halogen, alkoxy, -CN, -NO2, -OH, -NH2, - C(O)NH2, and -C(O)OH; R1is methyl; a is 1; and b is 1. In certain embodiments of Formula (III)-(VB), including any of the foregoing, Rais hydrogen; Rbis selected from hydrogen, alkyl, halogen, alkoxy, -CN, -NO2, -OH, -NH2, -C(O)NH2, and -C(O)OH; R1is methyl; a is 2; and b is 1. In certain embodiments of Formula (III)-(VB), including any of the foregoing, Rais hydrogen; Rbis selected from hydrogen, alkyl, halogen, alkoxy, -CN, -NO2, -OH, -NH2, - C(O)NH2, and -C(O)OH; R1is methyl; a is 3, and b is 1.

[0379] In certain embodiments, including any of the foregoing of Formula (III)-(VB), Raand Rbare both hydrogen; R1is hydrogen; a is 1, and b is 1. In certain embodiments of Formula (III)-(VB), including any of the foregoing, Raand Rbare both hydrogen; R1is hydrogen; a is 2, and b is 1. In certain embodiments of Formula (III)-(VB), including any of the foregoing, Raand Rbare both hydrogen; R1is hydrogen; a is 3, and b is 1. In certain embodiments of Formula (III)- (VB), including any of the foregoing, Raand Rbare both hydrogen; R1is hydrogen; a is 4, and b is 1. In certain embodiments of Formula (III)-(VB), including any of the foregoing, Raand Rbare both hydrogen; R1is hydrogen; a is 5, and b is 1. In certain embodiments of Formula (III)- (VB), including any of the foregoing, Raand Rbare both hydrogen; R1is hydrogen; a is 6, and b is 1.

[0380] In certain embodiments of Formula (III)-(VB), including any of the foregoing, Raand Rbare both hydrogen; a is 1; and b is 0. In certain embodiments of Formula (III)-(VB), including any of the foregoing, Raand Rbare both hydrogen; a is 2; and b is 0. In certain embodiments of Formula (III)-(VB), including any of the foregoing, Raand Rbare both hydrogen; a is 3; and b is 0. In certain embodiments of Formula (III)-(VB), including any of the foregoing, Raand Rbare both hydrogen; a is 4; and b is 0. In certain embodiments of Formula (III)-(VB), including any of the foregoing, Raand Rbare both hydrogen; a is 5; and b is 0. In certain embodiments of Formula (III)-(VB), including any of the foregoing, Raand Rbare both hydrogen; a is 6; and b is 0.

[0381] In certain embodiments of Formula (III)-(VB), including any of the foregoing, Raand Rbare both hydrogen; R1is methyl; a is 1; and b is 0. In certain embodiments of Formula (III)-(VB), including any of the foregoing, Raand Rbare both hydrogen; R1is methyl; a is 2; and b is 0. In certain embodiments of Formula (III)-(VB), including any of the foregoing, Raand Rbare both hydrogen; R1is methyl; a is 3; and b is 0. In certain embodiments of Formula (III)- (VB), including any of the foregoing, Raand Rbare both hydrogen; R1is methyl; a is 4; and b is 0. In certain embodiments of Formula (III)-(VB), including any of the foregoing, Raand Rbare both hydrogen; R1is methyl; a is 5; and b is 0. In certain embodiments of Formula (III)-(VB), including any of the foregoing, Raand Rbare both hydrogen; R1is methyl; a is 6; and b is 0.

[0382] In certain embodiments of Formula (III)-(IVB), including any of the foregoing, Rais hydrogen; Rbis selected from hydrogen, alkyl, halogen, alkoxy, -CN, -NO2, -OH, -NH2, -C(O)NH2, and -C(O)OH; a is 1; and c is 1. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, Rais hydrogen; Rbis selected from hydrogen, alkyl, halogen, alkoxy, -CN, -NO2, -OH, -NH2, -C(O)NH2, and -C(O)OH; a is 2; and c is 1. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, Rais hydrogen; Rbis selected from hydrogen, alkyl, halogen, alkoxy, -CN, -NO2, -OH, -NH2, -C(O)NH2, and -C(O)OH; a is 3; and c is 1.

[0383] In certain embodiments of Formula (III)-(IVB), including any of the foregoing, Yais *-C(O)-(CRaRb)c-NH- wherein * represents where Yais bound to RL. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, Yais *-C(O)-(CH2)c-NH-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, Yais *-C(O)-(CH2)-NH-. In certain embodiments, including any of the foregoing, Yais *-C(O)-(CH2)2-NH-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, Yais *-C(O)-(CH2)3-NH- . In certain embodiments of Formula (III)-(IVB), including any of the foregoing, Yais *-C(O)- (CH2)4-NH-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, Yais *-C(O)-(CH2)5-NH-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, Yais *-C(O)-(CH2)6-NH-.

[0384] In certain embodiments of Formula (III)-(IVB), including any of the foregoing, Yais *-C(O)-(CRaRb)-NH-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, Yais *-C(O)-(CRaRb)2-NH-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, Yais *-C(O)-(CRaRb)3-NH-. In certain embodiments of Formula(III)-(IVB), including any of the foregoing, Yais *-C(O)-(CRaRb)4-NH-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, Yais *-C(O)-(CRaRb)5-NH-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, Yais *-C(O)-(CRaRb)6- NH-.

[0385] In certain embodiments of Formula (III)-(IVB), including any of the foregoing, Yais *-C(O)-(CRaRb)c-NH- wherein Rais hydrogen and Rbis selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, halogen, alkoxy, -CN, -NO2, -OH, -N(R2R3)2, -C(O)N(R2R3)2, -C(O)OR2, aminoalkyl, hydroxyalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, Yais *-C(O)- (CRaRb)2-NH-, *-C(O)-(CRaRb)3-NH-, or *-C(O)-(CRaRb)4-NH- wherein Rais hydrogen and Rbis selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, halogen, alkoxy, -CN, -NO2, -OH, -N(R2R3)2, -C(O)N(R2R3)2, -C(O)OR2, aminoalkyl, hydroxyalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl.

[0386] In certain embodiments of Formula (III)-(IVB), including any of the foregoing, Yais *-C(O)-(CRaRb)c- wherein * represents where Yais bound to RL. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, Yais *-C(O)-(CH2)c-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, Yais *-C(O)-(CH2)-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, Yais *-C(O)- (CH2)2-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, Yais *- C(O)-(CH2)3-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, Yais *-C(O)-(CH2)4-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing of Formula (III)-(IVB), Yais *-C(O)-(CH2)5-. In certain embodiments, including any of the foregoing, Yais *-C(O)-(CH2)6-.

[0387] In certain embodiments, including any of the foregoing of Formula (III)-(IVB), Yais *-C(O)-(CRaRb)-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, Yais *-C(O)-(CRaRb)2-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, Yais *-C(O)-(CRaRb)3-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, Yais *-C(O)-(CRaRb)4-. In certain embodiments of Formula (III)- (IVB), including any of the foregoing, Yais *-C(O)-(CRaRb)5-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, Yais *-C(O)-(CRaRb)6-.

[0388] In certain embodiments of Formula (III)-(IVB), including any of the foregoing, Yais *-C(O)-(CRaRb)c- wherein Rais hydrogen and Rbis selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, halogen, alkoxy, -CN, -NO2, -OH, -N(R2R3)2, -C(O)N(R2R3)2, -C(O)OR2, aminoalkyl, hydroxyalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, Yais *-C(O)-(CRaRb)2-, *-C(O)-(CRaRb)3-, or *-C(O)-(CRaRb)4- wherein Rais hydrogen and Rbis selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, halogen, alkoxy, -CN, -NO2, -OH, -N(R2R3)2, -C(O)N(R2R3)2, -C(O)OR2, aminoalkyl, hydroxyalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl.

[0389] In certain embodiments of Formula (III)-(IVB), including any of the foregoing, Yais *-C(O)-(CH2)2-NH- or *-C(O)-(CH2)4-.

[0390] In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is absent. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is a linker comprising a hydrophilic polymer residue.

[0391] In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is -(CRaRb)a-POLY1-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is -CH2-POLY1-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is -(CH2)2-POLY1-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is -(CH2)3-POLY1-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is -(CH2)4-POLY1-. In certain embodiments of Formula (III)- (IVB), including any of the foregoing, L2is –(CH2)5-POLY1-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is –(CH2)6-POLY1-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is -CRaRb-POLY1-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is –(CRaRb)2- POLY1-. In certain embodiments, including any of the foregoing, L2is –(CRaRb)3-POLY1-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is –(CRaRb)4- POLY1-.

[0392] In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is -POLY1-.

[0393] In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is –(CRaRb)a-POLY1-(CRaRb)a-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is –(CRaRb)a-POLY1-(CRaRb)a- wherein a is independently selected from 0, 1, 2, 3, 4, 5, or 6. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is –(CH2)a-POLY1-(CH2)a- wherein a is independently selected from 0, 1, 2, 3, 4, 5, or 6. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is –(CH2)a-POLY1-(CRaRb)a- wherein a is selected from 1, 2, 3, 4, 5, or 6. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is –(CRaRb)a-POLY1-(CH2)a- wherein a is independently selected from 0, 1, 2, 3, 4, 5, or 6.

[0394] In certain embodiments of Formula (III)-(IVB), including any of the foregoing, POLY1is a diavalent residue of a nonpeptidic, hydrophilic polymer. In certain embodiments of Formula (III)-(IVB), POLY1is a diavalent residue of polyethylene glycol (PEG), poly(propylene glycol) (PPG), copolymers of ethylene glycol and propylene glycol, poly(oxyethylated polyol), poly(olefinic alcohol), poly(vinylpyrrolidone), poly(hydroxyalkylmethacrylamide), poly(hydroxyalkylmethacrylate), poly(saccharides), poly(^-hydroxy acid), poly(vinyl alcohol), polyphosphazene, polyoxazolines (POZ), poly(N-acryloylmorpholine), polysarcosine, or a combination thereof. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, POLY1is a divalent residue of polyethylene glycol (PEG), poly(propylene glycol) (PPG), or a copolymer of ethylene glycol and propylene glycol.

[0395] In certain embodiments of Formula (III)-(IVB), including any of the foregoing, POLY1is a diavalent residue of polyethylene glycol (PEG). In certain embodiments of Formula (III)-(IVB), including any of the foregoing, POLY1is a diavalent residue of poly(propylene glycol) (PPG). In certain embodiments of Formula (III)-(IVB), including any of the foregoing, POLY1is a diavalent residue of copolymers of ethylene glycol and propylene glycol. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, POLY1is a diavalent residue of poly(oxyethylated polyol). In certain embodiments of Formula (III)-(IVB), including any of the foregoing, POLY1is a diavalent residue of poly(olefinic alcohol). In certain embodiments of Formula (III)-(IVB), including any of the foregoing, POLY1is a diavalent residue of poly(vinylpyrrolidone). In certain embodiments of Formula (III)-(IVB), including any of the foregoing, POLY1is a diavalent residue of poly(hydroxyalkylmethacrylamide). In certain embodiments of Formula (III)-(IVB), including any of the foregoing, POLY1is a diavalent residue of poly(hydroxyalkylmethacrylate). In certain embodiments of Formula (III)-(IVB),including any of the foregoing, POLY1is a diavalent residue of poly(saccharides). In certain embodiments of Formula (III)-(IVB), including any of the foregoing, POLY1is a diavalent residue of poly(^-hydroxy acid). In certain embodiments of Formula (III)-(IVB), including any of the foregoing, POLY1is a diavalent residue of poly(vinyl alcohol). In certain embodiments of Formula (III)-(IVB), including any of the foregoing, POLY1is a diavalent residue of polyphosphazene. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, POLY1is a diavalent residue of polyoxazolines (POZ). In certain embodiments of Formula (III)-(IVB), including any of the foregoing, POLY1is a diavalent residue of poly(N- acryloylmorpholine). In certain embodiments of Formula (III)-(IVB), including any of the foregoing, POLY1is a diavalent residue of polysarcosine.

[0396] In certain embodiments of Formula (III)-(IVB), including any of the foregoing,nc us ve, and represents attac ment to t e rema nder o t e compound or conjugate. n certain embodiments of Formula (III)-(IVB), including any of the foregoing, x is an integer between 1 to 25. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, x is an integer between 5 to 15. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 1. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 2. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 3. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 4. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 5. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 6. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 7. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 8. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 9. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 10. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 11. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 12. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 13. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 14. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 15. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 16. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 17. In someembodiments, including any of the foregoing, x is 18. In some embodiments of Formula (III)- (IVB), including any of the foregoing, x is 19. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 20. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, x is an integer between 25 and 50. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, x is an integer between 35 and 45. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, x is an integer between 50 and 75. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, x is an integer between 55 and 65. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, x is an integer between 75 and 100. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, x is an integer between 85 and 95. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, x is an integer in the range of 1 and 25, 20 and 45, 40 and 65, 60 and 85, 70 and 95, or 75 and 100.

[0397] In some embodiments of Formula (III)-(IVB), including any of the foregoing, R5is hydrogen. In some embodiments, including any of the foregoing, R5is methyl.

[0398] In certain embodiments of Formula (III)-(IVB), including any of the foregoing, isa- - w e e s . In certain embodiments of Formula (III)- (IVB), including any of the foregoing, L2is –(CRaRb)a-POLY1- wherein POLY1is. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is –(CH2)a- POLY1- wherein POLY1is. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is –(CH2)2-POLY1- wherein POLY1is. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is –(CRaRb)a- POLY1- wherein. certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is –(CRaRb)a-POLY1- wherein.certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is –(CH2)2- POLY1- wherein. certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is –(CH2)2-POLY1- wherein. certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is –(CH2)2- POLY1- wherein.

[0399] In certain embodiments of Formula (III)-(IVB), including any of the foregoing,. In certain embodiments, including any of the foregoing, L2is. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is,foregoing, L2is -(CRaRb)a-POLY1-(CRaRb)a- wherein POLY1is. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is -(CRaRb)a-POLY1- (CRaRb)a- wherein. In certain embodiments of Formula (III)-(IVB),including any of the foregoing, L2is -(CRaRb)a-POLY1-(CRaRb)a- wherein POLY1is. certain embodiments of Formula (III)-(IVB), including any of the foregoing,

[0400] In certain embodiments of Formula (III)-(IVB), including any of the foregoing,. In certain embodiments of Formula (III)-(IVB), including any of the foregoing,. certain embodiments of Formula (III)-(IVB), including any of the foregoing,.

[0401] In certain embodiments of Formula (III)-(IVB), including any of the foregoing,, . , of the foregoing,. certain embodiments of Formula (III)-(IVB), including any of the foregoing,. certain embodiments of Formula (III)-(IVB), including any of the foregoing,.

[0402] In certain embodiments of Formula (III)-(IVB), including any of the foregoing, POLY2is a residue of a nonpeptidic, hydrophilic polymer. In certain embodiments of Formula (III)-(IVB), POLY2is a residue of polyethylene glycol (PEG), methoxypolyethylene glycol (mPEG), poly(propylene glycol) (PPG), copolymers of ethylene glycol and propylene glycol, poly(oxyethylated polyol), poly(olefinic alcohol), poly(vinylpyrrolidone), poly(hydroxyalkylmethacrylamide), poly(hydroxyalkylmethacrylate), poly(saccharides), poly(^-hydroxy acid), poly(vinyl alcohol), polyphosphazene, polyoxazolines (POZ), poly(N- acryloylmorpholine), polysarcosine, or a combination thereof. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, POLY2is a residue of polyethylene glycol (PEG), methoxypolyethylene glycol (mPEG), poly(propylene glycol) (PPG), or a copolymer of ethylene glycol and propylene glycol. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, POLY2is a residue of methoxypolyethylene glycol (mPEG).

[0403] In certain embodiments of Formula (III)-(IVB), including any of the foregoing, POLY2is a residue of polyethylene glycol (PEG). In certain embodiments of Formula (III)- (IVB), including any of the foregoing, POLY2is a residue of poly(propylene glycol) (PPG). In certain embodiments, including any of the foregoing, POLY2is a residue of copolymers of ethylene glycol and propylene glycol. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, POLY2is a residue of poly(oxyethylated polyol). In certain embodiments of Formula (III)-(IVB), including any of the foregoing, POLY2is a residue of poly(olefinic alcohol). In certain embodiments of Formula (III)-(IVB), including any of the foregoing, POLY2is a residue of poly(vinylpyrrolidone). In certain embodiments of Formula (III)-(IVB), including any of the foregoing, POLY2is a residue of poly(hydroxyalkylmethacrylamide). In certain embodiments of Formula (III)-(IVB), including any of the foregoing, POLY2is a residue of poly(hydroxyalkylmethacrylate). In certain embodiments of Formula (III)-(IVB), including any of the foregoing, POLY2is a residue of poly(saccharides). In certain embodiments of Formula (III)-(IVB), including any of the foregoing, POLY2is a residue of poly(^-hydroxy acid). In certain embodiments of Formula (III)-(IVB), including any of the foregoing, POLY2is a residue of poly(vinyl alcohol). In certain embodiments of Formula (III)-(IVB), including any of the foregoing, POLY2is a residue of polyphosphazene. In certain embodiments of Formula (III)- (IVB), including any of the foregoing, POLY2is a residue of polyoxazolines (POZ). In certain embodiments of Formula (III)-(IVB), including any of the foregoing, POLY2is a residue of poly(N-acryloylmorpholine). In certain embodiments of Formula (III)-(IVB), including any of the foregoing, POLY2is a residue of polysarcosine.

[0404] In certain embodiments of Formula (III)-(IVB), including any of the foregoing,, wherein R5 is hydrogen or methyl, x is an integer from 1 to 100,inclusive, andrepresents attachment to the remainder of the compound or conjugate. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, x is an integer between 1 to 25. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, x is an integer between 5 to 15. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 1. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 2. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 3. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 4. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 5. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 6. In some embodiments, including any of the foregoing, x is 7. In some embodiments of Formula (III)- (IVB), including any of the foregoing, x is 8. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 9. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 10. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 11. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 12. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 13. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 14. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 15. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 16. In some embodiments of Formula (III)-(IVB), including any of the foregoing of Formula (III)-(IVB), x is 17. In some embodiments, including any of the foregoing of Formula (III)-(IVB), x is 18. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 19. In some embodiments of Formula (III)-(IVB), including any of the foregoing, x is 20. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, x is an integer between 25 and 50. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, x is an integer between 35 and 45. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, x is an integer between 50 and 75. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, x is an integer between 55 and 65. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, x is an integer between 75 and 100. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, x is an integer between 85 and 95. In certain embodiments of Formula (III)-(IVB), including any of theforegoing, x is an integer in the range of 1 and 25, 20 and 45, 40 and 65, 60 and 85, 70 and 95, or 75 and 100.

[0405] In some embodiments of Formula (III)-(IVB), including any of the foregoing, R5is hydrogen. In some embodiments of Formula (III)-(IVB), including any of the foregoing, R5is methyl.

[0406] In certain embodiments of Formula (III)-(IVB), including any of the foregoing,.

[0407] In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is selected from the group consisting,.

[0408] In certain embodiments of Formula (III)-(IVB), including any of the foregoing,

[0409] In certain embodiments of Formula (III)-(IVB), including any of the foregoing,certain embodiments of Formula (III)-(IVB), including any of the foregoing,

[0410] In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L3is -C(O)-AA-.

[0411] In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L3is -C(O)-AA-Z-(CRaRb)a-Z-(CRaRb)a-C(O)-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L3is -C(O)-AA-NR2-(CRaRb)a-NR2-(CRaRb)a-C(O)-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L3is -C(O)-AA-NH- (CRaRb)a-NH-(CRaRb)a-C(O)-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L3is -C(O)-AA-NH-(CH2)a-NH-(CH2)a-C(O)-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L3is -C(O)-AA-NH-(CH2)a-NH-(CH2)a- C(O)- wherein a is selected from 1, 2, and 3. In certain embodiments, including any of the foregoing, L3is -C(O)-AA-NH-CH2-NH-CH2-C(O)-

[0412] In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L3is -C(O)-AA-Z-(CRaRb)a. In certain embodiments, including any of the foregoing, L3is -C(O)-AA- NR2-(CH ) . In certain emb 3 2 a odiments of Formula (III)-(IVB), including any of the foregoing, L is -C(O)-AA-NH-(CH2)2.

[0413] In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L3is -AA-. In certain embodiments, including any of the foregoing,.

[0414] In certain embodiments of Formula (III)-(IVB), including any of the foregoing, - AA- is an amino acid residue. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, -AA- is a peptide residue. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, -AA- is a dipeptide residue, a tripeptide residue, a tetrapeptide residue, or a pentapeptide residue. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, -AA- comprises at least one amino acid residue selected from alanine, glycine, valine, and asparagine. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, -AA- comprises at least one amino acid residue selected from alanine and glycine. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, -AA- is selected.

[0415] In certain embodiments of Formula (III)-(IVB), including any of the foregoing, - AA- is selected from the group consisting of,, , ,,

[0416] In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L3is -C(O)-.

[0417] In certain embodiments of Formula (III)-(IVB), including any of the foregoing, ishexose form of a monosaccharide and d is an integer independently selected from 1, 2, and 3. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L3is -C(O)-NR2-(CRaRb)a- C(O)-NR2-L4-OC(O)-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L3is -C(O)-NR2-(CH2)2-C(O)-NR2-L4-OC(O)-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L3is -C(O)-NH-(CRaRb)a-C(O)-NH-L4-OC(O)-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L3is -C(O)-NH- (CH2)2-C(O)-NH-L4-OC(O)-.

[0418] In certain embodiments of Formula (III)-(IVB), including any of the foregoing,. certain embodiments of Formula (III)-(IVB), including any of theforegoing,. certain embodiments of Formula (III)-(IVB), including any of the foregoing,.

[0419] In some embodiments of Formula (III)-(IVB), including any of the foregoing, Su is a sugar moiety. In some embodiments, Su is a hexose form of a monosaccharide. Su may be a glucuronic acid or mannose residue. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, , wherein represents attachment to the remainder of the compound. In certain embodiments of Formula (III)-(IVB), including any of the foregoing,represents attachment to the remainder of the compound.

[0420] In certain embodiments of Formula (III)-(IVB), including any of the foregoing,.

[0421] In certain embodiments of Formula (III)-(IVB), including any of the foregoing, is. certainembodiments of Formula (III)-(IVB), including any of the foregoing, L3is -C(O)-NH-(CH2)2- C(O)-NH-L4-OC(O)- wherein.

[0422] In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is -(CRaRb)a-POLY1- and L3is -C(O)-AA-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is -(CRaRb)a-POLY1-; L3is is -C(O)-AA-; and, POLY1is. In certain embodiments of Formula (III)-(IVB), including any of the foregoing,integer between 10 and 15. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is -(CH2)2-POLY1-; L3is -C(O)-AA-; and, POLY1is. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is -(CH2)2-POLY1-; L3is -C(O)-AA-; POLY1is; and AA is a a dipeptide residue, a tripeptide residue, a tetrapeptide residue, or a pentapeptide residue.

[0423] In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is -(CRaRb)a-POLY1- and L3is -C(O)-AA-Z-(CRaRb)a-Z-(CRaRb)a-C(O)-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is -(CRaRb)a-POLY1-; L3is -C(O)- AA-Z-(CRaRb)a-Z-(CRaRb)a-C(O)-;, and Z is -NH-. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2isx is an integer between 10 and 15. In certain embodiments of Formula (III)-(IVB), including anyof the foregoing, L2is -(CH2)2-POLY1-; L3is -C(O)-AA-NH-CH2-NH-CH2-C(O)-; and, POLY1 is. In certain embodiments of Formula (III)-(IVB), including any of the foregoing,AA is a a dipeptide residue, a tripeptide residue, a tetrapeptide residue, or a pentapeptide residue.

[0424] In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is -(CRaRb)a-POLY1- and L3is -C(O). In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is -(CRaRb)a-POLY1-; L3is -C(O); and, POLY1is. In certain embodiments of Formula (III)-(IVB), including any of the foregoing,integer between 10 and 15. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is -(CH2)2-POLY1-; L3is -C(O); and, POLY1is. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is -(CH2)2-POLY1-; L3is -C(O); POLY1is; and AA is a dipeptide residue, a tripeptide residue, a tetrapeptide residue, or a pentapeptide residue.

[0425] In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is -(CRaRb)a-POLY1- and L3is absent. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is -(CRaRb)a-POLY1-; L3is absent; and, POLY1is. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is -(CH2)a- POLY1-; L3is absent; POLY1is; and x is an integer between 10 and 15. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is -(CH2)2-POLY1-; L3is absent; and, POLY1is. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is -(CH2)2-POLY1-; L3is absent; POLY1isAA is a dipeptide residue, a tripeptide residue, a tetrapeptide residue, or a pentapeptide residue.

[0426] In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is -(CRaRb)a-POLY1- and L3is -C(O)-AA-Z-(CRaRb)a-. In certain embodiments of Formula (III)- (IVB), including any of the foregoing, L2is -(CRaRb)a-POLY1-; L3is is -C(O)-AA-Z-(CRaRb)a- ; and, POLY1is. In certain embodiments of Formula (III)-(IVB), including any of the foregoing,x is an integer between 10 and 15. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is -(CH2)2-POLY1-; L3is -C(O)-AA-NH-(CRaRb)a-; and, POLY1is. In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2dipeptide residue, a tripeptide residue, a tetrapeptide residue, or a pentapeptide residue.

[0427] Non-limiting examples of -L2-L3- include:

[0428] Additional non-limiting examples of -L2-L3- include:.

[0429] In certain embodiments of Formula (III)-(IVB), including any of the foregoing, and L3is -C(O)-Z-(CRaRb)a-C(O)-Z-L4-OC(O)- wherein L4isSu is a hexose form of a monosaccharide and d is an integer independently selected from 1, 2, and 3. In certain embodiments of Formula (III)-(IVB),including any of the foregoing,OC(O)-.

[0430] In certain embodiments of Formula (III)-(IVB), including any of the foregoing,

[0431] In certain embodiments of Formula (III)-(IVB), including any of the foregoing,a s -C(O)-NH-(CRaRb)a-C(O)-NH-L4-OC(O)-.

[0432] In certain embodiments of Formula (III)-(IVB), including any of the foregoing,-C(O)-NH-(CRaRb)a-C(O)-NH-L4-OC(O)-.

[0433] In certain embodiments of Formula (III)-(IVB), including any of the foregoing, L2is selected from the group consisting of,.

[0434] In certain embodiments of Formula (III)-(IVB), including any of the foregoing,

[0435] In certain embodiments, including any of the foregoing, D is a cytotoxic payload selected from a tubulin inhibitor, a DNA topoisomerase I inhibitor, and a DNA topoisomerase II inhibitor. In some embodiments, including any of the foregoing, D is a tubulin inhibitor. In some embodiments, including any of the foregoing, D is a DNA topoisomerase I inhibitor. In some embodiments, including any of the foregoing, D is a DNA topoisomerase I inhibitor selected from the group consisting of irinotecan, SN-38, topotecan, exatecan. In some embodiments, including any of the foregoing, D is irinotecan. In some embodiments, including any of the foregoing, D is SN-38. In some embodiments, including any of the foregoing, D is topotecan. In some embodiments, including any of the foregoing, D is exatecan. In some embodiments, including any of the foregoing, D is a DNA topoisomerase II inhibitor. In some embodiments, including any of the foregoing, D is a DNA topoisomerase II inhibitor selected from the group consisting of etoposide, teniposide, and tafluposide. In some embodiments, including any of the foregoing, D is etoposide. In some embodiments, including any of the foregoing, D is teniposide. In some embodiments, including any of the foregoing, D is tafluposide. In some embodiments, including any of the foregoing, D is selected from the group consisting of hemiasterlins, camptothecins, and anthracyclines. Anthracyclines may include PNU-159682 and EDA PNU-159682 derivatives. In some embodiments, including any of the foregoing, D is an anthracycline selected from the group consisting of daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, and valrubicin. In some embodiments, including any of the foregoing, D is daunorubicin. In some embodiments, including any of the foregoing, D is doxorubicin. In some embodiments, including any of the foregoing, D is epirubicin. In some embodiments, including any of the foregoing, D is idarubicin. In some embodiments, including any of the foregoing, D is mitoxantrone. In some embodiments, including any of the foregoing, D is valrubicin. In some embodiments, including any of the foregoing, D is a hemiasterlin. In some embodiments, including any of the foregoing, D is a camptothecin. In some embodiments, including any of the foregoing, D is an anthracycline. Insome embodiments, including any of the foregoing, D is PNU-159682. In some embodiments, including any of the foregoing, D is an EDA PNU compound. In some embodiments, including any of the foregoing, D is an EDA PNU-159682 derivative. In some embodiments, including any of the foregoing, D is hemiasterlin, exatecan, PNU-159682, or an EDA PNU-159682 derivative. In some embodiments, including any of the foregoing, D is hemiasterlin. In some embodiments, including any of the foregoing, D is exatecan. In some embodiments, including any of the foregoing, D is of PNU-159682. In some embodiments, including any of the foregoing, D is EDA PNU-159682 compound or derivative.

[0436] In some embodiments, including any of the foregoing, D is an alkylating agent. In some embodiments, including any of the foregoing, D is a bifunctional alkylator. In some embodiments, including any of the foregoing, D is a bifunctional alkylator selected from the group consisting of cyclophosphamide, mechlorethamine, chlorambucil, and melphalan. In some embodiments, including any of the foregoing, D is cyclophosphamide. In some embodiments, including any of the foregoing, D is mechlorethamine. In some embodiments, including any of the foregoing, D is chlorambucil. In some embodiments, including any of the foregoing, D is melphalan. In some embodiments, including any of the foregoing, D is a monofunctional alkylator. In some embodiments, including any of the foregoing, D is a monofunctional alkylator selected from the group consisting of dacarbazine, nitrosourea, and temozolomide. In some embodiments, including any of the foregoing, D is dacarbazine. In some embodiments, including any of the foregoing, D is nitrosourea. In some embodiments, including any of the foregoing, D is temozolomide. In some embodiments, including any of the foregoing, D is a cytoskeletal disruptor (e.g., a taxane). In some embodiments, including any of the foregoing, D is a cytoskeletal disruptor selected from the group consisting of paclitaxel, docetaxel, abraxane, and taxotere. In some embodiments, including any of the foregoing, D is paclitaxel. In some embodiments, including any of the foregoing, D is docetaxel. In some embodiments, including any of the foregoing, D is abraxane. In some embodiments, including any of the foregoing, D is taxotere. In some embodiments, including any of the foregoing, D is an epothilone. In some embodiments, including any of the foregoing, D is an epothilone selected from the group consisting of epothilone A, epothilone B, epothilone C, epothilone D, and ixabepilone. In some embodiments, including any of the foregoing, D is epothilone A. In some embodiments, including any of the foregoing, D is epothilone B. In some embodiments, including any of the foregoing, D is epothilone C. In some embodiments, including any of the foregoing, D is epothilone D. In some embodiments, including any of the foregoing, D is ixabepilone. In some embodiments, including any of the foregoing, D is a histone deacetylase inhibitor. In someembodiments, including any of the foregoing, D is a histone deacetylase inhibitor selected from the group consisting of vorinostat and romidepsin. In some embodiments, including any of the foregoing, D is vorinostat. In some embodiments, including any of the foregoing, D is romidepsin. In some embodiments, including any of the foregoing, D is a kinase inhibitor. In some embodiments, including any of the foregoing, D is a kinase inhibitor selected from the group consisting of bortezomib, erlotinib, gefitinib, imatinib, vemurafenib, and vismodegib. In some embodiments, including any of the foregoing, D is bortezomib. In some embodiments, including any of the foregoing, D is erlotinib. In some embodiments, including any of the foregoing, D is gefitinib. In some embodiments, including any of the foregoing, D is imatinib. In some embodiments, including any of the foregoing, D is vemurafenib. In some embodiments, including any of the foregoing, D is vismodegib. In some embodiments, including any of the foregoing, D is a nucleotide analog and / or precursor analog. In some embodiments, including any of the foregoing, D is a nucleotide analog and / or precursor analog selected from the group consisting of azacitidine, azathioprine, capecitabine, cytarabine, doxifluridine, fluorouracil, gemcitabine, hydroxyurea, mercaptopurine, methotrexate, and tioguanine (formerly thioguanine). In some embodiments, including any of the foregoing, D is azacitidine. In some embodiments, including any of the foregoing, D is azathioprine. In some embodiments, including any of the foregoing, D is capecitabine. In some embodiments, including any of the foregoing, D is cytarabine. In some embodiments, including any of the foregoing, D is doxifluridine. In some embodiments, including any of the foregoing, D is fluorouracil. In some embodiments, including any of the foregoing, D is gemcitabine. In some embodiments, including any of the foregoing, D is hydroxyurea. In some embodiments, including any of the foregoing, D is mercaptopurine. In some embodiments, including any of the foregoing, D is methotrexate. In some embodiments, including any of the foregoing, D is tioguanine (formerly thioguanine). In some embodiments, including any of the foregoing, D is a peptide antibiotic. In some embodiments, including any of the foregoing, D is a peptide antibiotic selected from the group consisting of bleomycin and actinomycin. In some embodiments, including any of the foregoing, D is bleomycin. In some embodiments, including any of the foregoing, D is actinomycin. In some embodiments, including any of the foregoing, D is a platinum-based agent. In some embodiments, including any of the foregoing, D is a platinum-based agent selected from the group consisting of carboplatin, cisplatin, and oxaliplatin. In some embodiments, including any of the foregoing, D is carboplatin. In some embodiments, including any of the foregoing, D is cisplatin. In some embodiments, including any of the foregoing, D is oxaliplatin. In some embodiments, including any of the foregoing, D is a retinoid. In some embodiments, including any of the foregoing, D is a retinoid selected from the group consisting of tretinoin, alitretinoin,and bexarotene. In some embodiments, including any of the foregoing, D is tretinoin. In some embodiments, including any of the foregoing, D is alitretinoin. In some embodiments, including any of the foregoing, D is bexarotene. In some embodiments, including any of the foregoing, D is a vinca alkaloid and derivatives thereof. In some embodiments, including any of the foregoing, D is a vinca alkaloid and derivatives thereof selected from the group consisting of vinblastine, vincristine, vindesine, vinorelbine. In some embodiments, including any of the foregoing, D is a residue of vinblastine. In some embodiments, including any of the foregoing, D is vincristine. In some embodiments, including any of the foregoing, D is vindesine.

[0437] In any of the foregoing embodiments, the conjugate comprises n2 number of linker-payloads, wherein n2 is an integer from 1 to 10. In some embodiments, n2 is 2. In some embodiments, n2 is 3. In some embodiments, n2 is 4. In some embodiments, n2 is 5. In some embodiments, n2 is 6. In some embodiments, n2 is 7. In some embodiments, n2 is 8. In some embodiments, n2 is 9. In some embodiments, n2 is 10.

[0438] In some embodiments, provided herein are anti-Tissue Factor conjugates having the structure of any of Conjugates A-E in the table below. In some embodiments, n2 is an integer from 1 to 8. In some embodiments, n2 is 2. In some embodiments, n2 is 4. In some embodiments, n2 is 6. In some embodiments, n2 is 8. The present disclosure encompasses each and every regioisomer of the conjugate structures depicted below.A;D;E .

[0439] In some embodiments, provided herein are anti-Tissue Factor conjugates having the structure of any of Conjugates A1-E1 in the table below. In some embodiments, n2 is an integer from 1 to 8. In some embodiments, n2 is 2. In some embodiments, n2 is 4. In some embodiments, n2 is 6. In some embodiments, n2 is 8. The present disclosure encompasses each and every regioisomer of the conjugate structures depicted below.A1;E1.

[0440] It should be understood that in certain embodiments, other linker payloads and conjugation structures are provided such as those discussed in International Patent Application No. PCT / US2023 / 023688, filed June 27, 2023 entitled β-Glucuronide Linker-Payloads, Protein Conjugates Thereof, And Methods Thereof as well as U.S. Provisional Application No. 61 / 516,579, filed July 31, 2023, entitled STING Agonist Compounds and Conjugates, each of which is incorporated herein by reference in its entirety. In some embodiments provided herein are anti-Tissue Factor conjugates comprising an antibody described herein linked to one or more linker-payloads as described in PCT Application PCT / US2023 / 26338, PCT / US / 2020 / 031052, PCT / US / 2018 / 051364, PCT / US2018 / 051322, PCT / US2017 / 015501, PCT / US2017 / 015503, and PCT / US2016 / 015844, each of which are incorporated by reference in its entirety.

[0441] In any of the foregoing embodiments wherein the anti-Tissue Factor conjugate has a structure according to any one of Conjugates A-E, the bracketed structure can be covalently bonded to one or more non-natural amino acids of the antibody, wherein the one or more non-natural amino acids are located at sites selected from the group consisting of: HC- F404, HC-Y180, HC-F241, LC-K42, and LC-E161, according to the Kabat or EU numbering scheme of Kabat. In some embodiments, the bracketed structure is covalently bonded to one or more non-natural amino acids at site HC-F404 of the antibody. In some embodiments, the bracketed structure is covalently bonded to one or more non-natural amino acids at site HC-Y180 of the antibody. In some embodiments, the bracketed structure is covalently bonded to one or more non-natural amino acids at site HC-F241of the antibody. In some embodiments, the bracketed structure is covalently bonded to one or more non-natural amino acids at site LC-K42 of the antibody. In some embodiments, the bracketed structure is covalently bonded to one or more non-natural amino acids at site LC-E161of the antibody. In some embodiments, the bracketed structures are covalently bonded to non-natural amino acids at sites HC-F404 and HC-Y180 of the antibody. In some embodiments, the bracketed structures are covalently bondedto non-natural amino acids at sites HC-F404, HC-Y180, and LC-K42 of the antibody. In some embodiments, the bracketed structures are covalently bonded to non-natural amino acids at sites HC-F404, HC-Y180, LC-K42, and LC-E161 of the antibody. In some embodiments, the bracketed structures are covalently bonded to non-natural amino acids at sites HC-F404, HC- Y180, and HC-F241 of the antibody. In some embodiments, the bracketed structures are covalently bonded to non-natural amino acids at sites HC-F404, HC-Y180, HC-F241, and LC- K42 of the antibody. In some embodiments, the bracketed structures are covalently bonded to non-natural amino acids at sites HC-F404 and HC-F241.

[0442] In particular embodiments, provided herein are anti-Tissue Factor conjugates according to any of the conjugates described herein wherein COMP indicates a residue of the non-natural amino acid according to Formula (30), below. In particular embodiments, provided herein are anti- Tissue Factor conjugates according to any of the conjugates described herein wherein COMP indicates a residue of the non-natural amino acid according to Formula (30), below, at heavy chain position 404 according to the EU numbering system. In particular embodiments, provided herein are anti- Tissue Factor conjugates according to any of the conjugates described herein wherein COMP indicates a residue of the non-natural amino acid according to Formula (30), below, at heavy chain position 180 according to the EU numbering system. In particular embodiments, provided herein are anti- Tissue Factor conjugates according to any of the conjugates described herein wherein COMP indicates a residue of the non-natural amino acid according to Formula (30), below, at heavy chain position 241 according to the EU numbering system. In particular embodiments, provided herein are anti- Tissue Factor conjugates according to any of the conjugates described herein wherein COMP indicates a residue of the non-natural amino acid according to Formula (30), below, at heavy chain position 222 according to the EU numbering system. In particular embodiments, provided herein are anti- Tissue Factor conjugates according to any of the conjugates described herein wherein COMP indicates a residue of the non-natural amino acid according to Formula (30), below, at light chain position 7 according to the Kabat or Chothia numbering system. In particular embodiments, provided herein are anti-Tissue Factor conjugates according to any of the conjugates described herein wherein COMP indicates a residue of the non-natural amino acid according to Formula (30), below, at light chain position 42 according to the Kabat or Chothia numbering system. In certain embodiments, PAY is selected from the group consisting of maytansine, hemiasterlin, amanitin, camptothecin, exatecan, exatecan derivative (DXd), SN-38, anthracycline, PNU- 159682, PNU derivative (PNU-EDA), pyrrolobenzodiazepine (PBD), MMAF, and MMAE. In certain embodiments, PAY is maytansine. In certain embodiments, PAY is hemiasterlin. Incertain embodiments, PAY is amanitin. In certain embodiments, PAY is exatecan. In certain embodiments, PAY is exatecan derivative Dxd. In certain embodiments, PAY is anthracycline. In certain embodiments, PAY is PNU-159682. In certain embodiments, PAY is PNU derivative (PNU-EDA). In certain embodiments, PAY is pyrrolobenzodiazepine. In certain embodiments, PAY is MMAF. In certain embodiments, PAY is MMAE.

[0443] In particular embodiments, provided herein are anti- Tissue Factor conjugates according to any of the conjugates described herein wherein COMP indicates a residue of the non-natural amino acid according to Formula (56), below. In particular embodiments, provided herein are anti-Tissue Factor conjugates according to any of the conjugates described herein wherein COMP indicates a residue of the non-natural amino acid according to Formula (56), below, at heavy chain position 404 according to the EU numbering system. In particular embodiments, provided herein are anti-Tissue Factor conjugates according to any of the conjugates described herein wherein COMP indicates a residue of the non-natural amino acid according to Formula (56), below, at heavy chain position 180 according to the EU numbering system. In particular embodiments, provided herein are anti-Tissue Factor conjugates according to any of the conjugates described herein wherein COMP indicates a residue of the non-natural amino acid according to Formula (56), below, at heavy chain position 241 according to the EU numbering system. In particular embodiments, provided herein are anti-Tissue Factor conjugates according to any of the conjugates described herein wherein COMP indicates a residue of the non-natural amino acid according to Formula (56), below, at heavy chain position 222 according to the EU numbering system. In particular embodiments, provided herein are anti-Tissue Factor conjugates according to any of the conjugates described herein wherein COMP indicates a residue of the non-natural amino acid according to Formula (56), below, at light chain position 7 according to the Kabat or Chothia numbering system. In particular embodiments, provided herein are anti-Tissue Factor conjugates according to any of the conjugates described herein wherein COMP indicates a residue of the non-natural amino acid according to Formula (56), below, at light chain position 42 according to the Kabat or Chothia numbering system. In certain embodiments, PAY is selected from the group consisting of maytansine, hemiasterlin, amanitin,camptothecin, exatecan, exatecan derivative (DXd), SN-38, anthracycline, PNU-159682, PNU derivative (PNU-EDA), pyrrolobenzodiazepine (PBD), MMAF, and MMAE. In certain embodiments, PAY is maytansine. In certain embodiments, PAY is hemiasterlin. In certain embodiments, PAY is amanitin. In certain embodiments, PAY is exatecan. In certain embodiments, PAY is exatecan derivative (Dxd). In certain embodiments, PAY is deruxtecan. In certain embodiments, PAY is anthracycline. In certain embodiments, PAY is PNU-159682. In certain embodiments, PAY is PNU derivative (PNU-EDA). In certain embodiments, PAY is pyrrolobenzodiazepine. In certain embodiments, PAY is MMAF. In certain embodiments, PAY is MMAE.

[0444] In particular embodiments, provided herein are anti-Tissue Factor conjugates according to any of the conjugates described herein wherein COMP indicates a non-natural amino acid residue of para-azido-L-phenylalanine. In particular embodiments, provided herein are anti-Tissue Factor conjugates according to any of the conjugates described herein wherein COMP indicates the non-natural amino acid residue para-azido-phenylalanine at heavy chain position 404 according to the EU numbering system. In particular embodiments, provided herein are anti-Tissue Factor conjugates according to any of the conjugates described herein wherein COMP indicates a non-natural amino acid residue of para-azido-L-phenylalanine at heavy chain position 180 according to the EU numbering system. In particular embodiments, provided herein anti-Tissue Factor conjugates according to any of the conjugates described herein wherein COMP indicates a non-natural amino acid residue para-azido-L-phenylalanine at heavy chain position 241 according to the EU numbering system. In particular embodiments, provided herein are anti-Tissue Factor conjugates according to any of the conjugates described herein wherein COMP indicates a non-natural amino acid residue para-azido-L-phenylalanine at heavy chain position 222 according to the EU numbering system. In particular embodiments, provided herein are anti-Tissue Factor conjugates according to any of the conjugates described herein wherein COMP indicates a non-natural amino acid residue para-azido-L-phenylalanine at light chain position 7 according to the Kabat or Chothia numbering system. In particular embodiments, provided herein are anti-Tissue Factor conjugates according to any of the conjugates described herein wherein COMP indicates a non-natural amino acid residue para-azido-L-phenylalanine at light chain position 42 according to the Kabat or Chothia numbering system. In certainembodiments, PAY is selected from the group consisting of maytansine, hemiasterlin, amanitin, camptothecin, exatecan, exatecan derivative (DXd), SN-38, anthracycline, PNU-159682, pyrrolobenzodiazepine (PBD), MMAF, and MMAE. In certain embodiments, PAY is maytansine. In certain embodiments, PAY is hemiasterlin. In certain embodiments, PAY is amanitin. In certain embodiments, PAY is exatecan. In certain embodiments, PAY is exatecan derivative (Dxd). In certain embodiments, PAY is anthracycline. In certain embodiments, PAY is PNU-159682. In certain embodiments, PAY is PNU derivative (PNU-EDA). In certain embodiments, PAY is pyrrolobenzodiazepine. In certain embodiments, PAY is MMAF. In certain embodiments, PAY is MMAE.

[0445] It is expected without being bound to theory that the antibody conjugates of the present disclosure can avoid Factor X inhibition and bleeding issues by selection of an antibody that does not interfere with Tissue Factor binding to coagulation factors. The exatecan payload is believed to inhibit TOPO-1 causing DNA disruption which elicits potent tumor cell killing, bystander activity and immunogenic cell death.

[0446] In some embodiments, an antibody conjugate of the present disclosure can include (a) an antibody comprising: (1) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising at least one of SEQ ID NOs: 1430 and 1755; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR- L3 comprising SEQ ID NO; 2512; (2) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 161 and 486; a CDR-H2 comprising at least one of SEQ ID NOs: 811 and 1136; and a CDR-H3 comprising at least one of SEQ ID NOs: 1461 and 1786; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR- L3 comprising SEQ ID NO; 2512; (3) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 189 and 514; a CDR-H2 comprising at least one of SEQ ID NOs: 839 and 1164; and a CDR-H3 comprising at least one of SEQ ID NOs: 1489 and 1814; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR- L3 comprising SEQ ID NO; 2512; (4) a VHcomprising: a CDR-H1 comprising at least one of SEQ ID NOs: 192 and 517; a CDR-H2 comprising at least one of SEQ ID NOs: 842 and 1167; and a CDR-H3 comprising at least one of SEQ ID NOs: 1492 and 1817; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR- L3 comprising SEQ ID NO; 2512; (5) a VHcomprising: a CDR-H1 comprising at least one of SEQ ID NOs: 211 and 536; a CDR-H2 comprising at least one of SEQ ID NOs: 861 and 1186; and a CDR-H3 comprising at least one of SEQ ID NOs: 1511 and 1836; and a VL comprising: aCDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR- L3 comprising SEQ ID NO; 2512; (6) a VHcomprising: a CDR-H1 comprising at least one of SEQ ID NOs: 214 and 539; a CDR-H2 comprising at least one of SEQ ID NOs: 864 and 1189; and a CDR-H3 comprising at least one of SEQ ID NOs: 1514 and 1839; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR- L3 comprising SEQ ID NO; 2512; (7) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 218 and 543; a CDR-H2 comprising at least one of SEQ ID NOs: 868 and 1210; and a CDR-H3 comprising at least one of SEQ ID NOs: 1518 and 1843; and a VLcomprising: a CDR-L1 comprising at least one of SEQ ID NOs: 1974 and 2086; a CDR-L2 comprising at least one of SEQ ID NOs: 2198 and 2310; and a CDR-L3 comprising at least one of SEQ ID NOs: 2422 and 2534; (8) a VHcomprising: a CDR-H1 comprising at least one of SEQ ID NOs: 105 and 430; a CDR-H2 comprising at least one of SEQ ID NOs: 755 and 1080; and a CDR-H3 comprising at least one of SEQ ID NOs: 1405 and 1730; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO; 2512; (9) a VHcomprising: a CDR-H1 comprising at least one of SEQ ID NOs: 114 and 439; a CDR-H2 comprising at least one of SEQ ID NOs: 764 and 1089; and a CDR-H3 comprising at least one of SEQ ID NOs: 1414 and 1739; and a VL comprising: a CDR- L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO; 2512; (10) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 117 and 442; a CDR-H2 comprising at least one of SEQ ID NOs: 767 and 1092; and a CDR-H3 comprising at least one of SEQ ID NOs: 1417 and 1742; and a VLcomprising: a CDR- L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO; 2512; (b) para-azidomethylphenylalanine residues at antibody sites selected from the group consisting of HC180, HC241, HC404, LC42, LC161 and combinations thereof; and (c) a linker-payload selected from the group consisting of:,,, wherein n2 is 2, 4, 6, 8 or 10 and each linker-payload is bonded to one of the para- azidomethylphenylalanine residue side chains.

[0447] In some embodiments, an antibody conjugate of the present disclosure can include (a) an antibody comprising: (1) a VHcomprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising at least one of SEQ ID NOs: 1430 and 1755; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR- L3 comprising SEQ ID NO; 2512; (2) a VHcomprising: a CDR-H1 comprising at least one of SEQ ID NOs: 161 and 486; a CDR-H2 comprising at least one of SEQ ID NOs: 811 and 1136; and a CDR-H3 comprising at least one of SEQ ID NOs: 1461 and 1786; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR- L3 comprising SEQ ID NO; 2512; (3) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 189 and 514; a CDR-H2 comprising at least one of SEQ ID NOs: 839 and 1164; and a CDR-H3 comprising at least one of SEQ ID NOs: 1489 and 1814; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR- L3 comprising SEQ ID NO; 2512; (4) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 192 and 517; a CDR-H2 comprising at least one of SEQ ID NOs: 842 and 1167; and a CDR-H3 comprising at least one of SEQ ID NOs: 1492 and 1817; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR- L3 comprising SEQ ID NO; 2512; (5) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 211 and 536; a CDR-H2 comprising at least one of SEQ ID NOs: 861 and 1186; and a CDR-H3 comprising at least one of SEQ ID NOs: 1511 and 1836; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR- L3 comprising SEQ ID NO; 2512; (6) a VHcomprising: a CDR-H1 comprising at least one of SEQ ID NOs: 214 and 539; a CDR-H2 comprising at least one of SEQ ID NOs: 864 and 1189; and a CDR-H3 comprising at least one of SEQ ID NOs: 1514 and 1839; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR- L3 comprising SEQ ID NO; 2512; (7) a VHcomprising: a CDR-H1 comprising at least one ofSEQ ID NOs: 218 and 543; a CDR-H2 comprising at least one of SEQ ID NOs: 868 and 1210; and a CDR-H3 comprising at least one of SEQ ID NOs: 1518 and 1843; and a VLcomprising: a CDR-L1 comprising at least one of SEQ ID NOs: 1974 and 2086; a CDR-L2 comprising at least one of SEQ ID NOs: 2198 and 2310; and a CDR-L3 comprising at least one of SEQ ID NOs: 2422 and 2534; (8) a VHcomprising: a CDR-H1 comprising at least one of SEQ ID NOs: 105 and 430; a CDR-H2 comprising at least one of SEQ ID NOs: 755 and 1080; and a CDR-H3 comprising at least one of SEQ ID NOs: 1405 and 1730; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO; 2512; (9) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 114 and 439; a CDR-H2 comprising at least one of SEQ ID NOs: 764 and 1089; and a CDR-H3 comprising at least one of SEQ ID NOs: 1414 and 1739; and a VLcomprising: a CDR- L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO; 2512; (10) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 117 and 442; a CDR-H2 comprising at least one of SEQ ID NOs: 767 and 1092; and a CDR-H3 comprising at least one of SEQ ID NOs: 1417 and 1742; and a VLcomprising: a CDR- L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO; 2512; (b) para-azidomethylphenylalanine residues at antibody sites selected from the group consisting of HC180, HC241, HC404, LC42, LC161 and combinations thereof; and (c) a linker-payload selected from the group consisting of:,, wherein n2 is 2, 4, 6, 8 or 10 and each linker-payload is bonded to one of the para- azidomethylphenylalanine residue side chains.

[0448] In some embodiments, an antibody conjugate is provided that comprises: (a) an antibody comprising a VHcomprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising at least one of SEQ ID NOs: 1430 and 1755; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites selected from the group consisting of HC180, HC241, HC404, LC42, LC161 and combinations thereof; and (c) a linker-payload selected from the group consisting of:,, and, wherein n2 is 2, 4, 6, 8 or 10 and each linker-payload is bonded to one of the para- azidomethylphenylalanine residue side chains.

[0449] In some embodiments, an antibody conjugate is provided that comprises: (a) an antibody comprising a VHcomprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising at least one of SEQ ID NOs: 1430 and 1755; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites selected from the group consisting of HC180, HC241, HC404, LC42, LC161 and combinations thereof; and (c) a linker-payload selected from the group consisting of:,, wherein n2 is 2, 4, 6, 8 or 10 and each linker-payload is bonded to one of the para- azidomethylphenylalanine residue side chains.

[0450] In some embodiments, an antibody conjugate is provided that comprises: (a) an antibody comprising a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising at least one of SEQ ID NOs: 1430 and 1755; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC241 and HC404; and (c) a linker-payload, wherein n2 is 4 and each linker-payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

[0451] In some embodiments, an antibody conjugate is provided that comprises: (a) an antibody comprising a VHcomprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising at least one of SEQ ID NOs: 1430 and 1755; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC241 and HC404; and (c) a linker-payload, wherein n2 is 4 and each linker-payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

[0452] In some embodiments, an antibody conjugate is provided that comprises: (a) an antibody comprising a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising at least one of SEQ ID NOs: 1430 and 1755; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC241, HC404, HC180, and HC391; and (c) a linker-payload, wherein n2 is 8 and each linker- payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

[0453] In some embodiments, an antibody conjugate is provided that comprises: (a) an antibody comprising a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising at least one of SEQ ID NOs: 1430 and 1755; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC180 and HC404; and (c) a linker-payload, wherein n2 is 4 and each linker-payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

[0454] In some embodiments, an antibody conjugate is provided that comprises: (a) an antibody comprising a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising at least one of SEQ ID NOs: 1430 and 1755; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC180 and HC404; and (c) a linker-payload, wherein n2 is 4 and each linker-payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

[0455] In some embodiments, an antibody conjugate is provided that comprises: (a) an antibody comprising a VHcomprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising at least one of SEQ ID NOs: 1430 and 1755; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC241 and HC404; and (c) a linker-payload, wherein n2 is 4 and each linker-payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

[0456] In some embodiments, an antibody conjugate is provided that comprises: (a) an antibody comprising a VHcomprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising at least one of SEQ ID NOs: 1430 and 1755; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC241 and HC404; and (c) a linker-payload, wherein n2 is 4 and each linker-payload is bondedto one of the para-azidomethylphenylalanine residue side chains:.

[0457] In some embodiments, an antibody conjugate is provided that comprises: (a) an antibody comprising a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising at least one of SEQ ID NOs: 1430 and 1755; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC180, HC404 and LC42; and (c) a linker-payload, wherein n2 is 6 and each linker-payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

[0458] In some embodiments, an antibody conjugate is provided that comprises: (a) an antibody comprising a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising at least one of SEQ ID NOs: 1430 and 1755; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC180, HC404 and LC42; and (c) a linker-payload, wherein n2 is 6 and each linker-payload isbonded to one of the para-azidomethylphenylalanine residue side chains:.

[0459] In some embodiments, an antibody conjugate is provided that comprises: (a) an antibody comprising a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising at least one of SEQ ID NOs: 1430 and 1755; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC180, HC241 and HC404; and (c) a linker-payload, wherein n2 is 6 and each linker-payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

[0460] In some embodiments, an antibody conjugate is provided that comprises: (a) an antibody comprising a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising at least one of SEQ ID NOs: 1430 and 1755; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC180, HC241 and HC404; and (c) a linker-payload, wherein n2 is 6 and each linker-payloadis bonded to one of the para-azidomethylphenylalanine residue side chains:.

[0461] In some embodiments, an antibody conjugate is provided that comprises: (a) an antibody comprising a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising at least one of SEQ ID NOs: 1430 and 1755; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC180, HC404, LC42 and LC161; and (c) a linker-payload, wherein n2 is 8 and each linker- payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

[0462] In some embodiments, an antibody conjugate is provided that comprises: (a) an antibody comprising a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising at least one of SEQ ID NOs: 1430 and 1755; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC180, HC404, LC42 and LC161; and (c) a linker-payload, wherein n2 is 8 and each linker-payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

[0463] In some embodiments, an antibody conjugate is provided that comprises: (a) an antibody comprising a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising at least one of SEQ ID NOs: 1430 and 1755; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC180, HC241, HC404 and LC42; and (c) a linker-payload, wherein n2 is 8 and each linker- payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

[0464] In some embodiments, an antibody conjugate is provided that comprises: (a) an antibody comprising a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising at least one of SEQ ID NOs: 1430 and 1755; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC180, HC241, HC404 and LC42; and (c) a linker-payload, wherein n2 is 8 and each linker-payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

[0465] In some embodiments, an antibody conjugate is provided that comprises: (a) an antibody comprising a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and 1105; and a CDR-H3 co...

Claims

WHAT IS CLAIMED IS:

1. An antibody conjugate comprising an antibody that specifically binds to tissue factor (TF) linked site-specifically to at least one payload moiety, wherein the antibody comprises one or more non-natural amino acids.

2. The antibody conjugate of claim 1, wherein the one or more non-natural amino acids is at an antibody amino acid site other than the amino terminus of the antibody.

3. The antibody conjugate of claim 1, wherein the one or more non-natural amino acids is at an antibody amin acid site other than the carboxy terminus of the antibody.

4. The antibody conjugate of any one of the previous claims, wherein the antibody comprises one or more non-natural amino acids selected from the group consisting of: HC-F404, HC-K121, HC-Y180, HC-F241, HC-221, HC-Y391, LC-T22, LC-S7, LC-N152, LC-K42, LC-E161, LC-D170, HC-S136, HC-S25, HC-A40, HC-S119, HC-S190, HC-K222, HC-R19, HC-Y52, and HC-S70, according to the Kabat, Chothia, or EU numbering scheme.

5. The antibody conjugate of claim 4, wherein the antibody comprises one or more non-natural amino acids selected from the group consisting of: HC-F404, HC-Y180, HC-F241, HC-Y391, LC-K42, and LC-E161, according to the Kabat, Chothia, or EU numbering scheme.

6. The antibody conjugate of claim 4, wherein the antibody comprises one or more non-natural amino acids at sites selected from the group consisting of: HC-F404, HC-Y180, HC-Y391, LC-K42, and LC-E161, according to the Kabat or EU numbering scheme of Kabat.

7. The antibody conjugate of claim 4, wherein the antibody comprises one or more non-natural amino acids at sites selected from the group consisting of: HC-F404, HC-Y180, HC-Y391, HC-F241, and LC-K42, according to the Kabat or EU numbering scheme of Kabat.

8. The antibody conjugate of claim 4, wherein the antibody comprises one or more non-natural amino acids at sites HC-Y180 and HC-F404.

9. The antibody conjugate of claim 4, wherein the antibody comprises one or more non-natural amino acids at sites HC-F241 and HC-F404.

10. The antibody conjugate of claim 4, wherein the antibody comprises one or more non-natural amino acids at sites HC-Y180, HC-F404, and LC-K42.

11. The antibody conjugate of claim 4, wherein the antibody comprises one or more non-natural amino acids at sites HC-Y180, HC-F241 and HC-F404.

12. The antibody conjugate of claim 4, wherein the antibody comprises one or more non-natural amino acids at sites HC-Y180, HC-F404, LC-K42, and LC-E161.

13. The antibody conjugate of claim 4, wherein the antibody comprises one or more non-natural amino acids at sites HC-Y180, HC-F241, HC-F404, and LC-K42.

14. The antibody conjugate of claim 4, wherein the antibody comprises one or more non-natural amino acids at sites HC-Y180, HC-F241, HC-F404, and HC-Y391.

15. The antibody conjugate of any one of the preceding claims, wherein a residue of the one or more non-natural amino acids is linked to the payload moiety via a linker that is hydrolytically stable.

16. The antibody conjugate of any one of the preceding claims, wherein a residue of the one or more non-natural amino acids is linked to the payload moiety via a linker that is cleavable.

17. The antibody conjugate of any one of the preceding claims, wherein the one or more non-natural amino acids is selected from the group consisting of p-acetyl-L- phenylalanine, O-methyl-L-tyrosine, an -3-(2-naphthyl)alanine, 3-methyl-phenylalanine, O-4- allyl-L-tyrosine, 4-propyl-L-tyrosine, a tri-O-acetyl-GlcNAcβ-serine, L-Dopa, fluorinated phenylalanine, isopropyl-L-phenylalanine, p-azido-L-phenylalanine, p-azido-methyl-L- phenylalanine, compound 56, p-acyl-L-phenylalanine, p-benzoyl-L-phenylalanine, L- phosphoserine, phosphonoserine, phosphonotyrosine, p-iodo-phenylalanine, p- bromophenylalanine, p-amino-L-phenylalanine, isopropyl-L-phenylalanine, and p- propargyloxy-phenylalanine.

18. The antibody conjugate of any one of the preceding claims, wherein the residue of the one or more non-natural amino acids is a residue of compound (30) or compound (56).

19. The antibody conjugate of any one of the preceding claims, wherein the one or more non-natural amino acids is p-azidomethylphenylalanine.

20. The antibody conjugate of any one of the preceding claims, wherein the one or more non-natural amino acids is p-azido-methyl-L-phenylalanine.

21. The antibody conjugate of any one of the preceding claims, wherein the payload moiety is selected from the group consisting of maytansines, hemiasterlins, amanitins, camptothecins, exatecans, anthracyclines, pyrrolobenzodiazepines, and auristatins.

22. The antibody conjugate of any one of the preceding claims wherein the payload moiety is selected from the group consisting of DM1, hemiasterlin, amanitin, camptothecin, exatecan, deruxtecan (DXd), SN-38, PNU-159862, PNU-EDA, pyrrolobenzodiazepine, MMAF, and MMAE.

23. The antibody conjugate of any one of the preceding claims, according to the structure of Formula I:or a pharmaceutically acceptable salt thereof, wherein COMP is a residue of the anti-TF antibody; L1is -C1-6alkylene-; Y is –X1-C1-6 alkylene-[X1-C1-6 alkylene]n-[X1]p–, –X1-C2-6 alkenylene-[X1-C2-6 alkenylene]n-[X1]p–, –X1-C2-6 alkynylene-[X1-C2-6 alkynylene]n- [X1]p–, wherein at least one alkylene, alkenylene or alkynylene in Y is substituted with one or more substituents selected from R50; and wherein the alkylene, alkenylene, or alkynylene in Y is optionally substituted with one or more substituents selected from R51; R50is –C1-6 alkylene-X2-[C1-6 alkylene]m-POLY, –C2-6 alkenylene-X2-[C2-6 alkenylene]m-POLY, or –C2-6 alkynylene-X2-[C2-6 alkynylene]m- POLY, wherein each alkylene, alkenylene or alkynylene of R50is optionally substituted withone or more substituents selected from halogen, -CN, -NO2, -OH, -N(R10)2, -C(O)N(R10)2, -C(O)-, -C(S)-, -C(O)OCH2C6H5, -NHC(O)OCH2C6H5, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, C3-12 carbocycle, 3- to 12-membered heterocycle, and C1-10 haloalkyl; R51is independently selected from halogen, -CN, -NO2, -OH, -N(R10)2, -C(O)N(R10)2, - C(O)-, -C(S)-, -C(O)OCH2C6H5, -NHC(O)OCH2C6H5, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-12 carbocycle, 3- to 12- membered heterocycle, and C1-10 haloalkyl; X1and X2are independently selected from –C(O)– and –N(R10)C(O)–; R10is independently selected at each occurrence from hydrogen, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-12 carbocycle, 3- to 12-membered heterocycle, and C1-10 haloalkyl; POLY is a water-soluble polymer; n is an integer selected from zero, one, two, and three; m is an integer selected from zero and one; p is an integer selected from zero and one; Su is a hexose form of a monosaccharide; D is a drug moiety; and RL is a reactive group residue.

24. The antibody conjugate of any one of the preceding claims, according to the structure of Formula II:or a pharmaceutically acceptable salt thereof, wherein COMP is a residue of the TF antibody; L1is -C1-6 alkylene-; Y is –X1-C1-6alkylene-[X1-C1-6alkylene]n-X1–, –X1-C2-6alkenylene-[X1-C2-6alkenylene]n-X1–, –X1-C2-6 alkynylene-[X1-C2-6 alkynylene]n-X1–, wherein at least one alkylene, alkenylene or alkynylene in Y is substituted with one or more substituents selected from R50; R50is –C1-6alkylene-X2-[C1-6alkylene]m-POLY, –C2-6alkenylene-X2-[C2-6alkenylene]m-POLY, or –C2-6 alkynylene-X2-[C2-6 alkynylene]m-POLY, wherein each alkylene, alkenylene or alkynylene of R50is optionally substituted with one or moresubstituents selected from halogen, -CN, -NO2, -OH, -N(R10)2, -C(O)N(R10)2, -C(O)-, -C(S)-, - C(O)OCH2C6H5, -NHC(O)OCH2C6H5, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, C3-12carbocycle, 3- to 12-membered heterocycle, and C1-10 haloalkyl; X1and X2are independently selected from –C(O)– and –N(R10)C(O)–; R10is independently selected at each occurrence from hydrogen, C1-10alkyl, C2-10alkenyl, C2-10 alkynyl, C3-12 carbocycle, 3- to 12-membered heterocycle, and C1-10 haloalkyl; POLY is a water-soluble polymer; n is an integer selected from zero, one, two, and three; m is an integer selected from zero and one; Su is a hexose form of a monosaccharide; D is a drug moiety; and RL is a reactive group residue.

25. The antibody conjugate of claim 24, wherein the compound of Formula (II) is according to Formula (IIA).

26. The antibody conjugate of any one of claims 22 to 24, wherein Su is, w e e represents attachment to the remainder of the compound.

27. The antibody conjugate of any one of claims 23 to 26, wherein Su is, w e e represents attachment to the remainder of the compound.

28. The antibody conjugate of any one of claims 23 to 27, wherein D is a cytotoxic payload.

29. The antibody conjugate of claim 28, wherein the cytotoxic payload is a tubulin inhibitor, a DNA topoisomerase I inhibitor, or a DNA topoisomerase II inhibitor.

30. The antibody conjugate of any one of claims 23 to 29, wherein D is selected from the group consisting of hemiasterlins, camptothecins, anthracyclines, PNU-159682, and EDA PNU-159682 derivatives.

31. The antibody conjugate of any one of claims 23 to 29, wherein D is a hemiasterlin, exatecan, PNU-159682, or EDA PNU-159682 derivatives.

32. The antibody conjugate of any one of claims 23 to 31, wherein L1is -C1-3alkylene-.

33. The antibody conjugate of any one of claims 23 to 32, wherein Y is –X1-C1-6alkylene-[X1-C1-6alkylene]n-X1–, wherein at least one alkylene in Y is substituted with one or more substituents selected from R50.

34. The antibody conjugate of any one of claims 23 to 33, wherein Y is –X1-C1-4 alkylene-X1-C1-4 alkylene-X1-C1-4 alkylene-X1–, wherein at least one alkylene in Y is substituted with one or more substituents selected from R50.

35. The antibody conjugate of any one of claims 23 to 33, wherein Y is –X1-C1-4 alkylene-X1-C1-4 alkylene-X1–, wherein at least one alkylene in Y is substituted with one or more substituents selected from R50.

36. The antibody conjugate of any one of claims 23 to 35, wherein R50is –C1-6 alkylene-X2-[C1-6 alkylene]m-POLY, wherein each alkylene of R50is optionally substituted with one or more substituents selected from halogen, -CN, -NO2, -OH, -N(R10)2, -C(O)N(R10)2, -C(O)-, -C(S)-, -C(O)OCH2C6H5, -NHC(O)OCH2C6H5, C1-10alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-12 carbocycle, 3- to 12-membered heterocycle, and C1-10 haloalkyl.

37. The antibody conjugate of any one of claims 23 to 36, wherein m is one.

38. The antibody conjugate of any one of claims 23 to 37, wherein POLY is polyethylene glycol (PEG), methoxypolyethylene glycol (mPEG), poly(propylene glycol)(PPG), copolymers of ethylene glycol and propylene glycol, poly(oxyethylated polyol), poly(olefinic alcohol), poly(vinylpyrrolidone), poly(hydroxyalkylmethacrylamide), poly(hydroxyalkylmethacrylate), poly(saccharides), poly(^-hydroxy acid), poly(vinyl alcohol), polyphosphazene, polyoxazolines (POZ), poly(N-acryloylmorpholine), polysarcosine, or a combination thereof.

39. The antibody conjugate of any one of claims 23 to 38, wherein POLY comprises a polyethylene glycol (PEG) or methoxypolyethylene glycol (mPEG).

40. The antibody conjugate of any one of claims 23 to 39, wherein RL comprises an alkyne, cyclooctyne, a strained alkene, a tetrazine, a thiol, a para-acetyl-phenylalanine residue, an oxyamine, amine, a maleimide, or an azide.

41. The antibody conjugate of any one of claims 23 to 40, wherein RL is selected42. The antibody conjugate of any one of claims 1-22, according to the structure of Formula III:or a pharmaceutically acceptable salt thereof; whereinRing A is an optionally substituted bridged, fused, or spirocyclic bicyclic carbocycle, or an optionally substituted bridged, fused, or spirocyclic bicyclic heterocycle, wherein the carbocycle or the heterocycle of Ring A are optionally substituted with one or more substituents selected from alkyl, alkenyl, alkynyl, cycloalkyl, halogen, alkoxy, -CN, -NO2, - OH, -N(R2R3)2, -C(O)-, -C(O)N(R2R3)2, -C(O)OR2, aminoalkyl, hydroxyalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl; Ring B is an optionally substituted N-linked bridged, fused, or spirocyclic bicyclic heterocycle, wherein Ring B is optionally substituted with one or more substituents selected from alkyl, alkenyl, alkynyl, cycloalkyl, halogen, alkoxy, -CN, -NO2, -OH, -N(R2R3)2, -C(O)-, -C(O)N(R2R3)2, -C(O)OR2, aminoalkyl, hydroxyalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl; Raand Rbare independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, halogen, alkoxy, -CN, -NO2, -OH, -N(R2R3)2, -C(O)N(R2R3)2, -C(O)OR2, aminoalkyl, hydroxyalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl; a is an integer independently selected from 0, 1, 2, 3, 4, 5, and 6; b is an integer selected from 0 or 1; R1is hydrogen or alkyl optionally substituted with one or more substituents selected from cycloalkyl, halogen, alkoxy, -CN, -NO2, -OH, -N(R2R3)2, -C(O)N(R2R3)2, -C(O)OR2, aryl, and heteroaryl; R2and R3are independently selected from hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl; Yais *-C(O)-(CRaRb)c-NH- or *-C(O)-(CRaRb)c-, wherein * represents where Yais bound to RL; c is an integer selected from 1, 2, 3, 4, 5, or 6; RL is a reactive group residue; L2is absent or a linker comprising a hydrophilic polymer residue;L3is absent, -C(O)-AA-, -C(O)-AA-Z-(CRaRb)a-Z-(CRaRb)a-C(O)-, -C(O)-Z-(CRaRb)a- C(O)-Z-L4-OC(O)-, -Z-AA-, -AA-, -C(O)-, -C(O)-AA-Z-(CRaRb)a-,-AA-C(O)-, -C(O)-(CRaRb)a-Z-(CRaRb)-Z-AA-C(O)-, -C(O)O-L4-Z-C(O)-(CRaRb)a-Z-C(O)-, - AA-Z-; and –(CRaRb)a-Z-AA-C(O)-; Z is selected from -NR2- and -O-; AA is an amino acid residue or a peptide residue;wherein Su is a hexose form of a monosaccharide; d is an integer independently selected from 1, 2, and 3; D is a drug moiety; COMP is a residue of the TF antibody; and represents attachment to the remainder of the compound.

43. The antibody conjugate of any one of claims 1-22, according to the structure of Formula (V):or a pharmaceutically acceptable salt and / or regioisomer thereof; wherein L5is a linker comprising an unnatural amino acid; Yais *-C(O)-(CRaRb)c-NH- or *-C(O)-(CRaRb)c-, wherein * represents where Yais bound to RL; c is an integer selected from 1, 2, 3, 4, 5, or 6; RL is a reactive group residue; L2is absent or a linker comprising a hydrophilic polymer residue; L3is absent, -C(O)-AA-, -C(O)-AA-Z-(CRaRb)a-Z-(CRaRb)a-C(O)-, -C(O)-Z- (CRaRb)a-C(O)-Z-L4-OC(O)-, -Z-AA-, -AA-, -C(O)-, -C(O)-AA-Z-(CRaRb)a-, -AA- C(O)-, -C(O)-(CRaRb)a-Z-(CRaRb)-Z-AA-C(O)-, -C(O)O-L4-Z-C(O)-(CRaRb)a-Z-C(O)- , -AA-Z-; and –(CRaRb)a-Z-AA-C(O)-;Raand Rbare independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, halogen, alkoxy, -CN, -NO2, -OH, -N(R2R3)2, -C(O)N(R2R3)2, -C(O)OR2, aminoalkyl, hydroxyalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl; a is an integer independently selected from 0, 1, 2, 3, 4, 5, and 6; Z is selected from -NR2- and -O-; AA is an amino acid residue or a peptide residue;wherein Su is a hexose form of a monosaccharide; d is an integer independently selected from 1, 2, and 3; D is a drug moiety; COMP is a residue of the TF antibody; andrepresents attachment to the remainder of the compound.

44. The antibody conjugate of claim 42, wherein Ring B is selected from45. The antibody conjugate of claim 42, where Ring B is selected fromwherein X1a, X2a, X3, and X4are independently selected from -C(R4)2-, -NH-, -O-, and - S- wherein when X1a, X2a, and X3are present, at least one of X1a-X3is -C(R4)2- and when X1a, X2a, X3, and X4are present, at least two of X1a-X4are -C(R4)2; andR4is independently selected from hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-12cycloalkyl, halogen, alkoxy, -CN, -NO2, -OH, -N(R2R3)2, -C(O)N(R2R3)2, -C(O)OR2, aminoalkyl, hydroxyalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl; or two R4groups on the same carbon are taken together to form an oxo group.

46. The antibody conjugate of claim 42, wherein Ring B is selected from47. The antibody conjugate of claim 42, wherein Ring A is selected fromwherein X1a, X2a, X3, and X4are independently selected from -C(R4)2-, -NH-, -O-, and - S- wherein when X1a, X2a, and X3are present, at least one of X1a-X3is -C(R4)2- and when X1a, X2a, X3, and X4are present, at least two of X1a-X4are -C(R4)2; X5is N or CR4; and R4is independently selected from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, halogen, alkoxy, -CN, -NO2, -OH, -N(R2R3)2, -C(O)N(R2R3)2, -C(O)OR2, aminoalkyl, hydroxyalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl; or two R4groups on the same carbon are taken together to form an oxo group.

48. The antibody conjugate any one of claims 42 and 44-47, wherein L1ais49. The antibody conjugate of any one of claims 42-48, wherein L2is -(CRaRb)a- POLY1-.wherein POLY1- is a divalent residue of polyethylene glycol (PEG), poly(propylene glycol) (PPG), or a copolymer of ethylene glycol and propylene glycol; whereinrepresents attachment to the remainder of the compound.

50. The antibody conjugate of any one of claims 42-49, wherein L3is -C(O)-AA-, - C(O)-AA-Z-(CRaRb)a-Z-(CRaRb)a-C(O)-, -Z-AA-, or -AA-.

51. The antibody conjugate of any one of claims 42-50, wherein Su is.

52. The antibody conjugate of any one of claims 42-51, wherein the D is a drug moiety selected from a tubulin inhibitor, DNA damaging agents, a DNA topoisomerase I inhibitor, a DNA topoisomerase II inhibitor, RNA polymerase II inhibitor, a hemiasterlin residue, a camptothecin residue, camptothexin derivatives, an anthracycline residue, PNU- 159682 and PNU-159682 derivative, PBDs, and duocarmycins.

53. The antibody conjugate of any one of the previous claims, wherein the antibody conjugate has a structure selected from the group consisting of:wherein n2 is an integer from 1 to 10.

54. The antibody conjugate of claim 53, wherein the antibody conjugate has awherein n2 is an integer from 1 to 10.

55. The antibody conjugate of claim 53 or 54, wherein n2 is an integer from 2 to 8, 2 to 6, 2 to 4, or 6 to 10.

56. The antibody conjugate of claim 53 or 54, wherein n2 is 2, 4, 6, 8, or 10.

57. The antibody conjugate of any one of the preceding claims, wherein the antibody comprises three heavy chain CDRs from a VH sequence selected from SEQ ID NOs: 2727, 2736, 2739, 2751-2838, 2840, 2846, 2851, 2857, 2859, and 2860, or variants thereof, and three light chain CDRs from a VL sequence selected from SEQ ID NOs: 2951, 2957, 2962, 2968, 2970, 2971, and 3061, or variants thereof.

58. The antibody conjugate of any one of the preceding claims, wherein the antibody comprises three heavy chain CDRs, or variants thereof, and three light chain CDRs, or variants thereof, from a VH / VL pair selected from the group consisting of SEQ ID NOs: 2727 / 3061, 2736 / 3061, 2739 / 3061, 2751 / 3061, 2752 / 3061, 2753 / 3061, 2754 / 3061, 2755 / 3061, 2756 / 3061, 2757 / 3061, 2758 / 3061, 2759 / 3061, 2760 / 3061, 2761 / 3061, 2762 / 3061, 2763 / 3061, 2764 / 3061, 2765 / 3061, 2766 / 3061, 2767 / 3061, 2768 / 3061, 2769 / 3061, 2770 / 3061, 2771 / 3061, 2772 / 3061, 2773 / 3061, 2774 / 3061, 2775 / 3061, 2776 / 3061, 2777 / 3061, 2778 / 3061, 2779 / 3061, 2780 / 3061, 2781 / 3061, 2782 / 3061, 2783 / 3061, 2784 / 3061, 2785 / 3061, 2786 / 3061, 2787 / 3061, 2788 / 3061, 2789 / 3061, 2790 / 3061, 2791 / 3061, 2792 / 3061, 2793 / 3061, 2794 / 3061, 2795 / 3061, 2796 / 3061, 2797 / 3061, 2798 / 3061, 2799 / 3061, 2800 / 3061, 2801 / 3061, 2802 / 3061, 2803 / 3061, 2804 / 3061, 2805 / 3061, 2806 / 3061, 2807 / 3061, 2808 / 3061, 2809 / 3061, 2810 / 3061, 2811 / 3061, 2812 / 3061, 2813 / 3061, 2814 / 3061, 2815 / 3061, 2816 / 3061, 2817 / 3061, 2818 / 3061, 2819 / 3061, 2820 / 3061, 2821 / 3061, 2822 / 3061, 2823 / 3061, 2824 / 3061, 2825 / 3061, 2826 / 3061, 2827 / 3061, 2828 / 3061, 2829 / 3061, 2830 / 3061, 2831 / 3061, 2832 / 3061, 2833 / 3061, 2834 / 3061, 2835 / 3061,2836 / 3061, 2837 / 3061, 2838 / 3061, 2840 / 2951, 2846 / 2957, 2851 / 2962, 2857 / 2968, 2859 / 2970, and 2860 / 2971.

59. The antibody conjugate of any one of the preceding claims, wherein the antibody comprises a VH selected from SEQ ID NOs: 2727, 2736, 2739, 2751-2838, 2840, 2846, 2851, 2857, 2859, and 2860.

60. The antibody conjugate of any one of the preceding claims, wherein the antibody comprises a VL selected from SEQ ID NOs: 2951, 2957, 2962, 2968, 2970, 2971, and 3061.

61. The antibody conjugate of any one of the preceding claims, wherein the antibody comprises a VH / VL pair, or a variant thereof, selected from the group consisting of SEQ ID NOs: 2727 / 3061, 2736 / 3061, 2739 / 3061, 2751 / 3061, 2752 / 3061, 2753 / 3061, 2754 / 3061, 2755 / 3061, 2756 / 3061, 2757 / 3061, 2758 / 3061, 2759 / 3061, 2760 / 3061, 2761 / 3061, 2762 / 3061, 2763 / 3061, 2764 / 3061, 2765 / 3061, 2766 / 3061, 2767 / 3061, 2768 / 3061, 2769 / 3061, 2770 / 3061, 2771 / 3061, 2772 / 3061, 2773 / 3061, 2774 / 3061, 2775 / 3061, 2776 / 3061, 2777 / 3061, 2778 / 3061, 2779 / 3061, 2780 / 3061, 2781 / 3061, 2782 / 3061, 2783 / 3061, 2784 / 3061, 2785 / 3061, 2786 / 3061, 2787 / 3061, 2788 / 3061, 2789 / 3061, 2790 / 3061, 2791 / 3061, 2792 / 3061, 2793 / 3061, 2794 / 3061, 2795 / 3061, 2796 / 3061, 2797 / 3061, 2798 / 3061, 2799 / 3061, 2800 / 3061, 2801 / 3061, 2802 / 3061, 2803 / 3061, 2804 / 3061, 2805 / 3061, 2806 / 3061, 2807 / 3061, 2808 / 3061, 2809 / 3061, 2810 / 3061, 2811 / 3061, 2812 / 3061, 2813 / 3061, 2814 / 3061, 2815 / 3061, 2816 / 3061, 2817 / 3061, 2818 / 3061, 2819 / 3061, 2820 / 3061, 2821 / 3061, 2822 / 3061, 2823 / 3061, 2824 / 3061, 2825 / 3061, 2826 / 3061, 2827 / 3061, 2828 / 3061, 2829 / 3061, 2830 / 3061, 2831 / 3061, 2832 / 3061, 2833 / 3061, 2834 / 3061, 2835 / 3061, 2836 / 3061, 2837 / 3061, 2838 / 3061, 2840 / 2951, 2846 / 2957, 2851 / 2962, 2857 / 2968, 2859 / 2970, and 2860 / 2971.

62. The antibody conjugate of any one of the preceding claims, wherein the antibody comprises: (1) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 105 and 430; a CDR-H2 comprising one or more of SEQ ID NOs: 755 and 1080; and a CDR-H3 comprising one or more of SEQ ID NOs: 1405 and 1730; (2) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 114 and 439; a CDR-H2 comprising one or more of SEQ ID NOs: 764 and 1089; and a CDR-H3 comprising one or more of SEQ ID NOs: 1414 and 1739;(3) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 117 and 442; a CDR-H2 comprising one or more of SEQ ID NOs: 767 and 1092; and a CDR-H3 comprising one or more of SEQ ID NOs: 1417 and 1742; (4) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 129 and 454; a CDR-H2 comprising one or more of SEQ ID NOs: 779 and 1104; and a CDR-H3 comprising one or more of SEQ ID NOs: 1429 and 1754; (5) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 130 and 455; a CDR-H2 comprising one or more of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising one or more of SEQ ID NOs: 1430 and 1755; (6) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 131 and 456; a CDR-H2 comprising one or more of SEQ ID NOs: 781 and 1106; and a CDR-H3 comprising one or more of SEQ ID NOs: 1431 and 1756; (7) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 132 and 457; a CDR-H2 comprising one or more of SEQ ID NOs: 782 and 1107; and a CDR-H3 comprising one or more of SEQ ID NOs: 1432 and 1757; (8) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 133 and 458; a CDR-H2 comprising one or more of SEQ ID NOs: 783 and 1108; and a CDR-H3 comprising one or more of SEQ ID NOs: 1433 and 1758; (9) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 134 and 459; a CDR-H2 comprising one or more of SEQ ID NOs: 784 and 1109; and a CDR-H3 comprising one or more of SEQ ID NOs: 1434 and 1759; (10) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 135 and 460; a CDR-H2 comprising one or more of SEQ ID NOs: 785 and 1110; and a CDR-H3 comprising one or more of SEQ ID NOs: 1435 and 1760; (11) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 136 and 461; a CDR-H2 comprising one or more of SEQ ID NOs: 786 and 1111; and a CDR-H3 comprising one or more of SEQ ID NOs: 1436 and 1761; (12) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 137 and 462; a CDR-H2 comprising one or more of SEQ ID NOs: 787 and 1112; and a CDR-H3 comprising one or more of SEQ ID NOs: 1437 and 1762; (13) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 138 and 463; a CDR-H2 comprising one or more of SEQ ID NOs: 788 and 1113; and a CDR-H3 comprising one or more of SEQ ID NOs: 1438 and 1763; (14) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 139 and 464; a CDR-H2 comprising one or more of SEQ ID NOs: 789 and 1114; and a CDR-H3 comprising one or more of SEQ ID NOs: 1439 and 1764; (15) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 140 and 465; a CDR-H2 comprising one or more of SEQ ID NOs: 790 and 1115; and a CDR-H3 comprising one or more of SEQ ID NOs: 1440 and 1765;(16) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 141 and 466; a CDR-H2 comprising one or more of SEQ ID NOs: 791 and 1116; and a CDR-H3 comprising one or more of SEQ ID NOs: 1441 and 1766; (17) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 142 and 467; a CDR-H2 comprising one or more of SEQ ID NOs: 792 and 1117; and a CDR-H3 comprising one or more of SEQ ID NOs: 1442 and 1767; (18) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 143 and 468; a CDR-H2 comprising one or more of SEQ ID NOs: 793 and 1118; and a CDR-H3 comprising one or more of SEQ ID NOs: 1443 and 1768; (19) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 144 and 469; a CDR-H2 comprising one or more of SEQ ID NOs: 794 and 1119; and a CDR-H3 comprising one or more of SEQ ID NOs: 1444 and 1769; (20) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 145 and 470; a CDR-H2 comprising one or more of SEQ ID NOs: 795 and 1120; and a CDR-H3 comprising one or more of SEQ ID NOs: 1445 and 1770; (21) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 146 and 471; a CDR-H2 comprising one or more of SEQ ID NOs: 796 and 1121; and a CDR-H3 comprising one or more of SEQ ID NOs: 1446 and 1771; (22) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 147 and 472; a CDR-H2 comprising one or more of SEQ ID NOs: 797 and 1122; and a CDR-H3 comprising one or more of SEQ ID NOs: 1447 and 1772; (23) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 148 and 473; a CDR-H2 comprising one or more of SEQ ID NOs: 798 and 1123; and a CDR-H3 comprising one or more of SEQ ID NOs: 1448 and 1773; (24) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 149 and 474; a CDR-H2 comprising one or more of SEQ ID NOs: 799 and 1124; and a CDR-H3 comprising one or more of SEQ ID NOs: 1449 and 1774; (25) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 150 and 475; a CDR-H2 comprising one or more of SEQ ID NOs: 800 and 1125; and a CDR-H3 comprising one or more of SEQ ID NOs: 1450 and 1775; (26) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 151 and 476; a CDR-H2 comprising one or more of SEQ ID NOs: 801 and 1126; and a CDR-H3 comprising one or more of SEQ ID NOs: 1451 and 1776; (27) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 152 and 477; a CDR-H2 comprising one or more of SEQ ID NOs: 802 and 1127; and a CDR-H3 comprising one or more of SEQ ID NOs: 1452 and 1777; (28) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 153 and 478; a CDR-H2 comprising one or more of SEQ ID NOs: 803 and 1128; and a CDR-H3 comprising one or more of SEQ ID NOs: 1453 and 1778;(29) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 154 and 479; a CDR-H2 comprising one or more of SEQ ID NOs: 804 and 1129; and a CDR-H3 comprising one or more of SEQ ID NOs: 1454 and 1779; (30) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 155 and 480; a CDR-H2 comprising one or more of SEQ ID NOs: 805 and 1130; and a CDR-H3 comprising one or more of SEQ ID NOs: 1455 and 1780; (31) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 156 and 481; a CDR-H2 comprising one or more of SEQ ID NOs: 806 and 1131; and a CDR-H3 comprising one or more of SEQ ID NOs: 1456 and 1781; (32) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 157 and 482; a CDR-H2 comprising one or more of SEQ ID NOs: 807 and 1132; and a CDR-H3 comprising one or more of SEQ ID NOs: 1457 and 1782; (33) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 158 and 483; a CDR-H2 comprising one or more of SEQ ID NOs: 808 and 1133; and a CDR-H3 comprising one or more of SEQ ID NOs: 1458 and 1783; (34) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 159 and 484; a CDR-H2 comprising one or more of SEQ ID NOs: 809 and 1134; and a CDR-H3 comprising one or more of SEQ ID NOs: 1459 and 1784; (35) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 160 and 485; a CDR-H2 comprising one or more of SEQ ID NOs: 810 and 1135; and a CDR-H3 comprising one or more of SEQ ID NOs: 1460 and 1785; (36) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 161 and 486; a CDR-H2 comprising one or more of SEQ ID NOs: 811 and 1136; and a CDR-H3 comprising one or more of SEQ ID NOs: 1461 and 1786; (37) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 162 and 487; a CDR-H2 comprising one or more of SEQ ID NOs: 812 and 1137; and a CDR-H3 comprising one or more of SEQ ID NOs: 1462 and 1787; (38) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 163 and 488; a CDR-H2 comprising one or more of SEQ ID NOs: 813 and 1138; and a CDR-H3 comprising one or more of SEQ ID NOs: 1463 and 1788; (39) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 164 and 489; a CDR-H2 comprising one or more of SEQ ID NOs: 814 and 1139; and a CDR-H3 comprising one or more of SEQ ID NOs: 1464 and 1789; (40) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 165 and 490; a CDR-H2 comprising one or more of SEQ ID NOs: 815 and 1140; and a CDR-H3 comprising one or more of SEQ ID NOs: 1465 and 1790; (41) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 166 and 491; a CDR-H2 comprising one or more of SEQ ID NOs: 816 and 1141; and a CDR-H3 comprising one or more of SEQ ID NOs: 1466 and 1791;(42) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 167 and 492; a CDR-H2 comprising one or more of SEQ ID NOs: 817 and 1142; and a CDR-H3 comprising one or more of SEQ ID NOs: 1467 and 1792; (43) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 168 and 493; a CDR-H2 comprising one or more of SEQ ID NOs: 818 and 1143; and a CDR-H3 comprising one or more of SEQ ID NOs: 1468 and 1793; (44) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 169 and 494; a CDR-H2 comprising one or more of SEQ ID NOs: 819 and 1144; and a CDR-H3 comprising one or more of SEQ ID NOs: 1469 and 1794; (45) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 170 and 495; a CDR-H2 comprising one or more of SEQ ID NOs: 820 and 1145; and a CDR-H3 comprising one or more of SEQ ID NOs: 1470 and 1795; (46) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 171 and 496; a CDR-H2 comprising one or more of SEQ ID NOs: 821 and 1146; and a CDR-H3 comprising one or more of SEQ ID NOs: 1471 and 1796; (47) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 172 and 497; a CDR-H2 comprising one or more of SEQ ID NOs: 822 and 1147; and a CDR-H3 comprising one or more of SEQ ID NOs: 1472 and 1797; (48) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 173 and 498; a CDR-H2 comprising one or more of SEQ ID NOs: 823 and 1148; and a CDR-H3 comprising one or more of SEQ ID NOs: 1473 and 1798; (49) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 174 and 499; a CDR-H2 comprising one or more of SEQ ID NOs: 824 and 1149; and a CDR-H3 comprising one or more of SEQ ID NOs: 1474 and 1799; (50) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 175 and 500; a CDR-H2 comprising one or more of SEQ ID NOs: 825 and 1150; and a CDR-H3 comprising one or more of SEQ ID NOs: 1475 and 1800; (51) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 176 and 501; a CDR-H2 comprising one or more of SEQ ID NOs: 826 and 1151; and a CDR-H3 comprising one or more of SEQ ID NOs: 1476 and 1801; (52) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 177 and 502; a CDR-H2 comprising one or more of SEQ ID NOs: 827 and 1152; and a CDR-H3 comprising one or more of SEQ ID NOs: 1477 and 1802; (53) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 178 and 503; a CDR-H2 comprising one or more of SEQ ID NOs: 828 and 1153; and a CDR-H3 comprising one or more of SEQ ID NOs: 1478 and 1803; (54) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 179 and 504; a CDR-H2 comprising one or more of SEQ ID NOs: 829 and 1154; and a CDR-H3 comprising one or more of SEQ ID NOs: 1479 and 1804;(55) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 180 and 505; a CDR-H2 comprising one or more of SEQ ID NOs: 830 and 1155; and a CDR-H3 comprising one or more of SEQ ID NOs: 1480 and 1805; (56) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 181 and 506; a CDR-H2 comprising one or more of SEQ ID NOs: 831 and 1156; and a CDR-H3 comprising one or more of SEQ ID NOs: 1481 and 1806; (57) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 182 and 507; a CDR-H2 comprising one or more of SEQ ID NOs: 832 and 1157; and a CDR-H3 comprising one or more of SEQ ID NOs: 1482 and 1807; (58) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 183 and 508; a CDR-H2 comprising one or more of SEQ ID NOs: 833 and 1158; and a CDR-H3 comprising one or more of SEQ ID NOs: 1483 and 1808; (59) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 184 and 509; a CDR-H2 comprising one or more of SEQ ID NOs: 834 and 1159; and a CDR-H3 comprising one or more of SEQ ID NOs: 1484 and 1809; (60) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 185 and 510; a CDR-H2 comprising one or more of SEQ ID NOs: 835 and 1160; and a CDR-H3 comprising one or more of SEQ ID NOs: 1485 and 1810; (61) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 186 and 511; a CDR-H2 comprising one or more of SEQ ID NOs: 836 and 1161; and a CDR-H3 comprising one or more of SEQ ID NOs: 1486 and 1811; (62) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 187 and 512; a CDR-H2 comprising one or more of SEQ ID NOs: 837 and 1162; and a CDR-H3 comprising one or more of SEQ ID NOs: 1487 and 1812; (63) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 188 and 513; a CDR-H2 comprising one or more of SEQ ID NOs: 838 and 1163; and a CDR-H3 comprising one or more of SEQ ID NOs: 1488 and 1813; (64) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 189 and 514; a CDR-H2 comprising one or more of SEQ ID NOs: 839 and 1164; and a CDR-H3 comprising one or more of SEQ ID NOs: 1489 and 1814; (65) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 190 and 515; a CDR-H2 comprising one or more of SEQ ID NOs: 840 and 1165; and a CDR-H3 comprising one or more of SEQ ID NOs: 1490 and 1815; (66) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 191 and 516; a CDR-H2 comprising one or more of SEQ ID NOs: 841 and 1166; and a CDR-H3 comprising one or more of SEQ ID NOs: 1491 and 1816; (67) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 192 and 517; a CDR-H2 comprising one or more of SEQ ID NOs: 842 and 1167; and a CDR-H3 comprising one or more of SEQ ID NOs: 1492 and 1817;(68) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 193 and 518; a CDR-H2 comprising one or more of SEQ ID NOs: 843 and 1168; and a CDR-H3 comprising one or more of SEQ ID NOs: 1493 and 1818; (69) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 194 and 519; a CDR-H2 comprising one or more of SEQ ID NOs: 844 and 1169; and a CDR-H3 comprising one or more of SEQ ID NOs: 1494 and 1819; (70) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 195 and 520; a CDR-H2 comprising one or more of SEQ ID NOs: 845 and 1170; and a CDR-H3 comprising one or more of SEQ ID NOs: 1495 and 1820; (71) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 196 and 521; a CDR-H2 comprising one or more of SEQ ID NOs: 846 and 1171; and a CDR-H3 comprising one or more of SEQ ID NOs: 1496 and 1821; (72) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 197 and 522; a CDR-H2 comprising one or more of SEQ ID NOs: 847 and 1172; and a CDR-H3 comprising one or more of SEQ ID NOs: 1497 and 1822; (73) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 198 and 523; a CDR-H2 comprising one or more of SEQ ID NOs: 848 and 1173; and a CDR-H3 comprising one or more of SEQ ID NOs: 1498 and 1823; (74) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 199 and 524; a CDR-H2 comprising one or more of SEQ ID NOs: 849 and 1174; and a CDR-H3 comprising one or more of SEQ ID NOs: 1499 and 1824; (75) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 200 and 525; a CDR-H2 comprising one or more of SEQ ID NOs: 850 and 1175; and a CDR-H3 comprising one or more of SEQ ID NOs: 1500 and 1825; (76) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 201 and 526; a CDR-H2 comprising one or more of SEQ ID NOs: 851 and 1176; and a CDR-H3 comprising one or more of SEQ ID NOs: 1501 and 1826; (77) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 202 and 527; a CDR-H2 comprising one or more of SEQ ID NOs: 852 and 1177; and a CDR-H3 comprising one or more of SEQ ID NOs: 1502 and 1827; (78) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 203 and 528; a CDR-H2 comprising one or more of SEQ ID NOs: 853 and 1178; and a CDR-H3 comprising one or more of SEQ ID NOs: 1503 and 1828; (79) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 204 and 529; a CDR-H2 comprising one or more of SEQ ID NOs: 854 and 1179; and a CDR-H3 comprising one or more of SEQ ID NOs: 1504 and 1829; (80) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 205 and 530; a CDR-H2 comprising one or more of SEQ ID NOs: 855 and 1180; and a CDR-H3 comprising one or more of SEQ ID NOs: 1505 and 1830;(81) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 206 and 531; a CDR-H2 comprising one or more of SEQ ID NOs: 856 and 1181; and a CDR-H3 comprising one or more of SEQ ID NOs: 1506 and 1831; (82) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 207 and 532; a CDR-H2 comprising one or more of SEQ ID NOs: 857 and 1182; and a CDR-H3 comprising one or more of SEQ ID NOs: 1507 and 1832; (83) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 208 and 533; a CDR-H2 comprising one or more of SEQ ID NOs: 858 and 1183; and a CDR-H3 comprising one or more of SEQ ID NOs: 1508 and 1833; (84) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 209 and 534; a CDR-H2 comprising one or more of SEQ ID NOs: 859 and 1184; and a CDR-H3 comprising one or more of SEQ ID NOs: 1509 and 1834; (85) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 210 and 535; a CDR-H2 comprising one or more of SEQ ID NOs: 860 and 1185; and a CDR-H3 comprising one or more of SEQ ID NOs: 1510 and 1835; (86) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 211 and 536; a CDR-H2 comprising one or more of SEQ ID NOs: 861 and 1186; and a CDR-H3 comprising one or more of SEQ ID NOs: 1511 and 1836; (87) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 212 and 537; a CDR-H2 comprising one or more of SEQ ID NOs: 862 and 1187; and a CDR-H3 comprising one or more of SEQ ID NOs: 1512 and 1837; (88) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 213 and 538; a CDR-H2 comprising one or more of SEQ ID NOs: 863 and 1188; and a CDR-H3 comprising one or more of SEQ ID NOs: 1513 and 1838; (89) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 214 and 539; a CDR-H2 comprising one or more of SEQ ID NOs: 864 and 1189; and a CDR-H3 comprising one or more of SEQ ID NOs: 1514 and 1839; (90) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 215 and 540; a CDR-H2 comprising one or more of SEQ ID NOs: 865 and 1190; and a CDR-H3 comprising one or more of SEQ ID NOs: 1515 and 1840; (91) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 216 and 541; a CDR-H2 comprising one or more of SEQ ID NOs: 866 and 1191; and a CDR-H3 comprising one or more of SEQ ID NOs: 1516 and 1841; (92) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 218 and 543; a CDR-H2 comprising one or more of SEQ ID NOs: 868 and 1193; and a CDR-H3 comprising one or more of SEQ ID NOs: 1518 and 1843; (93) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 224 and 549; a CDR-H2 comprising one or more of SEQ ID NOs: 874 and 1199; and a CDR-H3 comprising one or more of SEQ ID NOs: 1524 and 1849;(94) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 229 and 554; a CDR-H2 comprising one or more of SEQ ID NOs: 879 and 1204; and a CDR-H3 comprising one or more of SEQ ID NOs: 1529 and 1854; (95) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 235 and 560; a CDR-H2 comprising one or more of SEQ ID NOs: 885 and 1210; and a CDR-H3 comprising one or more of SEQ ID NOs: 1535 and 1860; (96) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 237 and 562; a CDR-H2 comprising one or more of SEQ ID NOs: 887 and 1212; and a CDR-H3 comprising one or more of SEQ ID NOs: 1537 and 1862; or (97) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 238 and 563; a CDR-H2 comprising one or more of SEQ ID NOs: 888 and 1213; and a CDR-H3 comprising one or more of SEQ ID NOs: 1538 and 1863.

63. The antibody conjugate of claim 60, wherein the antibody comprises: (1) a VL comprising: a CDR-L1 comprising one or more of SEQ ID NOs: 1954 and 2066; a CDR-L2 comprising one or more of SEQ ID NOs: 2178 and 2290; and a CDR-L3 comprising one or more of SEQ ID NOs: 2402 and 2514; (2) a VLcomprising: a CDR-L1 comprising one or more of SEQ ID NOs: 1960 and 2072; a CDR-L2 comprising one or more of SEQ ID NOs: 2184 and 2296; and a CDR-L3 comprising one or more of SEQ ID NOs: 2408 and 2520; (3) a VL comprising: a CDR-L1 comprising one or more of SEQ ID NOs: 1965 and 2077; a CDR-L2 comprising one or more of SEQ ID NOs: 2189 and 2301; and a CDR-L3 comprising one or more of SEQ ID NOs: 2413 and 2525; (4) a VL comprising: a CDR-L1 comprising one or more of SEQ ID NOs: 1971 and 2083; a CDR-L2 comprising one or more of SEQ ID NOs: 2195 and 2307; and a CDR-L3 comprising one or more of SEQ ID NOs: 2419 and 2531; (5) a VLcomprising: a CDR-L1 comprising one or more of SEQ ID NOs: 1973 and 2085; a CDR-L2 comprising one or more of SEQ ID NOs: 2197 and 2309; and a CDR-L3 comprising one or more of SEQ ID NOs: 2421 and 2533; (6) a VL comprising: a CDR-L1 comprising one or more of SEQ ID NOs: 1974 and 2086; a CDR-L2 comprising one or more of SEQ ID NOs: 2198 and 2310; and a CDR-L3 comprising one or more of SEQ ID NOs: 2422 and 2534; or (7) a VLcomprising: a CDR-L1 comprising one or more of SEQ ID NOs: 2064 and 2176; a CDR-L2 comprising one or more of SEQ ID NOs: 2288 and 2400; and a CDR-L3 comprising one or more of SEQ ID NOs: 2512 and 2624.

64. The antibody conjugate of any of claims 57-63, wherein the variant thereof has 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid substitutions.

65. The antibody conjugate of claim 64, wherein the amino acid substitutions are conservative amino acid substitutions.

66. The antibody conjugate of any of claims 57-65, wherein the variant thereof has 90%, 95%, 96%, 97%, 98%, or 99% sequence identity.

67. The antibody conjugate of any one of the preceding claims, wherein the antibody conjugate comprises: (a) an antibody comprising: (i) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising at least one of SEQ ID NOs: 1430 and 1755; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO; 2512; (ii) a VHcomprising: a CDR-H1 comprising at least one of SEQ ID NOs: 161 and 486; a CDR-H2 comprising at least one of SEQ ID NOs: 811 and 1136; and a CDR-H3 comprising at least one of SEQ ID NOs: 1461 and 1786; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO; 2512; (iii) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 189 and 514; a CDR-H2 comprising at least one of SEQ ID NOs: 839 and 1164; and a CDR-H3 comprising at least one of SEQ ID NOs: 1489 and 1814; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO; 2512; (iv) a VHcomprising: a CDR-H1 comprising at least one of SEQ ID NOs: 192 and 517; a CDR-H2 comprising at least one of SEQ ID NOs: 842 and 1167; and a CDR-H3 comprising at least one of SEQ ID NOs: 1492 and 1817; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO; 2512; (v) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 211 and 536; a CDR-H2 comprising at least one of SEQ ID NOs: 861 and 1186; and a CDR-H3 comprising at least one of SEQ ID NOs: 1511 and 1836; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO; 2512; (vi) a VHcomprising: a CDR-H1 comprising at least one of SEQ ID NOs: 214 and 539; a CDR-H2 comprising at least one of SEQ ID NOs: 864 and 1189; and a CDR-H3 comprising at least one of SEQ ID NOs: 1514 and 1839; and a VL comprising: aCDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO; 2512; (vii) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 218 and 543; a CDR-H2 comprising at least one of SEQ ID NOs: 868 and 1210; and a CDR-H3 comprising at least one of SEQ ID NOs: 1518 and 1843; and a VLcomprising: a CDR-L1 comprising at least one of SEQ ID NOs: 1974 and 2086; a CDR-L2 comprising at least one of SEQ ID NOs: 2198 and 2310; and a CDR-L3 comprising at least one of SEQ ID NOs: 2422 and 2534; (viii) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 105 and 430; a CDR-H2 comprising at least one of SEQ ID NOs: 755 and 1080; and a CDR-H3 comprising at least one of SEQ ID NOs: 1405 and 1730; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO; 2512; (ix) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 114 and 439; a CDR-H2 comprising at least one of SEQ ID NOs: 764 and 1089; and a CDR-H3 comprising at least one of SEQ ID NOs: 1414 and 1739; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO; 2512; (x) a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 117 and 442; a CDR-H2 comprising at least one of SEQ ID NOs: 767 and 1092; and a CDR-H3 comprising at least one of SEQ ID NOs: 1417 and 1742; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO; 2512; (b) para-azidomethylphenylalanine residues at antibody sites selected from the group consisting of HC180, HC241, HC404, HC391, LC42, LC161 and combinations thereof; and (c) a linker-payload selected from the group consisting of:,,, and,wherein n2 is 2, 4, 6, 8 or 10 and each linker-payload is bonded to one of the para- azidomethylphenylalanine residue side chains.

68. The antibody conjugate of any one of the preceding claims, wherein the antibody conjugate comprises: (a) an antibody comprising a VHcomprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising at least one of SEQ ID NOs: 1430 and 1755; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites selected from the group consisting of HC180, HC241, HC404, HC391, LC42, LC161 and combinations thereof; and (c) a linker-payload selected from the group consisting of:,,, wherein n2 is 2, 4, 6, 8 or 10 and each linker-payload is bonded to one of the para- azidomethylphenylalanine residue side chains.

69. The antibody conjugate of any one of claims 1-67, wherein the antibody conjugate comprises: (a) an antibody comprising a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising at least one of SEQ ID NOs: 1430 and 1755; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC241 and HC404; (c) the following linker-payload, wherein n2 is 4 and each linker-payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

70. The antibody conjugate of any one of claims 1-67, wherein the antibody conjugate comprises:(a) an antibody comprising a VHcomprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising at least one of SEQ ID NOs: 1430 and 1755; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC241, HC404, HC180, and HC391; (c) the following linker-payload, wherein n2 is 8 and each linker-payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

71. The antibody conjugate of any one of claims 1-67, wherein the antibody conjugate comprises: (a) an antibody comprising a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising at least one of SEQ ID NOs: 1430 and 1755; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC180 and HC404; (c) the following linker-payload, wherein n2 is 4 and each linker-payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

72. The antibody conjugate of any one of claims 1-68, wherein the antibody conjugate comprises: (a) an antibody comprising a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising at least one of SEQ ID NOs: 1430 and 1755; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC241 and HC404; (c) the following linker-payload, wherein n2 is 4 and each linker-payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

73. The antibody conjugate of any one of claims 1-67, wherein the antibody conjugate comprises: (a) an antibody comprising a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising at least one of SEQ ID NOs: 1430 and 1755; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512;(b) para-azidomethylphenylalanine residues at antibody sites HC180, HC404 and LC42; (c) the following linker-payload, wherein n2 is 6 and each linker-payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

74. The antibody conjugate of any one of claims 1-68, wherein the antibody conjugate comprises: (a) an antibody comprising a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising at least one of SEQ ID NOs: 1430 and 1755; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC180, HC241 and HC404; (c) the following linker-payload, wherein n2 is 6 and each linker-payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

75. The antibody conjugate of any one of claims 1-67, wherein the antibody conjugate comprises:(a) an antibody comprising a VHcomprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising at least one of SEQ ID NOs: 1430 and 1755; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC180, HC404, LC42 and LC161; (c) the following linker-payload, wherein n2 is 8 and each linker-payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

76. The antibody conjugate of any one of claims 1-67, wherein the antibody conjugate comprises: (a) an antibody comprising a VHcomprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising at least one of SEQ ID NOs: 1430 and 1755; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC180, HC241, HC404 and LC42; (c) the following linker-payload, wherein n2 is 8 and each linker-payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

77. The antibody conjugate of any one of claims 1-67, wherein the antibody conjugate comprises: (a) an antibody comprising a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising at least one of SEQ ID NOs: 1430 and 1755; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC180, HC241, HC404 and LC42; (c) the following linker-payload, wherein n2 is 8 and each linker-payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

78. The antibody conjugate of any one of claims 1-67, wherein the antibody conjugate comprises:(a) an antibody comprising a VHcomprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising at least one of SEQ ID NOs: 1430 and 1755; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC180 and HC404; (c) the following linker-payload, wherein n2 is 4 and each linker-payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

79. The antibody conjugate of any one of claims 1-67, wherein the antibody conjugate comprises: (a) an antibody comprising a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising at least one of SEQ ID NOs: 1430 and 1755; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC180 and HC404; (c) the following linker-payload, wherein n2 is 4 and each linker-payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

80. The antibody conjugate of any one of claims 1-67, wherein the antibody conjugate comprises: (a) an antibody comprising a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising at least one of SEQ ID NOs: 1430 and 1755; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC180 and HC404; (c) the following linker-payload, wherein n2 is 4 and each linker-payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

81. The antibody conjugate of any one of claims 1-67, wherein the antibody conjugate comprises: (a) an antibody comprising a VHcomprising: a CDR-H1 comprising at least one of SEQ ID NOs: 130 and 455; a CDR-H2 comprising at least one of SEQ ID NOs: 780 and1105; and a CDR-H3 comprising at least one of SEQ ID NOs: 1430 and 1755; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC180 and HC404; (c) the following linker-payload structure, wherein n2 is 4 and each linker- payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

82. The antibody drug conjugate of any of the preceding claims, wherein the antibody comprises the VH / VLpair SEQ ID NOs: 2752 / 3061.

83. The antibody drug conjugate of any one of claims 1-67, wherein the antibody conjugate comprises: (a) an antibody comprising a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 161 and 486; a CDR-H2 comprising at least one of SEQ ID NOs: 811 and 1136; and a CDR-H3 comprising at least one of SEQ ID NOs: 1461 and 1786; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC180 and HC404; (c) the following linker-payload, wherein n2 is 4 and each linker-payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

84. The antibody drug conjugate of claim 83, wherein the antibody comprises the VH / VLpair SEQ ID NOs: 2783 / 3061.

85. The antibody drug conjugate of any one of claims 1-67, wherein the antibody conjugate comprises: (a) an antibody comprising a VHcomprising: a CDR-H1 comprising at least one of SEQ ID NOs: 189 and 514; a CDR-H2 comprising at least one of SEQ ID NOs: 839 and 1164; and a CDR-H3 comprising at least one of SEQ ID NOs: 1489 and 1814; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC180 and HC404; (c) the following linker-payload, wherein n2 is 4 and each linker-payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

86. The antibody drug conjugate of claim 85, wherein the antibody comprises the VH / VLpair SEQ ID NOs: 2811 / 3061.

87. The antibody drug conjugate of any one of claims 1-67, wherein the antibody conjugate comprises: (a) an antibody comprising a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 192 and 517; a CDR-H2 comprising at least one of SEQ ID NOs: 842 and 1167; and a CDR-H3 comprising at least one of SEQ ID NOs: 1492 and 1817; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC180 and HC404; (c) the following linker-payload, wherein n2 is 4 and each linker-payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

88. The antibody drug conjugate of claim 87, wherein the antibody comprises the VH / VLpair SEQ ID NOs: 2814 / 3061.

89. The antibody drug conjugate of any one of claims 1-67, wherein the antibody conjugate comprises: (a) an antibody comprising a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 211 and 536; a CDR-H2 comprising at least one of SEQ ID NOs: 861 and 1186; and a CDR-H3 comprising at least one of SEQ ID NOs: 1511 and 1836; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC180 and HC404; (c) the following linker-payload, wherein n2 is 4 and each linker-payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

90. The antibody drug conjugate of claim 89, wherein the antibody comprises the VH / VL pair SEQ ID NOs: 2833 / 3061.

91. The antibody drug conjugate of any one of claims 1-67, wherein the antibody conjugate comprises: (a) an antibody comprising a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 214 and 539; a CDR-H2 comprising at least one of SEQ ID NOs: 864 and1189; and a CDR-H3 comprising at least one of SEQ ID NOs: 1514 and 1839; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC180 and HC404; (c) the following linker-payload, wherein n2 is 4 and each linker-payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

92. The antibody drug conjugate of claim 91, wherein the antibody comprises the VH / VLpair SEQ ID NOs: 2836 / 3061.

93. The antibody drug conjugate of any one of claims 1-67, wherein the antibody conjugate comprises: (a) an antibody comprising a VHcomprising: a CDR-H1 comprising at least one of SEQ ID NOs: 218 and 543; a CDR-H2 comprising at least one of SEQ ID NOs: 868 and 1210; and a CDR-H3 comprising at least one of SEQ ID NOs: 1518 and 1843; and a VLcomprising: a CDR-L1 comprising at least one of SEQ ID NOs: 1974 and 2086; a CDR-L2 comprising at least one of SEQ ID NOs:2198 and 2310; and a CDR-L3 comprising at least one of SEQ ID NOs: 2422 and 2534; (b) para-azidomethylphenylalanine residues at antibody sites HC180 and HC404;(c) the following linker-payload, wherein n2 is 4 and each linker-payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

94. The antibody drug conjugate of claim 93, wherein the antibody comprises the VH / VL pair SEQ ID NOs: 2855 / 2971.

95. The antibody drug conjugate of any one of claims 1-67, wherein the antibody conjugate comprises: (a) an antibody comprising a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 105 and 430; a CDR-H2 comprising at least one of SEQ ID NOs: 755 and 1080; and a CDR-H3 comprising at least one of SEQ ID NOs: 1405 and 1730; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC180 and HC404; (c) the following linker-payload, wherein n2 is 4 and each linker-payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

96. The antibody drug conjugate of claim 95, wherein the antibody comprises the VH / VLpair SEQ ID NOs: 2727 / 2961.

97. The antibody drug conjugate of any one of claims 1-67, wherein the antibody conjugate comprises: (a) an antibody comprising a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 114 and 439; a CDR-H2 comprising at least one of SEQ ID NOs: 764 and 1089; and a CDR-H3 comprising at least one of SEQ ID NOs: 1414 and 1739; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC180 and HC404; (c) the following linker-payload, wherein n2 is 4 and each linker-payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

98. The antibody drug conjugate of claim 97, wherein the antibody comprises the VH / VL pair SEQ ID NOs: 2736 / 2961.

99. The antibody drug conjugate of any one of claims 1-67, wherein the antibody conjugate comprises: (a) an antibody comprising a VHcomprising: a CDR-H1 comprising at least one of SEQ ID NOs: 117 and 442; a CDR-H2 comprising at least one of SEQ ID NOs: 767 and 1092; and a CDR-H3 comprising at least one of SEQ ID NOs: 1417 and 1742; and a VL comprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC180 and HC404;(c) the following linker-payload, wherein n2 is 4 and each linker-payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

100. The antibody drug conjugate of claim 99, wherein the antibody comprises the VH / VL pair SEQ ID NOs: 2739 / 2961.

101. The antibody drug conjugate of any one of claims 1-67, wherein the antibody conjugate comprises: (a) an antibody comprising a VH comprising: a CDR-H1 comprising at least one of SEQ ID NOs: 128 and 453; a CDR-H2 comprising at least one of SEQ ID NOs: 778 and 1103; and a CDR-H3 comprising at least one of SEQ ID NOs: 1428 and 1753; and a VLcomprising: a CDR-L1 comprising SEQ ID NO: 2064; a CDR-L2 comprising SEQ ID NO: 2288; and a CDR-L3 comprising SEQ ID NO: 2512; (b) para-azidomethylphenylalanine residues at antibody sites HC180 and HC404; (c) the following linker-payload, wherein n2 is 4 and each linker-payload is bonded to one of the para-azidomethylphenylalanine residue side chains:.

102. The antibody drug conjugate of claim 101, wherein the antibody comprises the VH / VLpair SEQ ID NOs: 2750 / 2961.

103. The antibody conjugate of any of the preceding claims, wherein the antibody binds to the same epitope as a second antibody comprising a VH / VLpair, or a variant thereof, selected from the group consisting of SEQ ID NOs: 2727 / 3061, 2736 / 3061, 2739 / 3061, 2751 / 3061, 2752 / 3061, 2753 / 3061, 2754 / 3061, 2755 / 3061, 2756 / 3061, 2757 / 3061, 2758 / 3061, 2759 / 3061, 2760 / 3061, 2761 / 3061, 2762 / 3061, 2763 / 3061, 2764 / 3061, 2765 / 3061, 2766 / 3061, 2767 / 3061, 2768 / 3061, 2769 / 3061, 2770 / 3061, 2771 / 3061, 2772 / 3061, 2773 / 3061, 2774 / 3061, 2775 / 3061, 2776 / 3061, 2777 / 3061, 2778 / 3061, 2779 / 3061, 2780 / 3061, 2781 / 3061, 2782 / 3061, 2783 / 3061, 2784 / 3061, 2785 / 3061, 2786 / 3061, 2787 / 3061, 2788 / 3061, 2789 / 3061, 2790 / 3061, 2791 / 3061, 2792 / 3061, 2793 / 3061, 2794 / 3061, 2795 / 3061, 2796 / 3061, 2797 / 3061, 2798 / 3061, 2799 / 3061, 2800 / 3061, 2801 / 3061, 2802 / 3061, 2803 / 3061, 2804 / 3061, 2805 / 3061, 2806 / 3061, 2807 / 3061, 2808 / 3061, 2809 / 3061, 2810 / 3061, 2811 / 3061, 2812 / 3061, 2813 / 3061, 2814 / 3061, 2815 / 3061, 2816 / 3061, 2817 / 3061, 2818 / 3061, 2819 / 3061, 2820 / 3061, 2821 / 3061, 2822 / 3061, 2823 / 3061, 2824 / 3061, 2825 / 3061, 2826 / 3061, 2827 / 3061, 2828 / 3061, 2829 / 3061, 2830 / 3061, 2831 / 3061, 2832 / 3061, 2833 / 3061, 2834 / 3061, 2835 / 3061, 2836 / 3061, 2837 / 3061, 2838 / 3061, 2840 / 2951, 2846 / 2957, 2851 / 2962, 2857 / 2968, 2859 / 2970, and 2860 / 2971.

104. The antibody conjugate of claim 103, wherein the antibody inhibits binding of the second antibody to TF by at least 50%, or wherein the second antibody inhibits binding of the isolated antibody to TF by at least 50%.

105. The antibody conjugate of any one of the preceding claims, wherein the antibody has a ka of about 5.4x104M-1×sec-1to about 5.47×105M-1×sec-1when associating with human TF at a temperature of 25°C.

106. The antibody conjugate of any one of the preceding claims, wherein the antibody has a kd of about 4.18×10-4sec-1to about 5.94×10-3sec-1when dissociating from human TF at a temperature of 25°C.

107. The antibody conjugate of any one of the preceding claims, wherein the antibody has a KD of about 3.59x10-9M to about 1.91x10-8M when bound to human TF at a temperature of 25°C.

108. The antibody conjugate of any one of the preceding claims, wherein the antibody comprises at least one constant region domain.

109. The antibody conjugate of claim 108, wherein the constant region comprises a sequence selected from SEQ ID NOs: 3062, 3063, 3064, 3065, and 3068.

110. The antibody conjugate of any of the preceding claims, wherein the antibody is a monoclonal antibody.

111. The antibody conjugate of any of the preceding claims, wherein the antibody is an IgA, an IgD, an IgE, an IgG, or an IgM.

112. The antibody conjugate of any of the preceding claims, wherein the antibody is humanized or human.

113. The antibody conjugate of any of the preceding claims, wherein the antibody is glycosylated.

114. The antibody conjugate of any of the preceding claims, wherein the antibody is an antibody fragment.

115. The antibody conjugate of claim 114, wherein the antibody fragment is selected from an Fv fragment, a Fab fragment, a F(ab’)2 fragment, a Fab’ fragment, an scFv (sFv) fragment, and an scFv-Fc fragment.

116. The antibody conjugate of claim 115, wherein the antibody is an scFv fragment.

117. An isolated antibody that specifically binds to tissue factor (TF), wherein the antibody comprises three heavy chain CDRs from a VHsequence selected from SEQ ID NOs:2727, 2736, 2739, 2751-2838, 2840, 2846, 2851, 2857, and 2859-2860, or variants thereof, and three light chain CDRs from a VL sequence selected from SEQ ID NOs:2951, 2957, 2962, 2968, 2970, 2971, and 3061, or variants thereof.

118. The isolated antibody of claim 117, wherein the antibody comprises three heavy chain CDRs, or variants thereof, and three light chain CDRs, or variants thereof, from a VH / VL pair selected from the group consisting of SEQ ID NOs: 2727 / 3061, 2736 / 30612739 / 3061, 2751 / 3061, 2752 / 3061, 2753 / 3061, 2754 / 3061, 2755 / 3061, 2756 / 3061, 2757 / 3061, 2758 / 3061, 2759 / 3061, 2760 / 3061, 2761 / 3061, 2762 / 3061, 2763 / 3061, 2764 / 3061, 2765 / 3061, 2766 / 3061, 2767 / 3061, 2768 / 3061, 2769 / 3061, 2770 / 3061, 2771 / 3061, 2772 / 3061, 2773 / 3061, 2774 / 3061,2775 / 3061, 2776 / 3061, 2777 / 3061, 2778 / 3061, 2779 / 3061, 2780 / 3061, 2781 / 3061, 2782 / 3061, 2783 / 3061, 2784 / 3061, 2785 / 3061, 2786 / 3061, 2787 / 3061, 2788 / 3061, 2789 / 3061, 2790 / 3061, 2791 / 3061, 2792 / 3061, 2793 / 3061, 2794 / 3061, 2795 / 3061, 2796 / 3061, 2797 / 3061, 2798 / 3061, 2799 / 3061, 2800 / 3061, 2801 / 3061, 2802 / 3061, 2803 / 3061, 2804 / 3061, 2805 / 3061, 2806 / 3061, 2807 / 3061, 2808 / 3061, 2809 / 3061, 2810 / 3061, 2811 / 3061, 2812 / 3061, 2813 / 3061, 2814 / 3061, 2815 / 3061, 2816 / 3061, 2817 / 3061, 2818 / 3061, 2819 / 3061, 2820 / 3061, 2821 / 3061, 2822 / 3061, 2823 / 3061, 2824 / 3061, 2825 / 3061, 2826 / 3061, 2827 / 3061, 2828 / 3061, 2829 / 3061, 2830 / 3061, 2831 / 3061, 2832 / 3061, 2833 / 3061, 2834 / 3061, 2835 / 3061, 2836 / 3061, 2837 / 3061, 2838 / 3061, 2840 / 2951, 2846 / 2957, 2851 / 2962, 2857 / 2968, 2859 / 2970, and 2860 / 2971.

119. The isolated antibody of claim 117, wherein the antibody comprises three heavy chain CDRs, or variants thereof, and three light chain CDRs, or variants thereof, from a VH / VLpair selected from the group consisting of SEQ ID NOs: 2727 / 3061, 2736 / 3061, 2736 / 3061, 2752 / 3061, 2783 / 3061, 2811 / 3061, 2814 / 3061, 2833 / 3061, 2836 / 3061, and 2857 / 2968.

120. The isolated antibody of any of claims 117-119, wherein the antibody comprises a VHselected from SEQ ID NOs: 2727, 2736, 2739, 2751-2838, 2840, 2846, 2851, 2857, and 2859-2860.

121. The antibody of claim 120, wherein the antibody comprises a VL selected from SEQ ID NOs: 2951, 2957, 2962, 2968, 2970, 2971, and 3061.

122. The antibody of any one of claims 117-121, wherein the antibody comprises a VH / VL pair, or a variant thereof, selected from the group consisting of SEQ ID NOs: 2727 / 3061, 2736 / 3061, 2739 / 3061, 2751 / 3061, 2752 / 3061, 2753 / 3061, 2754 / 3061, 2755 / 3061, 2756 / 3061, 2757 / 3061, 2758 / 3061, 2759 / 3061, 2760 / 3061, 2761 / 3061, 2762 / 3061, 2763 / 3061, 2764 / 3061, 2765 / 3061, 2766 / 3061, 2767 / 3061, 2768 / 3061, 2769 / 3061, 2770 / 3061, 2771 / 3061, 2772 / 3061, 2773 / 3061, 2774 / 3061, 2775 / 3061, 2776 / 3061, 2777 / 3061, 2778 / 3061, 2779 / 3061, 2780 / 3061, 2781 / 3061, 2782 / 3061, 2783 / 3061, 2784 / 3061, 2785 / 3061, 2786 / 3061, 2787 / 3061, 2788 / 3061, 2789 / 3061, 2790 / 3061, 2791 / 3061, 2792 / 3061, 2793 / 3061, 2794 / 3061, 2795 / 3061, 2796 / 3061, 2797 / 3061, 2798 / 3061, 2799 / 3061, 2800 / 3061, 2801 / 3061, 2802 / 3061, 2803 / 3061, 2804 / 3061, 2805 / 3061, 2806 / 3061, 2807 / 3061, 2808 / 3061, 2809 / 3061, 2810 / 3061, 2811 / 3061, 2812 / 3061, 2813 / 3061, 2814 / 3061, 2815 / 3061, 2816 / 3061, 2817 / 3061, 2818 / 3061, 2819 / 3061, 2820 / 3061, 2821 / 3061, 2822 / 3061, 2823 / 3061, 2824 / 3061, 2825 / 3061, 2826 / 3061, 2827 / 3061, 2828 / 3061, 2829 / 3061, 2830 / 3061, 2831 / 3061, 2832 / 3061, 2833 / 3061, 2834 / 3061, 2835 / 3061,2836 / 3061, 2837 / 3061, 2838 / 3061, 2840 / 2951, 2846 / 2957, 2851 / 2962, 2857 / 2968, 2859 / 2970, and 2860 / 2971.

123. The antibody of any one of claims 117-121, wherein the antibody comprises a VH / VL pair, or a variant thereof, selected from the group consisting of SEQ ID NOs: 2727 / 3061, 2736 / 3061, 2736 / 3061, 2752 / 3061, 2783 / 3061, 2811 / 3061, 2814 / 3061, 2833 / 3061, 2836 / 3061, and 2857 / 2968.

124. An isolated antibody that specifically binds to tissue factor (TF), wherein the antibody comprises: (1) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 105 and 430; a CDR-H2 comprising one or more of SEQ ID NOs: 755 and 1080; and a CDR- H3 comprising one or more of SEQ ID NOs: 1405 and 1730; (2) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 114 and 439; a CDR-H2 comprising one or more of SEQ ID NOs: 764 and 1089; and a CDR- H3 comprising one or more of SEQ ID NOs: 1414 and 1739; (3) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 117 and 442; a CDR-H2 comprising one or more of SEQ ID NOs: 767 and 1092; and a CDR- H3 comprising one or more of SEQ ID NOs: 1417 and 1742; (4) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 129 and 454; a CDR-H2 comprising one or more of SEQ ID NOs: 779 and 1104; and a CDR- H3 comprising one or more of SEQ ID NOs: 1429 and 1754; (5) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 130 and 455; a CDR-H2 comprising one or more of SEQ ID NOs: 780 and 1105; and a CDR- H3 comprising one or more of SEQ ID NOs: 1430 and 1755; (6) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 131 and 456; a CDR-H2 comprising one or more of SEQ ID NOs: 781 and 1106; and a CDR- H3 comprising one or more of SEQ ID NOs: 1431 and 1756;(7) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 132 and 457; a CDR-H2 comprising one or more of SEQ ID NOs: 782 and 1107; and a CDR- H3 comprising one or more of SEQ ID NOs: 1432 and 1757; (8) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 133 and 458; a CDR-H2 comprising one or more of SEQ ID NOs: 783 and 1108; and a CDR- H3 comprising one or more of SEQ ID NOs: 1433 and 1758; (9) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 134 and 459; a CDR-H2 comprising one or more of SEQ ID NOs: 784 and 1109; and a CDR- H3 comprising one or more of SEQ ID NOs: 1434 and 1759; (10) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 135 and 460; a CDR-H2 comprising one or more of SEQ ID NOs: 785 and 1110; and a CDR- H3 comprising one or more of SEQ ID NOs: 1435 and 1760; (11) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 136 and 461; a CDR-H2 comprising one or more of SEQ ID NOs: 786 and 1111; and a CDR- H3 comprising one or more of SEQ ID NOs: 1436 and 1761; (12) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 137 and 462; a CDR-H2 comprising one or more of SEQ ID NOs: 787 and 1112; and a CDR- H3 comprising one or more of SEQ ID NOs: 1437 and 1762; (13) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 138 and 463; a CDR-H2 comprising one or more of SEQ ID NOs: 788 and 1113; and a CDR- H3 comprising one or more of SEQ ID NOs: 1438 and 1763; (14) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 139 and 464; a CDR-H2 comprising one or more of SEQ ID NOs: 789 and 1114; and a CDR- H3 comprising one or more of SEQ ID NOs: 1439 and 1764; (15) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 140 and 465; a CDR-H2 comprising one or more of SEQ ID NOs: 790 and 1115; and a CDR- H3 comprising one or more of SEQ ID NOs: 1440 and 1765;(16) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 141 and 466; a CDR-H2 comprising one or more of SEQ ID NOs: 791 and 1116; and a CDR- H3 comprising one or more of SEQ ID NOs: 1441 and 1766; (17) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 142 and 467; a CDR-H2 comprising one or more of SEQ ID NOs: 792 and 1117; and a CDR- H3 comprising one or more of SEQ ID NOs: 1442 and 1767; (18) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 143 and 468; a CDR-H2 comprising one or more of SEQ ID NOs: 793 and 1118; and a CDR- H3 comprising one or more of SEQ ID NOs: 1443 and 1768; (19) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 144 and 469; a CDR-H2 comprising one or more of SEQ ID NOs: 794 and 1119; and a CDR- H3 comprising one or more of SEQ ID NOs: 1444 and 1769; (20) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 145 and 470; a CDR-H2 comprising one or more of SEQ ID NOs: 795 and 1120; and a CDR- H3 comprising one or more of SEQ ID NOs: 1445 and 1770; (21) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 146 and 471; a CDR-H2 comprising one or more of SEQ ID NOs: 796 and 1121; and a CDR- H3 comprising one or more of SEQ ID NOs: 1446 and 1771; (22) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 147 and 472; a CDR-H2 comprising one or more of SEQ ID NOs: 797 and 1122; and a CDR- H3 comprising one or more of SEQ ID NOs: 1447 and 1772; (23) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 148 and 473; a CDR-H2 comprising one or more of SEQ ID NOs: 798 and 1123; and a CDR- H3 comprising one or more of SEQ ID NOs: 1448 and 1773; (24) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 149 and 474; a CDR-H2 comprising one or more of SEQ ID NOs: 799 and 1124; and a CDR- H3 comprising one or more of SEQ ID NOs: 1449 and 1774;(25) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 150 and 475; a CDR-H2 comprising one or more of SEQ ID NOs: 800 and 1125; and a CDR- H3 comprising one or more of SEQ ID NOs: 1450 and 1775; (26) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 151 and 476; a CDR-H2 comprising one or more of SEQ ID NOs: 801 and 1126; and a CDR- H3 comprising one or more of SEQ ID NOs: 1451 and 1776; (27) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 152 and 477; a CDR-H2 comprising one or more of SEQ ID NOs: 802 and 1127; and a CDR- H3 comprising one or more of SEQ ID NOs: 1452 and 1777; (28) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 153 and 478; a CDR-H2 comprising one or more of SEQ ID NOs: 803 and 1128; and a CDR- H3 comprising one or more of SEQ ID NOs: 1453 and 1778; (29) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 154 and 479; a CDR-H2 comprising one or more of SEQ ID NOs: 804 and 1129; and a CDR- H3 comprising one or more of SEQ ID NOs: 1454 and 1779; (30) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 155 and 480; a CDR-H2 comprising one or more of SEQ ID NOs: 805 and 1130; and a CDR- H3 comprising one or more of SEQ ID NOs: 1455 and 1780; (31) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 156 and 481; a CDR-H2 comprising one or more of SEQ ID NOs: 806 and 1131; and a CDR- H3 comprising one or more of SEQ ID NOs: 1456 and 1781; (32) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 157 and 482; a CDR-H2 comprising one or more of SEQ ID NOs: 807 and 1132; and a CDR- H3 comprising one or more of SEQ ID NOs: 1457 and 1782; (33) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 158 and 483; a CDR-H2 comprising one or more of SEQ ID NOs: 808 and 1133; and a CDR- H3 comprising one or more of SEQ ID NOs: 1458 and 1783;(34) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 159 and 484; a CDR-H2 comprising one or more of SEQ ID NOs: 809 and 1134; and a CDR- H3 comprising one or more of SEQ ID NOs: 1459 and 1784; (35) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 160 and 485; a CDR-H2 comprising one or more of SEQ ID NOs: 810 and 1135; and a CDR- H3 comprising one or more of SEQ ID NOs: 1460 and 1785; (36) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 161 and 486; a CDR-H2 comprising one or more of SEQ ID NOs: 811 and 1136; and a CDR- H3 comprising one or more of SEQ ID NOs: 1461 and 1786; (37) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 162 and 487; a CDR-H2 comprising one or more of SEQ ID NOs: 812 and 1137; and a CDR- H3 comprising one or more of SEQ ID NOs: 1462 and 1787; (38) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 163 and 488; a CDR-H2 comprising one or more of SEQ ID NOs: 813 and 1138; and a CDR- H3 comprising one or more of SEQ ID NOs: 1463 and 1788; (39) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 164 and 489; a CDR-H2 comprising one or more of SEQ ID NOs: 814 and 1139; and a CDR- H3 comprising one or more of SEQ ID NOs: 1464 and 1789; (40) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 165 and 490; a CDR-H2 comprising one or more of SEQ ID NOs: 815 and 1140; and a CDR- H3 comprising one or more of SEQ ID NOs: 1465 and 1790; (41) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 166 and 491; a CDR-H2 comprising one or more of SEQ ID NOs: 816 and 1141; and a CDR- H3 comprising one or more of SEQ ID NOs: 1466 and 1791; (42) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 167 and 492; a CDR-H2 comprising one or more of SEQ ID NOs: 817 and 1142; and a CDR- H3 comprising one or more of SEQ ID NOs: 1467 and 1792;(43) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 168 and 493; a CDR-H2 comprising one or more of SEQ ID NOs: 818 and 1143; and a CDR- H3 comprising one or more of SEQ ID NOs: 1468 and 1793; (44) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 169 and 494; a CDR-H2 comprising one or more of SEQ ID NOs: 819 and 1144; and a CDR- H3 comprising one or more of SEQ ID NOs: 1469 and 1794; (45) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 170 and 495; a CDR-H2 comprising one or more of SEQ ID NOs: 820 and 1145; and a CDR- H3 comprising one or more of SEQ ID NOs: 1470 and 1795; (46) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 171 and 496; a CDR-H2 comprising one or more of SEQ ID NOs: 821 and 1146; and a CDR- H3 comprising one or more of SEQ ID NOs: 1471 and 1796; (47) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 172 and 497; a CDR-H2 comprising one or more of SEQ ID NOs: 822 and 1147; and a CDR- H3 comprising one or more of SEQ ID NOs: 1472 and 1797; (48) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 173 and 498; a CDR-H2 comprising one or more of SEQ ID NOs: 823 and 1148; and a CDR- H3 comprising one or more of SEQ ID NOs: 1473 and 1798; (49) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 174 and 499; a CDR-H2 comprising one or more of SEQ ID NOs: 824 and 1149; and a CDR- H3 comprising one or more of SEQ ID NOs: 1474 and 1799; (50) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 175 and 500; a CDR-H2 comprising one or more of SEQ ID NOs: 825 and 1150; and a CDR- H3 comprising one or more of SEQ ID NOs: 1475 and 1800; (51) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 176 and 501; a CDR-H2 comprising one or more of SEQ ID NOs: 826 and 1151; and a CDR- H3 comprising one or more of SEQ ID NOs: 1476 and 1801;(52) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 177 and 502; a CDR-H2 comprising one or more of SEQ ID NOs: 827 and 1152; and a CDR- H3 comprising one or more of SEQ ID NOs: 1477 and 1802; (53) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 178 and 503; a CDR-H2 comprising one or more of SEQ ID NOs: 828 and 1153; and a CDR- H3 comprising one or more of SEQ ID NOs: 1478 and 1803; (54) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 179 and 504; a CDR-H2 comprising one or more of SEQ ID NOs: 829 and 1154; and a CDR- H3 comprising one or more of SEQ ID NOs: 1479 and 1804; (55) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 180 and 505; a CDR-H2 comprising one or more of SEQ ID NOs: 830 and 1155; and a CDR- H3 comprising one or more of SEQ ID NOs: 1480 and 1805; (56) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 181 and 506; a CDR-H2 comprising one or more of SEQ ID NOs: 831 and 1156; and a CDR- H3 comprising one or more of SEQ ID NOs: 1481 and 1806; (57) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 182 and 507; a CDR-H2 comprising one or more of SEQ ID NOs: 832 and 1157; and a CDR- H3 comprising one or more of SEQ ID NOs: 1482 and 1807; (58) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 183 and 508; a CDR-H2 comprising one or more of SEQ ID NOs: 833 and 1158; and a CDR- H3 comprising one or more of SEQ ID NOs: 1483 and 1808; (59) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 184 and 509; a CDR-H2 comprising one or more of SEQ ID NOs: 834 and 1159; and a CDR- H3 comprising one or more of SEQ ID NOs: 1484 and 1809; (60) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 185 and 510; a CDR-H2 comprising one or more of SEQ ID NOs: 835 and 1160; and a CDR- H3 comprising one or more of SEQ ID NOs: 1485 and 1810;(61) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 186 and 511; a CDR-H2 comprising one or more of SEQ ID NOs: 836 and 1161; and a CDR- H3 comprising one or more of SEQ ID NOs: 1486 and 1811; (62) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 187 and 512; a CDR-H2 comprising one or more of SEQ ID NOs: 837 and 1162; and a CDR- H3 comprising one or more of SEQ ID NOs: 1487 and 1812; (63) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 188 and 513; a CDR-H2 comprising one or more of SEQ ID NOs: 838 and 1163; and a CDR- H3 comprising one or more of SEQ ID NOs: 1488 and 1813; (64) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 189 and 514; a CDR-H2 comprising one or more of SEQ ID NOs: 839 and 1164; and a CDR- H3 comprising one or more of SEQ ID NOs: 1489 and 1814; (65) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 190 and 515; a CDR-H2 comprising one or more of SEQ ID NOs: 840 and 1165; and a CDR- H3 comprising one or more of SEQ ID NOs: 1490 and 1815; (66) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 191 and 516; a CDR-H2 comprising one or more of SEQ ID NOs: 841 and 1166; and a CDR- H3 comprising one or more of SEQ ID NOs: 1491 and 1816; (67) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 192 and 517; a CDR-H2 comprising one or more of SEQ ID NOs: 842 and 1167; and a CDR- H3 comprising one or more of SEQ ID NOs: 1492 and 1817; (68) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 193 and 518; a CDR-H2 comprising one or more of SEQ ID NOs: 843 and 1168; and a CDR- H3 comprising one or more of SEQ ID NOs: 1493 and 1818; (69) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 194 and 519; a CDR-H2 comprising one or more of SEQ ID NOs: 844 and 1169; and a CDR- H3 comprising one or more of SEQ ID NOs: 1494 and 1819;(70) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 195 and 520; a CDR-H2 comprising one or more of SEQ ID NOs: 845 and 1170; and a CDR- H3 comprising one or more of SEQ ID NOs: 1495 and 1820; (71) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 196 and 521; a CDR-H2 comprising one or more of SEQ ID NOs: 846 and 1171; and a CDR- H3 comprising one or more of SEQ ID NOs: 1496 and 1821; (72) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 197 and 522; a CDR-H2 comprising one or more of SEQ ID NOs: 847 and 1172; and a CDR- H3 comprising one or more of SEQ ID NOs: 1497 and 1822; (73) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 198 and 523; a CDR-H2 comprising one or more of SEQ ID NOs: 848 and 1173; and a CDR- H3 comprising one or more of SEQ ID NOs: 1498 and 1823; (74) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 199 and 524; a CDR-H2 comprising one or more of SEQ ID NOs: 849 and 1174; and a CDR- H3 comprising one or more of SEQ ID NOs: 1499 and 1824; (75) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 200 and 525; a CDR-H2 comprising one or more of SEQ ID NOs: 850 and 1175; and a CDR- H3 comprising one or more of SEQ ID NOs: 1500 and 1825; (76) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 201 and 526; a CDR-H2 comprising one or more of SEQ ID NOs: 851 and 1176; and a CDR- H3 comprising one or more of SEQ ID NOs: 1501 and 1826; (77) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 202 and 527; a CDR-H2 comprising one or more of SEQ ID NOs: 852 and 1177; and a CDR- H3 comprising one or more of SEQ ID NOs: 1502 and 1827; (78) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 203 and 528; a CDR-H2 comprising one or more of SEQ ID NOs: 853 and 1178; and a CDR- H3 comprising one or more of SEQ ID NOs: 1503 and 1828;(79) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 204 and 529; a CDR-H2 comprising one or more of SEQ ID NOs: 854 and 1179; and a CDR- H3 comprising one or more of SEQ ID NOs: 1504 and 1829; (80) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 205 and 530; a CDR-H2 comprising one or more of SEQ ID NOs: 855 and 1180; and a CDR- H3 comprising one or more of SEQ ID NOs: 1505 and 1830; (81) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 206 and 531; a CDR-H2 comprising one or more of SEQ ID NOs: 856 and 1181; and a CDR- H3 comprising one or more of SEQ ID NOs: 1506 and 1831; (82) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 207 and 532; a CDR-H2 comprising one or more of SEQ ID NOs: 857 and 1182; and a CDR- H3 comprising one or more of SEQ ID NOs: 1507 and 1832; (83) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 208 and 533; a CDR-H2 comprising one or more of SEQ ID NOs: 858 and 1183; and a CDR- H3 comprising one or more of SEQ ID NOs: 1508 and 1833; (84) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 209 and 534; a CDR-H2 comprising one or more of SEQ ID NOs: 859 and 1184; and a CDR- H3 comprising one or more of SEQ ID NOs: 1509 and 1834; (85) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 210 and 535; a CDR-H2 comprising one or more of SEQ ID NOs: 860 and 1185; and a CDR- H3 comprising one or more of SEQ ID NOs: 1510 and 1835; (86) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 211 and 536; a CDR-H2 comprising one or more of SEQ ID NOs: 861 and 1186; and a CDR- H3 comprising one or more of SEQ ID NOs: 1511 and 1836; (87) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 212 and 537; a CDR-H2 comprising one or more of SEQ ID NOs: 862 and 1187; and a CDR- H3 comprising one or more of SEQ ID NOs: 1512 and 1837;(88) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 213 and 538; a CDR-H2 comprising one or more of SEQ ID NOs: 863 and 1188; and a CDR- H3 comprising one or more of SEQ ID NOs: 1513 and 1838; (89) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 214 and 539; a CDR-H2 comprising one or more of SEQ ID NOs: 864 and 1189; and a CDR- H3 comprising one or more of SEQ ID NOs: 1514 and 1839; (90) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 215 and 540; a CDR-H2 comprising one or more of SEQ ID NOs: 865 and 1190; and a CDR- H3 comprising one or more of SEQ ID NOs: 1515 and 1840; (91) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 216 and 541; a CDR-H2 comprising one or more of SEQ ID NOs: 866 and 1191; and a CDR- H3 comprising one or more of SEQ ID NOs: 1516 and 1841; (92) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 218 and 543; a CDR-H2 comprising one or more of SEQ ID NOs: 868 and 1193; and a CDR- H3 comprising one or more of SEQ ID NOs: 1518 and 1843; (93) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 224 and 549; a CDR-H2 comprising one or more of SEQ ID NOs: 874 and 1199; and a CDR- H3 comprising one or more of SEQ ID NOs: 1524 and 1849; (94) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 229 and 554; a CDR-H2 comprising one or more of SEQ ID NOs: 879 and 1204; and a CDR- H3 comprising one or more of SEQ ID NOs: 1529 and 1854; (95) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 235 and 560; a CDR-H2 comprising one or more of SEQ ID NOs: 885 and 1210; and a CDR- H3 comprising one or more of SEQ ID NOs: 1535 and 1860; (96) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 237 and 562; a CDR-H2 comprising one or more of SEQ ID NOs: 887 and 1212; and a CDR- H3 comprising one or more of SEQ ID NOs: 1537 and 1862; or(97) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 238 and 563; a CDR-H2 comprising one or more of SEQ ID NOs: 888 and 1213; and a CDR-H3 comprising one or more of SEQ ID NOs: 1538 and 1863.

125. The isolated antibody of claim 124, wherein the antibody comprises: (1) a VLcomprising: a CDR-L1 comprising one or more of SEQ ID NOs: 1954 and 2066; a CDR-L2 comprising one or more of SEQ ID NOs: 2178 and 2290; and a CDR- L3 comprising one or more of SEQ ID NOs: 2402 and 2514; (2) a VLcomprising: a CDR-L1 comprising one or more of SEQ ID NOs: 1960 and 2072; a CDR-L2 comprising one or more of SEQ ID NOs: 2184 and 2296; and a CDR- L3 comprising one or more of SEQ ID NOs: 2408 and 2520; (3) a VLcomprising: a CDR-L1 comprising one or more of SEQ ID NOs: 1965 and 2077; a CDR-L2 comprising one or more of SEQ ID NOs: 2189 and 2301; and a CDR- L3 comprising one or more of SEQ ID NOs: 2413 and 2525; (4) a VL comprising: a CDR-L1 comprising one or more of SEQ ID NOs: 1971 and 2083; a CDR-L2 comprising one or more of SEQ ID NOs: 2195 and 2307; and a CDR- L3 comprising one or more of SEQ ID NOs: 2419 and 2531; (5) a VL comprising: a CDR-L1 comprising one or more of SEQ ID NOs: 1973 and 2085; a CDR-L2 comprising one or more of SEQ ID NOs: 2197 and 2309; and a CDR- L3 comprising one or more of SEQ ID NOs: 2421 and 2533; (6) a VL comprising: a CDR-L1 comprising one or more of SEQ ID NOs: 1974 and 2086; a CDR-L2 comprising one or more of SEQ ID NOs: 2198 and 2310; and a CDR- L3 comprising one or more of SEQ ID NOs: 2422 and 2534; or (7) a VL comprising: a CDR-L1 comprising one or more of SEQ ID NOs: 2064 and 2176; a CDR-L2 comprising one or more of SEQ ID NOs: 2288 and 2400; and a CDR- L3 comprising one or more of SEQ ID NOs: 2512 and 2624.

126. An isolated antibody that specifically binds to tissue factor (TF), wherein the antibody comprises:(1) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 105 and 430; a CDR-H2 comprising one or more of SEQ ID NOs: 755 and 1080; and a CDR-H3 comprising one or more of SEQ ID NOs: 1405 and 1730; (2) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 114 and 439; a CDR-H2 comprising one or more of SEQ ID NOs: 764 and 1089; and a CDR-H3 comprising one or more of SEQ ID NOs: 1414 and 1739; (3) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 117 and 442; a CDR-H2 comprising one or more of SEQ ID NOs: 767 and 1092; and a CDR-H3 comprising one or more of SEQ ID NOs: 1417 and 1742; (4) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 130 and 455; a CDR-H2 comprising one or more of SEQ ID NOs: 780 and 1105; and a CDR-H3 comprising one or more of SEQ ID NOs: 1430 and 1755; (5) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 161 and 486; a CDR-H2 comprising one or more of SEQ ID NOs: 811 and 1136; and a CDR-H3 comprising one or more of SEQ ID NOs: 1461 and 1786; (6) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 189 and 514; a CDR-H2 comprising one or more of SEQ ID NOs: 839 and 1164; and a CDR-H3 comprising one or more of SEQ ID NOs: 1489 and 1814; (7) a VH comprising: a CDR-H1 comprising one or more of SEQ ID NOs: 192 and 517; a CDR-H2 comprising one or more of SEQ ID NOs: 842 and 1167; and a CDR-H3 comprising one or more of SEQ ID NOs: 1492 and 1817; (8) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 211 and 536; a CDR-H2 comprising one or more of SEQ ID NOs: 861 and 1186; and a CDR-H3 comprising one or more of SEQ ID NOs: 1511 and 1836; (9) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 214 and 539; a CDR-H2 comprising one or more of SEQ ID NOs: 864 and 1189; and a CDR-H3 comprising one or more of SEQ ID NOs: 1514 and 1839; or (10) a VHcomprising: a CDR-H1 comprising one or more of SEQ ID NOs: 218 and 543; a CDR-H2 comprising one or more of SEQ ID NOs: 868 and 1193; and a CDR-H3 comprising one or more of SEQ ID NOs: 1518 and 1843.

127. The isolated antibody of claim 126, wherein the antibody comprises: (1) a VLcomprising: a CDR-L1 comprising one or more of SEQ ID NOs: 1974 and 2086; a CDR-L2 comprising one or more of SEQ ID NOs: 2198 and 2310; and a CDR-L3 comprising one or more of SEQ ID NOs: 2422 and 2534; or (2) a VLcomprising: a CDR-L1 comprising one or more of SEQ ID NOs: 2064 and 2176; a CDR-L2 comprising one or more of SEQ ID NOs: 2288 and 2400; and a CDR-L3 comprising one or more of SEQ ID NOs: 2512 and 2624.

128. An isolated antibody that specifically binds to tissue factor, wherein the antibody binds to the same epitope as a second antibody comprising a VH / VL pair, or a variant thereof, selected from the group consisting of SEQ ID NOs: 2727 / 3061, 2736 / 3061, 2739 / 3061, 2751 / 3061, 2752 / 3061, 2753 / 3061, 2754 / 3061, 2755 / 3061, 2756 / 3061, 2757 / 3061, 2758 / 3061, 2759 / 3061, 2760 / 3061, 2761 / 3061, 2762 / 3061, 2763 / 3061, 2764 / 3061, 2765 / 3061, 2766 / 3061, 2767 / 3061, 2768 / 3061, 2769 / 3061, 2770 / 3061, 2771 / 3061, 2772 / 3061, 2773 / 3061, 2774 / 3061, 2775 / 3061, 2776 / 3061, 2777 / 3061, 2778 / 3061, 2779 / 3061, 2780 / 3061, 2781 / 3061, 2782 / 3061, 2783 / 3061, 2784 / 3061, 2785 / 3061, 2786 / 3061, 2787 / 3061, 2788 / 3061, 2789 / 3061, 2790 / 3061, 2791 / 3061, 2792 / 3061, 2793 / 3061, 2794 / 3061, 2795 / 3061, 2796 / 3061, 2797 / 3061, 2798 / 3061, 2799 / 3061, 2800 / 3061, 2801 / 3061, 2802 / 3061, 2803 / 3061, 2804 / 3061, 2805 / 3061, 2806 / 3061, 2807 / 3061, 2808 / 3061, 2809 / 3061, 2810 / 3061, 2811 / 3061, 2812 / 3061, 2813 / 3061, 2814 / 3061, 2815 / 3061, 2816 / 3061, 2817 / 3061, 2818 / 3061, 2819 / 3061, 2820 / 3061, 2821 / 3061, 2822 / 3061, 2823 / 3061, 2824 / 3061, 2825 / 3061, 2826 / 3061, 2827 / 3061, 2828 / 3061, 2829 / 3061, 2830 / 3061, 2831 / 3061, 2832 / 3061, 2833 / 3061, 2834 / 3061, 2835 / 3061, 2836 / 3061, 2837 / 3061, 2838 / 3061, 2840 / 2951, 2846 / 2957, 2851 / 2962, 2857 / 2968, 2859 / 2970, and 2860 / 2971.

129. The antibody of claim 128, wherein the isolated antibody inhibits binding of the second antibody to the tissue factor by at least 50%, or wherein the second antibody inhibits binding of the isolated antibody to the tissue factor by at least 50%.

130. The antibody of any one of claims 117-129, wherein the antibody has a ka of about 5.4×104M-1×sec-1to about 5.47×105M-1×sec-1when associating with human tissue factor at a temperature of 25°C.

131. The antibody of any one of claims 117-130, wherein the antibody has a kdof about 2.75×10-4sec-1to about 2.01×10-2sec-1when dissociating from human tissue factor at a temperature of 25°C.

132. The antibody of any one of claims 117-130, wherein the antibody has a KDof about 3.59×10-9M to about 1.91×10-8M when bound to human tissue factor at a temperature of 25°C.

133. The antibody of any one of claims 117-130, wherein the antibody has a kaof about 7.24×104M-1×sec-1to about 1.21×106M-1×sec-1when associating with cynomolgus tissue factor at a temperature of 25°C.

134. The antibody of any one of claims 117-130, wherein the antibody has a kdof about 3.09×10-4sec-1to about 3.93×102sec-1when dissociating from cynomolgus tissue factor at a temperature of 25°C.

135. The antibody of any one of claims 117-130, wherein the antibody has a KD of about 2.55×10-10M to about 6.07×10-8M when bound to cynomolgus tissue factor at a temperature of 25°C.

136. The antibody of any one of claims 117-133, wherein the antibody comprises at least one constant region domain.

137. The antibody of claim 136, wherein the constant region comprises a sequence selected from SEQ ID NOs: 3062, 3063, 3064, 3065, and 3068.

138. The antibody of any one of claims 117-137, wherein the antibody is a monoclonal antibody.

139. The antibody of any one of claims 117-138, wherein the antibody is an IgA, an IgD, an IgE, an IgG, or an IgM.

140. The antibody of any one of claims 117-139, wherein the antibody is humanized or human.

141. The antibody of any one of claims 117-140, wherein the antibody is glycosylated.

142. The antibody of any one of claims 117-140, wherein the antibody is aglycosylated.

143. The antibody of any one of claims 117-142, wherein the antibody is an antibody fragment.

144. The antibody of claim 143, wherein the antibody fragment is selected from an Fv fragment, a Fab fragment, a F(ab’)2 fragment, a Fab’ fragment, an scFv (sFv) fragment, and an scFv-Fc fragment.

145. The antibody of claim 144, wherein the antibody is an scFv fragment.

146. The antibody of claim 145, wherein the scFv fragment comprises an scFv sequence selected from SEQ ID NOs: 3073 and 3079, with or without the N-terminal M residue.

147. The antibody of claim 144, wherein the antibody is an scFv-Fc fragment.

148. The antibody of claim 147, wherein the scFv-Fc fragment comprises a sequence selected from SEQ ID NOs: 3072-3159, with or without the N-terminal M residue.

149. The antibody of any one of claims 117-148, wherein the antibody specifically binds cynomolgus tissue factor.

150. A kit comprising an antibody of any one of claims 117-149, the antibody conjugate of any one of claims 1-116 or the pharmaceutical composition of any one of claims 159-169, and instructions for use of the antibody, antibody conjugate or the pharmaceutical composition.

151. The kit of claim 150, wherein the antibody, antibody conjugate or pharmaceutical composition is lyophilized.

152. The kit of claim 151, further comprising a fluid for reconstitution of the lyophilized antibody, antibody conjugate or pharmaceutical composition.

153. A polynucleotide encoding an antibody of any of claims 117-149.

154. A vector comprising the polynucleotide of claim 153.

155. A recombinant host cell comprising the vector of claim 154.

156. The host cell of claim 155, wherein the host cell is selected from the group consisting of a bacterial cell, a fungal cell, and a mammalian cell.

157. The host cell of claim 155, wherein the host cell is selected from the group consisting of an E. coli cell, a Saccharomyces cerevisiae cell, and a CHO cell.

158. A cell-free expression reaction comprising the vector of claim 154.

159. A pharmaceutical composition comprising the isolated antibody of any of claims 117-149 or the antibody conjugate of any one of claims 1-116 and a pharmaceutically acceptable carrier.

160. A pharmaceutical composition comprising (a) the isolated antibody of any one of claims 117-149 or the antibody conjugate of any one of claims 1-116, (b) one or more additional active agents; and (c) a pharmaceutically acceptable carrier.

161. The pharmaceutical composition of claim 159 or 160, wherein the one or more additional active agents is one or more checkpoint inhibitors.

162. The pharmaceutical composition of claim 161, wherein the one or more checkpoint inhibitors are a PD-1 inhibitor, PD-L1 inhibitor, PD-L2 inhibitor, CTLA-4 inhibitor, LAG-3 inhibitor, or TIM-3 inhibitor.

163. The pharmaceutical composition of claim 162, wherein the one or more checkpoint inhibitors are a PD-1 inhibitor or PD-L1 inhibitor.

164. The pharmaceutical composition of claim 163, wherein the one or more PD-1 or PD-L1 inhibitors are a small molecule blocker of the PD-1 or PD-L1 pathway.

165. The pharmaceutical composition of claim 163, wherein the one or more PD-1 or PD-L1 inhibitors are an antibody that inhibits PD-1 or PD-L1 activity.

166. The pharmaceutical composition of any one of claims 162-165, wherein the one or more PD-1 or PD L1 inhibitors are selected from the group consisting of CA-170, BMS 8, BMS-202, BMS-936558, CK-301, AUNP12, avelumab, nivolumab, pembrolizumab, atezolizumab, durvalumab, AMP 224, MEDI0680 / AMP-514, PDR001, cemiplimab, TSR-042, Tizlelizumab / BGB-A317, CK 301, BMS-936559, camrelizumab, sintilimab, toripalimab, genolimzumab, A167, MGA012, PF-06801591, LY3300054, FAZ053, PD-11, CX-072, BGB- A333, BI 754091, JNJ 63723283, AGEN2034, CA-327, CX-188, STI –A1110, JTX-4014, (LLY) AM0001, CBT-502, FS118, XmAb20717, XmAb23104, AB122, KY1003, RXI-762, PRS-33, ALPN-202, TSR-075, MCLA 145, MGD013, and MGD019.

167. The pharmaceutical composition of claim 160, wherein the one or more additional active agents is one or more PARP inhibitors.

168. The pharmaceutical composition of claim 167, wherein the one or more PARP inhibitors are selected from olaparib, rucaparib, niraparib, and talazoparib.

169. The pharmaceutical composition of claim 167, wherein the one or more PARP inhibitors is olaparib.

170. A method for reducing cell proliferation in a subject in need thereof, comprising administering to the subject an effective amount of an isolated antibody of any one of claims 117-149, an antibody conjugate of any one of claims 1-116, or a pharmaceutical composition of anyone of claims 159-169.

171. A method for treating or preventing a disease or condition in a subject in need thereof, comprising administering to the subject an effective amount of an isolated antibody of any one of claims 117-149, an antibody conjugate of any one of claims 1-116, or a pharmaceutical composition of anyone of claims 159-169.

172. A method of diagnosing a disease or condition in a subject in need thereof, comprising administering to the subject an effective amount of an isolated antibody of any one of claims 117-149, an antibody conjugate of any one of claims 1-116, or a pharmaceutical composition of anyone of claims 159-169.

173. The method of any one of claims 170-172, further comprising administering to the subject one or more additional active agents.

174. The method of claim 173, wherein the one or more additional active agents is a checkpoint inhibitor.

175. The method of claim 174, wherein the checkpoint inhibitor is a PD-1 inhibitor, PD-L1 inhibitor, PD-L2 inhibitor, CTLA-4 inhibitor, LAG-3 inhibitor, or TIM-3 inhibitor.

176. The method of claim 175, wherein the checkpoint inhibitor is a PD-1 inhibitor or PD-L1 inhibitor.

177. The method of claim 176, wherein the PD-1 inhibitor or PD-L1 inhibitor is a small molecule blocker of the PD-1 or PD-L1 pathway.

178. The method of claim 176, wherein the PD-1 inhibitor or PD-L1 inhibitor is an antibody that inhibits PD-1 or PD-L1 activity.

179. The method of any one of claims 170-178, wherein the PD-1 inhibitor or PD L1 inhibitor is selected from the group consisting of CA-170, BMS 8, BMS-202, BMS-936558, CK-301, AUNP12, avelumab, nivolumab, pembrolizumab, atezolizumab, durvalumab, AMP 224, MEDI0680 / AMP-514, PDR001, cemiplimab, TSR-042, Tizlelizumab / BGB-A317, CK 301, BMS-936559, camrelizumab, sintilimab, toripalimab, genolimzumab, A167, MGA012, PF-06801591, LY3300054, FAZ053, PD-11, CX-072, BGB-A333, BI 754091, JNJ 63723283, AGEN2034, CA-327, CX-188, STI –A1110, JTX-4014, (LLY) AM0001, CBT-502, FS118, XmAb20717, XmAb23104, AB122, KY1003, RXI-762, PRS-33, ALPN-202, TSR-075, MCLA 145, MGD013, and MGD019.

180. The method of claim 173, wherein the one or more additional active agents is a PARP inhibitor.

181. The method of claim 180, wherein the PARP inhibitor is selected from olaparib, rucaparib, niraparib, and talazoparib.

182. The method of claim 181, wherein the PARP inhibitor is olaparib.

183. The method of any one of claims 173-182, wherein the isolated antibody, the antibody conjugate or the pharmaceutical composition, and the one or more additional agents are administered sequentially.

184. The method of any one of claims 173-182, wherein the isolated antibody, the antibody conjugate or the pharmaceutical composition, and the one or more additional agents are administered concurrently.

185. The method of any of claims 171-184, wherein the disease or condition is a cancer.

186. The method of any one of claims 171-184, wherein the disease or condition is a TF-expressing cancer.

187. The method of any one of claims 171-184, wherein the disease or condition is a solid tumor cancer.

188. The method of any one of claims 171-184, wherein the disease or condition is selected from the group consisting of cervical cancer, head and neck squamous cell carcinoma, endometrial cancer, esophageal cancer, non-small cell lung cancer, and prostate cancer.

189. The method of any of claims 171-184, wherein the disease or condition is colorectal cancer.

190. Use of an isolated antibody of any one of claims 117-149, an antibody conjugate of any one of claims 1-116, or a pharmaceutical composition of anyone of claims 159-169 for reducing cell proliferation in a subject in need thereof.

191. Use of an isolated antibody of any one of claims 117-149, an antibody conjugate of any one of claims 1-116, or a pharmaceutical composition of anyone of claims 159-169 for the preparation of a medicament for reducing cell proliferation in a subject in need thereof.

192. Use of an isolated antibody of any one of claims 117-149, an antibody conjugate of any one of claims 1-116, or a pharmaceutical composition of anyone of claims 159-169 for treating or preventing a disease or condition in a subject in need thereof.

193. Use of an isolated antibody of any one of claims 117-149, an antibody conjugate of any one of claims 1-116, or a pharmaceutical composition of anyone of claims159-169 for the preparation of a medicament for the treatment or prevention of a disease or condition in a subject in need thereof.

194. A method of diagnosing and treating cancer in a subject in need thereof, comprising (a) detecting the expression of TF in a cell or tissue of the subject to diagnose the cancer; and (b) administering to the subject an effective amount of a pharmaceutical composition of any one of claims 159-169.

Images